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P2X7 purinoceptor 7 
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TLR toll like receptor 
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TNF-a tumor necrosis factor alpha 
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2.  Streszczenie 
 
LL-37, jedyna ludzka katelicydyna, jest amfipatycznym, kationowym peptydem 
bakteriobójczym, który zawiera 37 reszt aminokwasowych. Dojrzały peptyd uwalniany jest z 
18 kDa białka prekursorowego (katelicydyny) przez proteazę-3 w neutrofilach lub przez 
proteazy serynowe z rodziny kallikrein w keratynocytach. Oprócz zdolności bezpośredniego 
zabijania mikroorganizmów, LL-37 pełni funkcję immunomodulacyjną. Jedną z nich jest 
tworzenie kompleksów z ujemnie naładowanymi oligonukleotydami pochodzącymi zarówno 
z obumierających komórek gospodarza, jak i patogenów. Interakcja ta ułatwia rozpoznawanie 
DNA przez receptory wewnątrzkomórkowe, takie jak TLR-9 prowadząc do indukcji 
odpowiedzi immunologicznej. W ostatnim czasie udokumentowano, że zdolność peptydu LL-
37 do pełnienia funkcji bakteriobójczych i immunomodulacyjnych zależy w dużym stopniu od 
jego modyfikacji potranslacyjnych, wśród których deiminacja odgrywa wyjątkową rolę. 
Struktura pierwszorzędowa LL-37 zawiera pięć reszt argininy (Arg), które są wydajnie 
cytrulinowane przez deiminazy peptydylo-argininowe (PADs), enzymy, które są zależnymi od 
wapnia hydrolazami katalizującymi konwersję dodatnio naładowanej argininy do neutralnej 
cytruliny. W związku z powyższym w niniejszej pracy skupiono się na roli deiminacji peptydu 
LL-37 w regulacji odpowiedzi zapalnej na kwasy nukleinowe. Uzyskane wyniki dowiodły, że 
cytrulinacja LL-37 katalizowana przez PAD2 ogranicza zależne od peptydu pochłanianie DNA 
przez fagocyty. Co ciekawe, karbamylacja peptydu (homocytrulinacja reszt lizyny) nie ma 
wpływu na jego interakcję z DNA, tak długo jak karbamylowany peptyd nie zostanie poddany 
działaniu PAD2. W badaniach zastosowano również syntetyczny peptyd LL-37 z resztami Arg 
zastąpionymi homoargininą (hArg-LL-37), która jest niewrażliwa na proces enzymatycznej 
deiminacji przez PADy. Dane te wykazały, że wiązanie peptydu LL-37 z DNA, a tym samym 
jego działanie immunoregulacyjne względem fagocytów nie zależy wyłącznie od ładunku 
dodatniego peptydu, ale od prawidłowego rozmieszczenia guanidynowych łańcuchów 
bocznych argininy w natywnej sekwencji peptydu. Aby zbadać, czy powyższe zjawisko 
odgrywa rolę w stanie zapalnym przeprowadzono badania z wykorzystaniem 
zewnątrzkomórkowych pułapek neutrofilowych (NETs, ang. neutrophil extracellular traps). 
Tworzenie tych struktur, zbudowanych z nici genomowego DNA udekorowanych białkami 
pochodzącymi z ziaren azurofilnych, w tym LL-37, zależy od aktywności PAD4. Szczegółowa 
analiza składu NETs i ich wpływu na profesjonalne fagocyty sugeruje, że katelicydyna/LL-37 
jest cytrulinowana przez PAD4 podczas tworzenia pułapek neutrofilowych. Proces ten 
odgrywa istotną rolę w kontroli potencjału zapalnego NETs, zwłaszcza w regulacji odpowiedzi 
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immunologicznej na uwolnione z obumierających komórek DNA, które jest rozpoznawane 
przez receptor TLR9. Przebieg procesu cytrulinacji w warunkach in vivo potwierdzają wyniki 
analizy serologicznej surowic pochodzących od pacjentów cierpiących na przewlekłe choroby 
zapalne, takie jak: paradontozę i reumatoidalne zapalenie stawów, w których wykazano 
podwyższony poziom przeciwciał rozpoznających cytrulinowaną formę peptydu LL-37. 
Ostatecznie, dowiedziono, że cytrulinowana forma peptydu LL-37 zwiększa powstawanie 
NETs, co sugeruje mechanizm pozytywnego sprzężenia zwrotnego. Podsumowując, 
cytrulinacja peptydu LL-37 odgrywa kluczową rolę w jego immunomodulacyjnym działaniu 
przeciwdziałając utracie tolerancji gospodarza na własne cząsteczki, w tym DNA.  
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3.  Abstract 
 
LL-37, the only human cathelicidin, is an amphipathic, cationic antimicrobial peptide 
that contains 37 amino acids residues. The mature peptide is released from an 18-kDa precursor 
protein (cathelicidin) by protease-3 in neutrophils or by serine proteases of the kallikrein family 
in keratinocytes. Besides playing antimicrobial role, LL-37 exerts several immunomodulatory 
functions that regulate host responses to pathogens. Among them is formation of complexes 
with negatively charged oligonucleotides derived from both dying host cells and pathogens. 
Such interaction facilitates the recognition of DNA by intracellular receptors such as TLR9, 
thereby stimulating the immune response. It was recently documented that the ability of peptide 
to execute its bactericidal and immunomodulatory functions strongly depends on 
posttranslational modifications, among which enzymatic deimination (citrullination) of Arg 
residues plays a unique role. The primary structure of LL-37 contains five arginine (Arg) 
residues that are effectively citrullinated by peptidyl-arginine deiminases (PADs), enzymes 
that are calcium-dependent hydrolases catalyzing the conversion of positively charged arginine 
to neutral citrulline. Therefore, presented study focused on the role of LL-37 deimination in 
the regulation of the host immune response to nucleic acids. Presented data revealed that 
citrullination of LL-37 by PADs hindered peptide-dependent DNA uptake and sensing by 
pDCs. In contrast, carbamylation of the peptide (homocitrullination of lysine residues) had no 
effect on its interaction with DNA. This activity was abolished by citrullination of Arg residues 
in the peptide by PAD2. We implemented in the study the synthetic peptide LL-37 with Arg 
residues substituted by homoarginine (hArg-LL-37), which is insensitive to enzymatic 
deimination. Using such peptide, we observed that regardless of PAD2 treatment hArg-LL-37 
preserved full biological activity. These data have showed that peptide binding to DNA and its 
immunoregulatory effects on myeloid cells do not depend entirely on the positive charge of 
LL-37 but on the proper distribution of guanidium side chains of Arg (or homo-Arg) in the 
native peptide sequence. To explore if above phenomenon plays a role in inflammatory 
conditions, we introduced in the study neutrophil extracellular traps (NETs). Formation of 
those structures, composed of genomic DNA and decorated with azurophilic proteins including 
LL-37, depends on PAD4 activity. Detailed analysis of NETs composition and their influence 
on myeloid cells suggest that cathelicidin/LL-37 is citrullinated by PADs during NETs 
formation. Such process makes a marked contribution to the inflammatory potential of NET 
structures especially in regulating the immunostimulatory response of cell-free DNA, which is 
mediated by TLR9. Such conclusion was additionally supported by an elevated antibody 
 13 
response against citrullinated LL-37 in blood serum obtained from patients suffering from 
chronic inflammatory diseases (periodontitis, rheumatoid arthritis). Finally, obtained data 
revealed that citrullinated LL-37 itself enhances the generation of NETs formation suggesting 
the mechanism of positive feedback. Taken together, by preventing the breakdown of tolerance 
to self-molecules, citrullination of LL-37 plays a critical role in immunomodulation of the host 
response.  
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4.  Introduction 
 
4.1. Innate Immunity 
  
The innate immune system is the first line of defence in vertebrates protecting against 
pathogens. Its action is characterized by a rapid and non-specific response to invaders. The 
cascade is initiated by the recognition of pathogen-associated molecular pattern molecules 
(PAMPs) via pattern recognition receptors (PRRs) expressed by the host cells. Among PAMPs 
are such microbial components, as lipopolysaccharides, flagellin, lipoproteins and nucleic 
acids [1]. PRRs can induce three major types of responses upon activation: (1) phagocytosis, 
(2) inflammation, and (3) maturation of antigen-presenting cells (e.g. macrophages and 
dendritic cells), which can lead to the activation of the adaptive immune system [2]. The 
process of receptor activation accompanies the release of inflammatory mediators, including: 
chemokines, cytokines and host defence peptides. Cytokines and chemokines play essential 
roles in coordinating and regulating immune responses, such as mediating cell activation and 
differentiation, modulating inflammation and altering signalling pathways. They are 
characterized as pleiotropic factors and can be generally categorized into two major types, pro- 
or anti-inflammatory cytokines. Chemokines are a specific group of cytokines, which influence 
cell trafficking and recruit immune cells, such as monocytes, neutrophils and lymphocytes to 
a specific location. The process of cytokines expression is strictly regulated, as its breakdown 
can lead to excessive or prolonged inflammatory response. Deregulation of cytokine network 
may result in detrimental effects as observed in rheumatoid arthritis (RA), chronic obstructive 
pulmonary disease (COPD), asthma, or systemic lupus erythematosus (SLE). Therefore, the 
innate immune system engages some other host molecules that are essential in the modulation 
of inflammatory response. Many studies have shown that among them is a family of molecules 
called host defence peptides [3]. 
 
4.2.  Host Defence Peptides (HDPs) 
  
Host defence peptides (HDPs), also known as antimicrobial peptides (AMPs) constitute 
important branch of innate immune system and has gained substantial attention over recent 
years. The rise in multidrug resistant bacteria by the end of 20th century has led HDPs to 
become an interesting alternative ‘drug’ to control bacterial infections [4]. These proteins kill 
bacteria, but also yeasts, fungi, viruses and even cancer cells. HDPs are usually cationic and 
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amphipathic, thus they exert direct microbicidal effect by binding and disrupting the microbes’ 
membranes. Therefore, antimicrobial activity of those molecules was considered for many 
years as their primary function [5]. More recent studies have reported their immunomodulatory 
activities. HDPs interact with surface receptors, such as G protein-coupled receptors e.g. 
formyl peptide receptor 2 in leukocytes and Mas-related gene X2 (MrgX2) in mast cells [6]. 
Moreover, they translocate across the cell membrane in a manner similar to that of cell-
penetrating peptides. Translocation is essential in altering the cellular activities and promotes 
immune responses. Upon translocation, HDPs bind to the intracellular receptors (such as 
GAPDH and sequestosome 1) stimulating multiple signal transduction pathways including p38, 
IRF and NF- kB [6]. The immunomodulatory properties of HDPs play significant role in the 
cooperation of innate immune system with adaptive immunity. HDPs serve as early links to 
effector cells of adaptive immunity and lead the recruitment of lymphocyte and DC-mediated 
T-cell modulation. For example, a-defensins are reported to attract T cells and C3d of the 
complement cascade that amplifies B-cell secretion of specific antibodies, whilst LL-37 attracts 
polymorphonuclear and CD4+ T cells [7][8]. What is important, as host molecules those 
peptides are tolerated by immune system. For these reasons, HDPs have made an attractive 
template in antimicrobial therapeutics development.  
There are more than 2,600 HDPs that have been identified within a variety of species, 
including bacteria, insects, fungi, amphibians, humans etc. [3]. Although there are different 
classification schemes, HDPs are categorized into four large families: α, β, αβ and non-αβ [9]. 
Peptides in the α family consist α-helical structure as their major secondary structure, such as 
human cathelicidin LL-37, histatins, dermcidin and granulysin. Whilst human α-defensins, 
hepcidins, human secretory leucoprotease inhibitor (SLPI) are categorized in the β family, 
containing at least a pair of two β-strands in the structure. The αβ family contains both α and β 
secondary structures, such as the β-defensins and antimicrobial chemokines (CCL1, CXCL10 
etc.). Peptides in non-αβ family contain neither α nor β structure, but consist of extended 
structures. Structural example for this family is still being studied [10].  
Defensins and cathelicidin families constitute the major groups of antimicrobial 
peptides in mammals. They are secreted by epithelial cells and professional phagocytes, such 
as macrophages and neutrophils [4]. Defensins are categorized into a, b, and q-defensins. They 
are non-glycosylated peptides with arginine as their major cationic residue and six conserved 
cysteine residues. Their β-sheet structure is stabilized by intramolecular disulfide bonds [11]. 
Cathelicidins have a distinctive feature of highly conserved cathelin domain (N-terminal 
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sequence) and a C-terminal antimicrobial domain. The cathelin-like domain is flanked by a 
signal peptide domain on the N-terminus, which directs the peptide to either storage or to the 
exterior of the cells, where the peptide plays a key role to rapid host defence [7]. Besides 
mammals, cathelicidin is also found in a variety of species such as amphibians, avian and fishes. 
Each species expresses different number of cathelicidins, however, in human and mice, only 
one cathelicidin was identified. The murine cathelicidin (CRAMP - cathelin-related 
antimicrobial peptide) shares 67% homology with human cathelicidin peptide. The human 
cathelicidin, known as hCAP18 is encoded by the CAMP gene located on the chromosome 
3p21. It consists of 4 exons. The first 3 encode the preproregion (signalling and cathelin-like 
domain) and the forth one codes the active domain [12]. hCAP18 is characterized by an N-
terminal signal peptide (30 amino acid residues), a highly conserved pro-sequence (103 amino 
acid residues), which is also known as the cathelin-like domain and a mature antimicrobial 
peptide called LL-37 (37 amino acid residues) (Fig. 1). hCAP18 with the molecular weight of 
18 kDa exhibits no antimicrobial activity [13]. However, upon cleavage of the C-terminal end 
of hCAP18 the 4.5 kDa-matured peptide termed LL-37 is formed [14]. Among enzymes 
catalysing this process are serine proteases of the kallikrein family in keratinocytes and/or 
proteinase 3 in neutrophils.  
 
                                      
 
Fig. 1. Processing of human cathelicidin. The preprotein (hCAP18) consists of a conserved 
region (signal sequence and cathelin domain) and variable region, which codes for the mature 
antimicrobial peptide (LL-37). Active peptide (LL-37) is processed by several serine proteases, 
depends on the cell type/tissue [Adapted from Vandamme et al. [14] ]. 
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4.3.  Peptide LL-37 
  
LL-37 consists of 37 amino acid residues with Leu-Leu at the N-terminus (NH2-
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-COOH), with the net positive 
charge of +6 at physiological pH [14]. The secondary structure of LL-37 depends on the 
environment as well as on peptide’s concentration. LL-37 has a disordered conformation in 
aqueous solution but it is able to fold into an amphipathic a-helix in contacts with lipid 
membranes. Furthermore, some studies have demonstrated that a random disordered 
conformation of LL-37 at micromolar concentration in water transforms to a-helix 
conformation in the presence of physiological concentrations of certain salt ions, with the ion 
compositions similar as found in plasma and intracellular fluid. The a-helix conformation is 
anion-, pH-, lipid- and concentration-dependent. The circular dichroism (CD) spectrum of LL-
37 has revealed the peptide adopted the characteristic of a-helical structure at the concentration 
of 10-3 M in the presence of 20 mM SO42-, with pH values over 13 [15][16][17]. The a-helical 
structure is essential for the peptide’s activities, such as anti-endotoxin, anti-microbial and anti-
biofilm [18]. Furthermore, LL-37 is able to form aggregates in solution and lipid bilayers, 
enabling the peptide to be protected from proteolytic degradation [19]. 
LL-37 is constitutively expressed in almost all tissues and is also present in body fluids, 
such as plasma and bone marrow [7]. Sørensen and co-workers’ studies have demonstrated that 
neutrophils are the main source of peptide. The concentration of pro-peptide found in 
secondary granules was estimated about 630 µg/109 cells [20]. The expression of LL-37 
significantly increases at the site of infection, during inflammation and can be upregulated by 
a wide variety of stimuli, such as cytokines, growth factors, bacterial and fungal products [21]. 
 
4.3.1. Functions of LL-37 
 
4.3.1.1. Antimicrobial role of LL-37 
  
LL-37 exerts antimicrobial activity against a broad range of both Gram-positive and 
Gram-negative bacteria, which includes Pseudomonas aeruginosa, Staphylococcus aureus or 
Escherichia coli. The exact mechanism by which AMPs exert their antimicrobial properties is 
still unclear, however, the general accepted idea is that cationic peptide LL-37 interacts with 
the negatively charged phospholipids of bacterial cell wall. Such electrostatic interaction 
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provides the process of covering the surface of the bacterial membrane by peptide. The 
consequence is disruption of the membrane via a ‘carpet-like’ mechanism and pore formation 
[22]. The established minimum inhibitory concentration (MIC) of LL-37 against Gram-
positive and Gram-negative bacteria range between 0.2 – 32 µM. Apart from that, LL-37 has 
strong anti-biofilm properties. This was shown in a study conducted by Overhage and co-
workers on biofilms formed by P. aeruginosa. It was revealed that subinhibitory concentrations 
of the MIC (0.5 µg/ml) led to an approximately 40% decrease in P. aeruginosa biofilm mass 
[23]. Such observation was explained by the broad activity of LL-37 against biofilm 
development. Firstly, peptide significantly reduces the attachment of bacteria to the surface, 
causing a smaller number of bacteria involved in the initial steps of biofilm formation. 
Secondly, LL-37 also affects existing, pregrown P. aeruginosa biofilm by increasing the 
bacteria motility, limited their attachment to the surface and further biofilm growth.  The 
conclusion comes from the observation of biofilm morphology, which is thin and flat without 
the mushroom-like structure [23]. And last but not least, LL-37 could affect the two major 
quorum-sensing system of bacteria, the Las and Rhl systems, by downregulating the key 
components, which are part of the respective regulons [23]. Besides in vitro studies, the 
antimicrobial role of LL-37 was confirmed using mice deficient in CRAMP. Mice deficient in 
CRAMP were more susceptible to pathogenic bacteria colonization and invasion when 
compared to wild-type animals, as reported by Chromek et al. [24]. It is proposed that as 
CRAMP is similar to LL-37 in structure, tissue distribution and antimicrobial activity, thus 
CRAMP knockout model would be useful to study the function of human cathelicidin. Strong 
clinical evidence showing antibacterial role of LL-37 comes from patients with Morbus 
Kostmann syndrome treated with G-CSF. These patients’ neutrophils although in normal 
numbers lacks LL-37. In a consequence, those patients are more susceptible to develop oral 
infections [25]. LL-37 has also shown to exhibit antiviral activity against herpes simplex virus 
and vaccinia virus [26]. The peptide was also reported to inhibit the replication of HIV-1 in 
peripheral blood mononuclear cells, including the primary CD4+ T cells [27].  
 
4.3.1.2. Immunomodulatory role of LL-37 
  
Along with its antimicrobial properties, LL-37 plays an important role as a potent 
immunomodulator of the host immune response as presented in Fig. 2. LL-37 exerts both pro- 
and anti-inflammatory functions, depending on the microenvironment and cellular contexts 
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[28]. Upon stimulation by pro-inflammatory signals, LL-37 is able to direct macrophage 
differentiation to M1 phenotype characterized by proinflammatory signature, which involves 
the internalization of LL-37 by monocytes and activation of p38 mitogen-activated protein 
kinase (MAPK) signalling [29]. Peptide acting on the P2X7 receptor efficiently contributes to 
the inflammasome activation leading to the generation of IL-1b and IL-18 [30]. LL-37 also 
promotes type I IFN production providing protection, recognition and engulfment of both RNA 
and DNA into professional phagocytes leading to the activation of TLR7 and TLR9 
respectively [31]. Besides that, LL-37 promotes NETosis as being integral component of NETs 
peptide is recognized by anti-LL-37 autoantibodies [32]. Another notable pro-inflammatory 
feature of LL-37 is its chemotactic activity. Peptide induces the migration of neutrophils and 
eosinophils by acting via the formyl peptide receptor 2 [28]. LL-37 also modulates the 
production of chemokines in keratinocytes by inducing the transcription of CXCL8 which 
acting in synergy with TNF-a [33].  
Nevertheless, LL-37 plays an important anti-inflammatory role. The crucial one is 
neutralization of bacterial endotoxin and inhibition of TLR4 signalling in dendritic cells and 
macrophages [34]. LL-37 also exerts antagonistic role towards host inflammatory mediators, 
such as: IFN-g, TNF-a, IL-4 and IL-12 [35]. The peptide has protective effects against invasion 
of pathogenic bacteria in intestine. Studies utilizing mice deficient in CRAMP have 
demonstrated such function for this peptide, such as providing protective effects against 
Clostridium difficile toxin-mediated colonic and ileal damage [36]. Altogether, the LL-37 
peptide is a potent and pleiotropic host factor and its immunomodulation mechanism needs to 
be further elucidated. 
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Fig. 2. Immunomodulatory role of LL-37. The figure was created with images adapted 
from Servier medical art by Servier [Adapted from Kahlenberg and Kaplan [28] ]. 
 
4.3.1.3. The role of LL-37 in wound healing and angiogenesis 
 
LL-37 is actively involved in tissue repair and wound healing, especially 
revascularization and cell growth. Increased expression of LL-37 was reported in human 
keratinocytes and in wounds. The peptide can be induced by wound-healing growth factors, 
such as transforming growth factor (TGF)-a and insulin-like growth factor 1 (IGF-1) [37]. The 
chemoattractant properties of the peptide, which enhance migration of epithelial and immune 
cells, increase synthesis of extracellular matrix proteoglycans and cellular proliferation that 
contributes to the wound healing process. Besides that, its anti-infective activities reduce 
microbial burden at the wound site [6]. LL-37 was also reported to promote IL-8 release and 
wound closure through the epidermal growth factor receptor (EGFR) and MAPK signalling 
pathway in human bronchial epithelial cells [38]. 
Moreover, the peptide has another interesting function, which is induction of 
angiogenesis by direct activation of endothelial cells, their increased proliferation and 
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formation of vessel-like structures [7]. Koczulla et al. have shown that LL-37 induces 
angiogenesis via a formyl peptide receptor-like 1 (FPRL1) protein expressed on endothelial 
cells. They have also observed decreased vascularization during wound repair in mice deficient 
in CRAMP, emphasizing the importance of cathelicidin in mediating cutaneous wound 
neovascularization in vivo [39].  
 
4.3.2. Effects of LL-37 on disease pathogenesis 
 
Although LL-37 plays protective and beneficial role in host defence, it also contributes 
to the development of autoimmune disorders and inflammatory diseases, such as 
atherosclerosis, psoriasis, systemic lupus erythematosus, and arthritis. The detrimental function 
of LL-37 was initially observed in atherosclerosis. Peptide efficiently binds to DNA forming 
complexes that promote type I IFN signatures and causing the development of atherosclerotic 
lesion. Moreover, enhanced transcription of LL-37 was found in human atherosclerotic aortas 
[40]. Harmful effect of the peptide was also documented in psoriasis, disease characterized by 
enhanced type I IFN production and skin inflammation. In those patients overexpression of 
LL-37 was documented. It was revealed that peptide binds to DNA thus induces accelerated 
activation of dendritic cells. Furthermore, the role of LL-37 in psoriasis development relays on 
its antiapoptotic influence on keratinocytes, causing the increased cellular proliferation [41]. 
Another serious inflammatory disease in which the role of LL-37 was documented is SLE. In 
sera of those patients LL-37-DNA complexes were detected. Moreover, the generation of 
autoantibodies against LL-37 promotes formation of immune complexes and further NETs 
induction. Such events accelerate inflammatory reaction [32][42][43]. The elevated expression 
of LL-37 was also documented in osteoclasts and granulocytes from patients suffer with RA, 
suggesting the role of LL-37 in development of joint disease. The mechanism of deleterious 
effect of LL-37 bases on induction of osteoblasts apoptosis causing the reduction of bone 
formation in arthritic joints [28]. Hoffman and co-workers have demonstrated the upregulation 
of CRAMP, the rat ortholog of LL-37 in granulocytes, macrophages in a pristine-induced 
arthritis model, suggesting the contribution of LL-37 in arthritis development, however, further 
studies are needed to clarify its role [44]. 
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4.3.3. Post-translational modifications of LL-37 
  
The interest in deciphering protein modifications and their impact on cellular 
microenvironment and disease pathophysiology was greatly enhanced in the past few decades. 
Post-translational modifications (PTMs) play a key role in multiple cellular processes, such as 
cell signalling, differentiation and regulation of gene expression. The result of PTMs that 
change properties of a protein, by adding or modifying chemical groups in a sequence of amino 
acids, has been reported to affect protein function via changes in protein structure and dynamics 
[45]. We focused on the major modifications of LL-37, which recently gained interest by the 
research community. 
 
4.3.3.1. Proteolysis 
  
Proteolysis of LL-37 is a common strategy used by pathogens that utilize proteases to 
confer resistance against the antimicrobial activities of peptide. An example is Staphylococcus 
aureus, which produces two major proteinases, metalloproteinase (aureolysin) and 
glutamylendopeptidase (V8 protease). Both enzymes cleave and inactivate LL-37, contributing 
to the resistance of the pathogen to the host innate immune system [46]. Furthermore, 
proteolysis of LL-37 has been reported to be associated with severe periodontal disease. 
Treponema denticola, Porphyromonas gingivalis and Tannerella forsythia are characterized 
by their high proteolytic and peptidolytic activities, which can degrade LL-37 in vitro [47]. For 
example, it was identified that a metalloprotease from T. forsythia, karilysin, can inactivate the 
bactericidal activity of LL-37 in a time- and concentration-dependent manner. This contributes 
to the development of chronic inflammatory response in periodontitis patients [48]. 
Apart from enzymatic degradation by bacteria, LL-37 can be proteolytically cleaved by 
protease b-tryptase released by human mast cells, causing the change in the function of the 
peptide, such as lacking the microbicidal and LPS-neutralizing activities [49]. Another 
proteolytic degradation of LL-37 was reported in cystic fibrosis bronchoalveolar lavage fluid 
by neutrophil elastase and cathepsin D. The truncated peptide fragments of LL-37 resulting 
from the proteolytic activity may alter the inflammatory and antimicrobial effect of the peptide, 
reducing the immunomodulatory properties compared with the intact LL-37 [50].  
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4.3.3.2. Carbamylation 
  
Carbamylation, is a non-enzymatic post translational modification in which cyanate 
(OCN-) reacts with the primary amino groups (NH3+) at the N-termini of proteins, and with the 
lysine residues in the polypeptide chain, generating α-carbamyl amino acids and homocitrulline 
respectively [51] (Fig. 3). Other amino acids such as arginine and cysteine contain side chains 
that can react with cyanate, however such binding is rarely reported apart from lysine. Cyanate 
is a reactive species which is always in equilibrium with urea in physiological conditions, 
however, that’s not the case in uremic patients, with 150 nmol/L plasma concentrations of 
cyanate was reported, which is three times higher comparing to healthy individuals (50 nmol/L). 
High level of cyanate explains the intensity of carbamylation reaction in patients with renal 
dysfunction [52].  
Carbamylation has attracted the attention as such modification can be enhanced in the 
context of chronic inflammatory diseases where myeloperoxidase (MPO) are found abundantly 
[53]. The concomitant release of LL-37 and MPO by activated neutrophils creates the perfect 
conditions for LL-37 carbamylation. When MPO acts on thiocyanate in the presence of 
hydrogen peroxide, cyanate is generated. Such reaction provides further carbamylation process. 
As thiocyanate can be brought by smoke, thus few studies have suggested a link between 
inflammation and smoking [53][54]. 
 
Fig. 3. The major biochemical pathways in carbamylation. Chemical modification that 
generates a-carbamylated proteins/peptides/amino acids and homocitrulline in the 
presence of cyanate [Adapted from Jaisson et al. [55] ]. 
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Mass spectrometry analysis has identified three possible common variants of 
carbamylated LL-37 by incubating LL-37 with 10 mM of potassium cyanate (KCNO), which 
is an equivalent to cyanate level detected in inflammatory milieu [51]. LL-37 bearing a 
carbamylated N-terminus (LL-37C1) was the predominant form. The second most common 
single-modified peptide was LL-37 bearing homocitrulline residue at position 8 (LL-37C8), 
while prolonged incubation of LL-37 with KCNO generates LL-37 bearing a double 
modification on Lys-12 and Lys-15 (LL-37C12,C15). The posttranslational modification of Lys 
residues to neutral homocitrulline was reported to abrogate the biological function of LL-37, 
such as affecting the chemotactic capacity of LL-37, where neutrophils were less responsive to 
the carbamylated versions of LL-37 and showed lower directional accuracy. Carbamylated 
forms of LL-37 were also reported to have impaired ability to inhibit bacterial growth [51]. 
This is most likely due to the loss of two positive charges, which would have led to a significant 
impact on the secondary structure of the peptide and hence modified its physiochemical 
properties. It was also documented that the chemical conversion is dependent on time of 
exposure and OCN- concentration [51]. Hence, administration of cathelicidin-derived peptides 
as therapeutic drugs should be considered carefully in the context of severe inflammation, 
where due to cyanate formation, lysine residues within LL-37 could undergo carbamylation 
leading to the inactivation of peptide. 
 
4.3.3.3. Citrullination 
  
Peptidyl arginine residues, such as present in LL-37, can undergo enzymatic 
deimination (often referred to as citrullination), which results in the conversion of arginine 
(Arg) to citrulline (Cit) (Fig. 4). Citrullination caused the reduction of overall net charge of a 
protein by the loss of a positive charge per citrulline residue. The conversion of ketimine groups 
(=NH2) of the arginines to ketone groups (=O), results in the production of citrulline and is 
catalyzed by PAD enzymes (peptidylarginine deiminases, EC 3.5.3.15) [56]. These enzymes 
work by attacking the active site cysteine residue on the substrate guanidinium, resulting in the 
formation of a tetrahedral intermediate. A water molecule then acts as a nucleophile and attacks 
the tetrahedral adduct that ultimately forms an acyl-enzyme intermediate which is subsequently 
hydrolysed to form citrulline [57]. Calcium is a key regulator of PADs activity, but it remains 
uncertain how intracellular calcium levels can be raised to sufficiently high levels to activate 
these enzymes [58].  
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Fig. 4. Process of citrullination. Peptidylarginine deiminase (PAD) catalysed the hydrolytic 
conversion of peptidyl-arginine to non-standard residue peptidyl-citrulline [Adapted from 
Vossenaar et al. [59] ]. 
  
Five isoenzymes of PAD have been identified (PAD1, 2, 3, 4, 6). They are differentially 
distributed in many tissue and cell types, as typical for epidermis and uterus is PAD1, for 
skeletal muscle, brain, inflammatory cells and secretory glands is PAD2, for hair follicles and 
keratinocytes is PAD3, for granulocytes is PAD4, while for oocytes and embryos is PAD6 [60]. 
PAD4 is the only isozyme that plays an essential role in histone deimination, however there’s 
a growing number of reports suggesting that PAD2 may play equally important role. Under 
physiological functions, PADs activity is limited as the calcium concentration is at very low 
levels inside the cell (10-8 to 10-6 M). However, in the event of cell death (for example, 
apoptosis), intracellular concentration of calcium increases thus activating PADs [61]. 
Citrullination has variable effects based on target substrates for each PAD isozymes [57]. 
Major substrates for each isoform of PAD are summarized in Table I. 
 
Isozyme Substrates 
PAD1 Keratin, filaggrin 
PAD2 Myelin basic protein, vimentin, actin, histones 
PAD3 Filaggrin, trichohyalin, vimentin, apoptosis-inducing factor 
PAD4 Histones, nucleophosmin, nuclear lamin C 
PAD6 Not known 
Table I. List of major substrates modified by respective isozymes of the PAD family [Adapted 
from Witalison et al. [57] ]. 
  
One of the earliest descriptions of physiological citrullination is the cornification of 
skin and the hardening of the hair follicle. Citrullination of filaggrin for example, provides 
 26 
structural support in cells undergoing terminal epidermal differentiation. On the other hand, 
citrullination of filaggrin increases its susceptibility to proteolysis and allowing it to be cleaved 
into amino acids that make up natural moisturizing factor [62]. Apart from that, PADs can 
regulate gene expression at physiological concentrations of calcium and a lot of research has 
been performed on PAD4 in this context. Especially interesting is the role of the PAD4-
mediated regulation of the p53 pathway, which is essential in responding to stresses that can 
disrupt the fidelity of DNA replication and cell division, although it is still unknown how PAD4 
is recruits to the p21 (the transcriptional targets of p53) at the p53-binding sites on the promoter 
region and functioned at physiological calcium levels [63]. The PAD enzymes could deiminate 
several nuclear and cytoskeletal proteins such as vimentin, causing structural changes and 
results in the disintegration of secondary and tertiary protein structures [64].  On the other hand, 
PADs may have a role in the induction of apoptosis. Deimination of histones H2A, H3 and H4 
could alter the chromatin organization and DNA susceptibility to fragmentation, leading to the 
induction of apoptosis through DNA damage signals [65]. As mentioned above citrullinated 
proteins play an important role in many cellular processes. It is crucial for the regulation of 
immune response, central nervous system, tissue structure generation and cytoskeletal stability. 
Dysregulation of citrullination can lead to serious abnormalities in immunological system. 
Rheumatoid arthritis, multiple sclerosis, psoriasis, Alzheimer’s disease are inflammatory 
disorders, which aetiology is related with citrullination [61]. The modification has piqued the 
interest in the research community with reports showing the upregulation of PADs due to the 
presence of pro-inflammatory stimuli. Moreover, it was revealed that increased level of cell 
death that contributes to the calcium rich environment leads to PADs activation [66]. Thus, 
PADs regulation has gained the attraction as promising target against autoimmune and 
inflammatory diseases related to protein deimination [57]. 
Main isoforms of PADs enzymes involved in inflammation are PAD2 and PAD4. Both 
enzymes can efficiently citrullinate LL-37 as it was documented in recently published studies 
[67] [68]. All five Arg residues are citrullinated but at different time and efficiency (Table II) 
[67]. Moreover, citrullination of LL-37 depends on the form of PADs. PAD2 was reported to 
citrullinate all Arg residues, whilst exposition of LL-37 to PAD4 results in a generation of 
partially citrullinated peptide [68]. Predominantly generated forms of peptide are Arg7Cit (LL-
377), Arg7,29,34Cit (LL-377,29,34), or Arg7,19,23,29,34Cit (LL-37all cit).  
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PADs PAD2 PAD4 
Citrullination 
of individual 
Arg residues in 
LL-37 
Cit-7 99.0% Cit-7 93.0% 
Cit-19 15.0% Cit-19   1.0% 
Cit-23   1.5% Cit-23   0.8% 
Cit-29 49.0% Cit-29 41.0% 
Cit-34 20.0% Cit-34 50.0% 
Table II. Percentage of citrullination of individual Arg residues in LL-37 treated with either 
PAD2 or PAD4, quantitated by amino acid sequence analysis using automated Edman 
degradation [Table reproduced from Koziel et al. [67] ]. 
 
The function of LL-37 largely depends on the cationic charge and the structure of the 
peptide, which is abrogated upon citrullination. Koziel et al. and Klisgård et al. have reported 
the loss of anti-inflammatory and bactericidal effects upon the citrullination of LL-37 [67][68]. 
Citrullinated LL-37 has reduced ability to quench the pro-inflammatory activity of LPS as 
documented in vitro using macrophages as model of immune cells. Moreover, citrullination 
abolishes the ability of LL-37 to prevent the mortality and morbidity associated with septic 
shock. Apart from that, citrullinated LL-37 is unable to downregulate cellular responses to 
other TLR ligands and host inflammatory mediators. Since the citrullination of LL-37 in vivo 
during inflammation, especially in sepsis patients, is highly possible, thus therapeutic strategy 
by administering LL-37 should be analysed in detail as it might contribute to severity of sepsis 
[67]. 
 
4.3.3.4. Other modifications 
  
The presence of five arginine residues in LL-37 has enabled this peptide to be subjected 
for ADP-ribosylation. Picchianti and co-workers have shown that LL-37 can be ADP-
ribosylated by ADP-ribosyltransferases (ART1), a surface-exposed enzyme expressed on the 
apical surface of human airway epithelial cells, at multiple arginine residues in vitro [69]. The 
attachment of one or more negatively charged ADP-ribose moieties to arginine residues result 
in a reduced cationicity of the peptide, which affects the ability of the peptide to interact with 
biological membranes or polyanionic molecules such as DNA, RNA or actin. This might be 
useful to develop new therapeutic compounds for cystic fibrosis and psoriasis patients, where 
the properties of LL-37 was affected due to the formation of DNA-LL-37 complexes [69].  
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LL-37 can be acetylated on the N-terminus and amidated on the C-terminus, which 
enables the peptide to have a marked reduction in proteolytic degradation by V8 and aureolysin 
in solution [70]. Hence, such stabilized peptides may improve antimicrobial properties which 
might due to the increase helicity by stabilizing the helix by hydrogen bonding to the NH group, 
results from the terminal acetylation and amidation [71].  
 
4.4. Immune recognition of DNA  
 
4.4.1. Distinguishing self from non-self DNA   
 
The mammalian immune system can recognize nucleic acids, however the process is 
regulated by their specific sequences, modifications or structures. The mammalian immune 
system selectively responds to DNA sequence motifs containing unmethylated CpG 
dinucleotides commonly found in bacterial DNA. The cellular activation in response to 
bacterial DNA is mediated by TLR9 and leads to the activation of host cells manifested with 
increase expression of cytokines. CpG DNA preferentially activates B cells and dendritic cells 
(DCs), but robust cytokines secretion increases the activity of other subsets of immune cells, 
such as monocytes, NK cells, or T cells, which lack TLR9 expression. That mechanism confers 
protection of the host from different pathogens containing unmethylated CpG motifs, which 
are classified as one of the PAMPs [72]. 
The unmethylated CpG oligonucleotides can be categorized into 2 different classes with 
distinct structures, sequence motifs and the subset of activated host cells. CpG-A (prototype 
ODN 2216) has a weaker activity on B cells or macrophages but induces strong response of 
type I IFN in dendritic cells. This is a consequence of the presence of poly-G tails that enable 
the formation of aggregated structures. Such aggregates retained longer in the early endosomes, 
creating a platform for extended activation of the signal-transducing complex, consisting 
MyD88 and IRF7, which leads to robust type I IFN production. Thus, plasmacytoid dendritic 
cells (pDCs) seem to detect aggregated DNA structures in the early endosomes, which express 
markers such as the transferrin receptor (TfR) and early endosomal antigen 1 (EEA1). 
Prolonged exposition of CpG to TLR9 receptors located inside early endosomes induces a 
signalling pathway enhancing the activation and recruitment of a signal-transducing complex, 
such as MyD88, interleukin-1 receptor associated kinase 1 (IRAK1), interleukin-1 receptor 
associated kinase 4 (IRAK4) and TNF receptor-associated factor 6 (TRAF6). IRAK-TRAF6 
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complex provides the phosphorylation of IRF7 and subsequent activation of type I IFN gene 
expression [31] (Fig. 5 – upper panel). 
 On the other hand, CpG-B (prototype ODN2006) is a potent activator of B cells but 
only trigger pDCs to produce proinflammatory cytokines (TNF-α and IL-6) and minute 
amounts of type I IFN, as well as induces the upregulation of CD80, CD83 and CD86 
molecules. As monomeric CpG-B lacks poly-G tails, thus it travels rapidly to late endosomes 
or lysosomes. Hence, it is thought that pDCs sense linear DNA structures in the late endosomes, 
which is marked by the presence of lysosomal-associated membrane protein 1 (LAMP-1). This 
activates a different set of signal mediators, where TGF-b activated kinase-1 (TAK1) triggers 
the activation of NF-kB, mitogen-activated protein kinases (MAPK) and IRF5, leading to TNF-
α and IL-6 production and pDC maturation [31] (Fig. 5 – lower panel). 
 
 
 
Fig. 5. Different CpG ODNs activates different signalling pathways. CpG-A ODNs tend to 
form aggregated structures, which are retained in early endosomes and cause a robust type I 
IFN-α response. CpG-B ODNs rapidly traffics to late endosomes or lysosomes and triggers the 
production of pro-inflammatory cytokines, TNF-α and IL-6 [Adapted from Gilliet et al. [31] ]. 
 
Mammalian DNA is methylated and characterized with the lower frequency of CpG 
dinucleotides, thus it usually remains neutral for host immune system [73]. However, the 
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release of host (self) DNA into an extracellular environment is inevitable due to the process of 
cell death. The mechanism, which can protect the host against accelerated response to self-
DNA, engages DNAses. Those enzymes deposited at high concentration in the extracellular 
environment should prevent against the development of the autoimmune response. The 
importance of DNase activity is reflected in SLE patients who fail to produce DNase in NETs 
degradation, as NETs is composed of nuclear DNA. The consequence is the formation of 
immune complexes comprising self-DNA and antibodies to DNA or nucleoproteins [31], 
which are proposed to break the host-tolerance. 
 
4.4.2. The role of dendritic cells in DNA sensing 
 
Dendritic cells are a specialized group of cells being capable to capture and process 
antigens, presenting them on major histocompatibility complex (MHC) molecules to be 
recognized by T cells [74]. The DCs family is divided into two subgroups, classical dendritic 
cells (CDCs) and plasmacytoid dendritic cells (pDCs). Classical dendritic cells are dedicated 
to antigen processing and different subsets of those cells are identified based on their 
localization and distinct functions [75]. CDCs are the most numerous DC subsets in lymphoid 
organs and can be cultured from the bone marrow or blood cells, such as blood monocytes 
(Table III). They have an enhanced ability to sense tissue injuries, capture and process and 
present antigens to T lymphocytes, inducing immunity to any foreign antigens that breach the 
tissue and enhance tolerance to self-antigens [76]. 
On the other hand, plasmacytoid dendritic cells (pDCs) are found mainly in the blood 
and lymphoid tissues, which acquire the morphology and functional properties of DCs only 
after activation. Plasmacytoid DCs constitute about 0.2 – 0.8% of all human peripheral blood 
cells and are reported to express low levels of MHC-II and co-stimulatory molecules (CD80, 
CD83 and CD86) [75]. In humans, the expression of TLR7 and TLR9 are restricted in pDCs 
and furthermore, the vertebrate immune system has established TLR9 and TLR7 to detect DNA 
and single stranded RNA respectively. Thus, these cells are unique as they produce an abundant 
amount of type I interferons upon the activation of TLR7 and TLR9 signalling pathways [77].  
TLR9 can distinguish between the host (mammalian) and foreign nucleic acids [78], whilst 
TLR7 was identified as receptor for viral single-stranded RNA (ssRNA). Besides the secretion 
of type-I interferon, pDCs are also able to produce other inflammatory cytokines, mainly TNF-
α, IL-6 and IL-12, serving as a bridge between the innate and adaptive immune response. Our 
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study focused on pDCs, as they constitutively express TLR9, remained inert to the exposure of 
some bacterial products such as lipopolysaccharide (LPS), flagellin, etc. [79]. 
 
Features Classical dendritic cells 
(CDCs) 
Plasmacytoid dendritic cells 
(pDCs) 
Surface markers CD11c high; CD11b high CD11c low; CD11b negative 
Expression of TLRs TLRs 4, 5, 8 TLRs 7,9 
Major cytokines 
produced 
TNF-a, IL-6 type I interferons 
Major functions Induction of T cell responses 
against most antigens 
Sense viral and bacterial 
pathogens and release high 
levels of type I interferons in 
response to infection  
Table III. The major subpopulations of dendritic cells. Comparison between CDCs and pDCs 
[Adapted from Abbas et al. [75] ]. 
 
4.4.3. The role of LL-37 in the recognition of nucleic acids 
 
It was documented that LL-37 can bind nucleic acids with high affinity due to an 
electrostatic interaction between anionic phosphate groups of nucleic acids and cationic amino 
acids in the peptide. The consequence is nucleic acid packaging into aggregated and condensed 
structures [80]. DNA-LL-37 complexes with the net positive charges bind to anionic 
proteoglycans followed by lipid raft-mediated endocytosis [81]. The efficient binding of LL-
37 with DNA promotes DNA translocation into the endocytic pathway of pDCs, breaking the 
safety mechanism for discrimination of pathogen derived DNA from self-DNA provided by 
the intracellular localization of TLR9. This allows the DNA-LL-37 complex to be retained in 
the early endosomes triggering TLR9 signalling and results in the production of type I IFNs, 
in a similar way to the anti-viral response. Described above interaction plays important role for 
bacterial DNA recognition. Hurtado and Peh have showed a significant reduction of time 
needed for pDCs to sense the presence of bacterial DNA via TLR9, which is beneficial 
especially when limiting quantities of bacterial DNA are present [82]. It was revealed that 
observed phenomenon plays also a crucial role in the initiation of autoimmune diseases, such 
as psoriasis or systemic lupus erythematosus etc. [32]. Ganguly et al. have also shown similar 
phenomenon for RNA, however in this case the mechanism is slightly different. Authors shown 
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that RNA-LL-37 complexes trigger TLR7 in pDCs and TLR8 in the classical myeloid DCs 
(CDCs) by interacting with heparan-sulfate-containing proteoglycans in the membranes of 
DCs [83].   
 The finding that LL-37 may contribute the delivery of bacterial DNA to the endosomal 
compartment of cells to stimulate TLR9 has opened up possibilities that other cationic peptides 
can share that function. For example, lactoferrin, an identified NET-associated protein [84] 
which is highly cationic and a major component of neutrophil secondary granules [85]. 
Britigan’s studies have showed the cationic N-terminal component of lactoferrin was capable 
to bind a variety of biologically important negatively charged molecules, including 
unmethylated CpG motifs in bacterial DNA, on the basis of a charge-charge interactions [85]. 
 
4.5.  Neutrophil extracellular traps (NETs) 
 
Neutrophils are dominant population of white blood cells, playing bactericidal role and 
thus being classified as the first line of defence against intruders. They use three major 
strategies against microbes, as: phagocytosis, degranulation and generation of neutrophil 
extracellular traps (NETs). NETs are formed by activated neutrophils, which release into 
extracellular milieu DNA structure decorated with components of azurophilic granules. Such 
multidimensional structure can efficiently capture, neutralize and kill a variety of pathogens 
[86]. It is postulated that NETs form a physical barrier against microbial invasion and increase 
the effective concentration of antimicrobial effectors [86]. NETosis can be initiated by different 
stimuli, including chemical compounds, as phorbol 12-myristate 13-acetate (PMA), but also 
selected pathogens and their virulence factors [87].  
The formation of NETs is a multistep process (Fig. 6), which results in generating large 
amounts of reactive oxygen species (ROS) upon the activation of the NADPH oxidase, which 
is the biochemical hallmark in NETosis [86]. Following stimulation, primary or azurophilic 
granules containing neutrophil elastase (HNE) and myeloperoxidase (MPO) are relocated into 
the nucleus. Morphological changes of the cells are the first observation for the event of 
NETosis. Neutrophils start to be flattened and gradually lose their lobes. In the nucleus, HNE 
degrades the linker histone H1 and the core histones, followed by chromatin decondensation 
and activation of PADs (particularly PAD4) which citrullinate histone. PADs are essential for 
NETs formation and their extrusion. It was documented that PAD4-deficient mice and cells 
treated with PAD4 inhibitors formed NETs at low yields. Moreover, PAD4-deficient mice are 
more susceptible to bacterial infections [88]. The loss of negative charge via citrullination 
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causes the uncoiling of heterochromatin, leading to the disintegration of nuclear and granular 
membranes, where the nucleoplasm and cytoplasm fused together. In this process, DNA is 
decorated with AMPs and proteins such as elastase and MPO, forming NETs complexes. 
Finally, the cytoplasmic membrane breaks and DNA is released in the form of thin filaments 
[89] (Fig. 6).  
 
 
Fig. 6. Stages of NETs formation. The production of ROS followed by (1) the transportation 
of elastase and MPO to the cell core, (2) histone modification by PAD4, (3) the rupture of the 
cytoplasmic membrane and (4) the release of chromatin. The figure was created with images 
adapted from Servier medical art by Servier [Adapted from Sorensen and Borregaard [90] ]. 
 
As NETs formation is considered beneficial during infectious process it can cause host 
cell damage too. It is postulated that large amount of neutrophil extracellular content being 
released upon septic or non-septic inflammation can lead to an autoimmune disorder. It was 
reported that NETs constitute a rich source of autoantigens. The reason for this is expression 
and activity of PAD, which catalyses the generation of a myriad of citrullinated 
proteins/peptides, which have significant effect on human health. Recent investigation has 
reported that about 84% of NETs components were identified as autoantigens in patients with 
autoimmune diseases (such as SLE, RA, vasculitis) [91]. Apart from playing an important role 
in modification of autoantigens, the generation of NETs may induce a potent activation of 
immune cells. The mechanism relies on formation of a complex between cationic molecules 
and DNA both derived from invaders or host. The consequence is accelerated stimulation of 
phagocytes or B cells [32]. 
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4.5.1. Neutrophil extracellular traps (NETs) and LL-37 
 
Neutrophil extracellular traps are decorated with bactericidal proteins such as LL-37, 
defensins, histones, elastase and MPO. The high levels of extracellular self-DNA complexed 
with LL-37 can activate TLR9 in pDCs, resulting in a robust release of interferon-α (Fig. 7), 
as reported by Lande et al. [32] in lupus patients. Self-DNA is unable to induce type I IFN 
production until it is combined with LL-37. Such interaction is responsible for the breach in 
the innate tolerance by converting self-DNA from being immunologically inert into a potent 
activator of host phagocytes. Generation of the complex with LL-37 allows for accelerated 
recognition and engulfment of DNA into endosomal compartments (Fig. 7). Moreover, such 
interaction efficiently protects the nucleic acids from extracellular degradation executed by 
circulating nucleases.  
There is a mutual relationship between NETs formation and production of IFN-α. 
Neutrophil priming by type I IFN causes phagocytes to be more responsive to external stimuli, 
augmenting the NETs formation. The SLE is characterized by the chronic activation of pDCs 
and production of autoantibodies directed against nuclear self-antigens such as nucleic acids. 
Lupus patients develop autoantibodies to LL-37 and self-DNA, which bind NETs (containing 
DNA complexed with LL-37) to form immune complexes (ICs), which are efficiently taken up 
by pDCs via the Fc receptor for IgG (FcgRIIA) and thereafter translocated to TLR9-containing 
endosomal compartments (Fig. 7) [31]. The chronic activation of plasmacytoid dendritic cells 
by these immune complexes is known to be the early trigger for autoimmunity in patients with 
SLE or psoriasis [92]. Moreover, the findings of Lande et al. and Garcia-Romo et al. has led 
to the prediction on the generation of anti-LL-37 autoantibodies that activate neutrophils and 
subsequently trigger the event of NETosis that releases the complexes containing DNA and 
antimicrobial peptide (LL-37), providing the feedback mechanism between NETs and 
secretion of type I IFN. This has indicated that the accelerated formation of LL-37-DNA 
complexes in NETs plays a role of potent stimulators of pDCs [32][42]. 
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Fig. 7. The model for breakdown of innate tolerance to self DNA. LL-37 facilitates the 
nucleic acid delivery across membrane and activates intracellular TLR9 and enhanced the 
production of interferon-α. In SLE, autoantibodies produced by autoreactive B cells bind to 
self-DNA-LL-37 complexes and translocate into TLR9-containing endosomes in pDCs 
through Fc receptor for IgG (FcgRIIA) [Adapted from Lande et al. [93] ]. 
 
Apart from triggering type I IFNs production in pDCs, DNA-LL-37 complexes found 
in NETs can directly activate human memory B cells (mBC) in lupus patients. The high 
immunogenic DNA-LL-37 complexes trigger polyclonal B cell activation via TLR9 with IgG 
production. NETs in lupus patients also led to the activation of self-reaction B cells that 
produce antibodies against LL-37 which are potent inducers of NETosis, creating a feedback 
loop. Besides that, NETs can induce NET-specific mBC of lupus patients as there was an 
increased frequency of NET-specific B cells in these patients compared to healthy individuals 
[94]. 
Besides dendritic cells, the inflammatory potential of NETs has been documented 
towards macrophages. Kahlenberg et al. observed the activation of the NALP3 inflammasome 
by lupus NETs and NET associated LL-37 in LPS-primed macrophages. This stimulation likely 
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leads to a self-perpetuating cycle of enhanced IL-1b and IL-18 production that promotes 
inflammation and NETosis [30]. 
As described above LL-37 is a molecule that plays the important role in the regulation 
of DNA recognition by host cells. As a component of NETs, structure characterized with high 
activity of PAD, is highly possible that LL-37 undergoes deimination changing the function of 
the peptide. Therefore, studies presented in my thesis are focused on that topic. 
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5.  Aims of this study  
 
 Post-translational modifications play an important role in the regulation of innate 
immunity. Several studies have reported their association with the development of 
inflammatory diseases, with the emphasis on citrullination process catalysed by peptidyl 
arginine deiminases [57][61]. The only human cathelicidin – peptide LL-37 consists five Arg 
residues, which are efficiently modified by PAD enzymes. As documented recently, 
deimination of LL-37 abolished the protective role of the peptide against endotoxin [67]. 
Therefore, presented study is focused on another immunological pathway effectively 
modulated by LL-37, which is formation of complexes with nucleic acids and subsequent 
activation of inflammatory response manifested by interferon type I pathway activation. 
Therefore, in the study we examined how citrullination of LL-37 affects the 
immunostimulatory potential of cell-free DNA. 
 
The particular aims of this study were as follows: 
1. To determine the efficiency and specificity of LL-37 deimination on the binding of 
nucleic acid.  
2. To determine the role of LL-37 citrullination on sensitization of TLR9 positive cells to 
DNA.  
3. To identify the presence of citrullinated LL-37 in vivo. 
4. To study the effect of LL-37 citrullination on immunomodulatory potential of NETs. 
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6.  Materials and Methods 
 
6.1. Materials 
 
6.1.1. Primary cells and cell lines 
 
Name Source 
Macrophages, plasmacytoid dendritic cells, neutrophils Blood from healthy 
human volunteers was 
obtained from Regional 
Blood Centre, Krakow, 
Poland. Description of the 
isolation methods is as 
per methods section 6.2.8. 
and 6.2.16. 
RAW264.7 (murine macrophage cell line) Obtained from ATCC 
(American Type Culture 
Collection) HeLa cell line (epithelial cells from human cervix) 
 
 
6.1.2. Human probes 
 
Name Source 
Inflamed sera and synovial fluid obtained from rheumatoid 
arthritis patients for the estimation of LL-37 half-life in 
biological fluids 
 
Courtesy of Piotr Mydel, 
Ph.D., MD.  
Sera from periodontitis, RA patients or patients with both 
diseases (periodontitis and RA) and control donors 
(patients without RA and periodontitis) for identification 
of antibodies against LL-37 and citrullinated LL-37 
 
Courtesy of Prof. Sigrun 
Eick, Ph.D., D.D.S. 
 
 
6.1.3. Reagents for cell cultures  
 
Reagents Source 
Autologous plasma Isolated from human 
peripheral blood from 
healthy donor 
BD IMAGTM buffer BD Biosciences 
Black 96-well microplates Thermo Fisher Scientific 
Dulbecco’s Phosphate Buffered Saline (DPBS - without 
calcium and magnesium) 
 
Gentamicin (50 mg/mL) 
Gibco DMEM (with High Glucose, i-Glutamine, HEPES) 
With/without Phenol Red 
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Gibco RPMI-1640 with L-glutamine 
Heat Inactivated Fetal Bovine Serum (FBS) 
BD IMagTM Human Dendritic Cell Enrichment Set BD Biosciences 
Lymphocyte Separation Medium (LSM 1077) PAA 
Penicillin-Streptomycin Solution (10,000 units Penicillin, 
10 mg Streptomycin/ml) (PEST) 
Sigma Aldrich 
Poly-D lysine Sigma Aldrich 
Polyvinyl alcohol (PVA) POCh 
 
 
6.1.4. Reagents for cell stimulation 
 
Name Source 
CpG oligodeoxynucleotides (ODN 2216) 
(5’ -ggGGGACGA:TCGTCgggggg- 3’) 
Hycult Biotech 
Cytochalasin D Sigma Aldrich 
Different variants of carbamylated LL-37*  The peptides were 
synthesized by 
ProImmune as per Koro 
et al. [51]. 
FITC labelled CpG (ODN 2216) 
(5’ -ggGGGACGA:TCGTCggggggFITC- 3’) 
InvivoGen 
Lipopolysaccharide from E. coli O111:B4 Sigma Aldrich 
Native LL-37, CRAMP, scrambled LL-37 (sLL-37), LL-
37 with arginine residues substituted by homoarginine 
(hArg-LL-37), different variants of the citrullinated 
peptide*  
The peptides were 
synthesized by Jan Pohl 
(Division of scientific 
resources, Centers for 
Disease Control and 
Prevention)  
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich 
* Sequences of the peptides is as per section 6.1.20 
 
 
6.1.5. Reagents for transduction of RAW264.7 
 
Name Source 
Cignal Lentiviral particles containing NF-kB luciferase 
reporters 
SA Biosciences 
Luciferase reporter assay system Promega 
Puromycin Gibco 
SureEntry transduction reagent Qiagen 
Opaque 96-well plate PerkinElmer 
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6.1.6. Bacteria 
 
Name Source 
Staphylococcus aureus (Newman) Collection of laboratory 
strains, Department of 
Microbiology, WBBiB, 
UJ 
 
 
6.1.7. Reagents for bacteria cultures  
 
Reagents Source 
Agar BioShop 
Tryptic Soy Broth (TSB) Fluka 
 
 
6.1.8. Reagents for in vitro citrullination of LL-37 
 
Reagent Source 
Recombinant human PAD2 or PAD4 Modiquest 
 
 
6.1.9. Reagents for genomic DNA isolation 
 
Reagent Source 
Genomic mini kit A & A Biotechnology 
Nuclease-free water Thermo Fisher Scientific 
 
 
6.1.10. Reagents for PCR  
 
Reagents Source 
dNTP mix Thermo Scientific 
Kit: PCR purification A&A Biotechnology 
Starters (sequences as per section 6.2.1.) Genomed 
Taq buffer KCl Thermo Scientific 
Taq DNA Polymerase Thermo Scientific 
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6.1.11. Reagents for electrophoretic mobility shift assay (EMSA) 
 
Reagents Source 
Agarose, Biotechnology Grade Bioshop 
Ethidium Bromide Sigma Aldrich 
GeneRulerTM Low Range DNA Ladder Thermo Fisher 
Scientific 
 
 
6.1.12. Reagents for fluorescence measurement and   
            immunocytochemistry 
 
Reagents Source 
Alexa-Fluor-647 goat anti-mouse antibody Jackson 
ImmunoResearch 
Laboratories 
Fluorescence Mounting Medium Dako 
Hoechst 33342 Molecular Probes 
Human Monoclonal Anti-LL-37/CAP18 Hycult Biotech 
Paraformaldehyde PoCh 
QuantiTTM PicoGreen® dsDNA Reagent Life Technologies 
Saponin Sigma Aldrich 
 
 
6.1.13. Reagents for measuring protein concentration 
 
Reagents Source 
Bicinchoninic Acid Protein Assay Kit (BCA) Thermo Fisher 
Scientific 
 
 
6.1.14. Reagents for SDS-PAGE and Western blot 
 
Reagents Source 
Acrylamide BioShop 
Ammonium Persulfate (APS) BioShop 
Anti-modified citrulline detection kit EMD Millipore 
Glycerol Sigma Aldrich 
Glycine ICN Biomedicals 
Methanol 99.9% PoCh 
N,N,N’,N’-tetramethyletyleneidamine (TEMED) Sigma Aldrich 
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N,N’-Methylenebisacrylamide Sigma Aldrich 
Ovalbumin Sigma Aldrich 
PageRuler™ Plus Prestained Protein Ladder Thermo Fisher 
Scientific 
Pierce™ ECL Western Blotting Substrate Thermo Fisher 
Scientific 
Pierce™ Lane Marker Reducing Sample Buffer Thermo Fisher 
Scientific 
Polyvinylidene difluoride (PVDF) membrane Amersham 
Sheep Anti-Mouse IgG, HRP conjugate Sigma Aldrich 
Skimmed Milk Bioshop 
Sodium Dodecyl Sulphate (SDS) ICN Biomedicals 
Tricine BioShop 
Tris Bioshop 
 
 
6.1.15. Reagents for ELISA 
 
Reagents Source 
Human LL-37 ELISA kit Hycult Biotech 
OptEIA Human IL-6 ELISA kit BD Biosciences 
 
OptEIA Human IL-1b ELISA kit 
OptEIA Mouse TNF-a ELISA kit 
VeriKine Human IFN-a kit PBL Interferon Source 
TransAM® IRF7 ELISA kit Active Motif 
TransAM® NF-kB ELISA kit Active Motif 
Nunc-ImmunoTM strip with MaxisorpTM surface 
Thermo Fisher 
Scientific 
Peroxidase-conjugated mouse anti-human IgG Genscript 
Sodium Bicarbonate PoCh 
Sodium Carbonate PoCh 
Sulphuric Acid  PoCh 
TMB Substrate Reagent Set BD Biosciences 
Tween-20 BioShop 
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6.1.16. Reagents for RNA isolation and cDNA synthesis 
 
Reagents Source 
Chloroform  PoCh 
Ethanol PoCh 
Isopropanol PoCh 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 
RNase-free water BioShop 
Starters (sequences as per section 6.2.28.) Genomed 
SYBRTM Green JumpStartTM Taq ReadyMixTM 
Sigma Aldrich 
TRIzol Reagent Sigma Aldrich 
 
 
6.1.17. Other chemicals 
 
Chemicals Source 
1,4-dithiothreitol (DTT) Biomol 
Acetate PoCh 
Acetic Acid 99% POCh 
Bovine Serum Albumin (BSA) Bioshop 
Calcium Chloride (CaCl2) PoCh 
Dimethyl Sulfoxide (DMSO) Sigma Aldrich 
RNase-free DNase I Promega 
Ethylenediaminetetraacetic acid (EDTA) Bioshop 
Hydroxyethyl piperazineethane sulfonic acid (HEPES) Sigma Aldrich 
L-Citrulline Sigma Aldrich 
Na-deoxycholate Sigma Aldrich 
Na-HEPES Sigma Aldrich 
Nonyl phenoxypolythoxylethanol (NP-40) Sigma Aldrich 
Phenylmethylsulfonyl fluoride (PMSF) Thermo Fisher 
Scientific 
Sodium Chloride (NaCl) POCh 
Trichloroacetic Acid Sigma Aldrich 
Triton X-100 Bioshop 
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6.1.18. List of equipment 
 
Equipment Trade Name Company 
Bright Field Microscope Hund Wilovert S 30 Helmut Hund 
GmbH 
Cell separation magnet BD IMAGNETTM BD Biosciences 
Centrifuges Heraeus Multifuge X1R 
Heraeus Fresco 21 microcentrifuge 
 
Thermo Scientific 
Electrophoresis apparatus Mini-PROTEAN II 
 
BioRad 
Flow cytometer BD FACSCaliburTM BD Biosciences 
Immunofluorescence 
Microscope 
Nikon Eclipse Ti Nikon 
Gel Imaging Gel DocTM EZ System BioRad 
Heat Block ThermoBlock TB941U JW Electronic 
Incubator HeraCell 150 Haraeus 
Laminar flow hood SafeFlow 1.2 BioAir Instruments 
Microplate reader FlexStationTM 3 Multi Mode 
microplate reader 
Molecular Devices 
NanoDrop NanoDropTM 1000 Thermo Scientific 
pH meter Lab 850 Global Water 
Instrumentation 
Real-Time Thermal 
Cycler 
CFX96 Touch™ Real-time PCR 
Detection System 
BioRad 
Spectrophotometer Cecil CE 3021 Cecil Instruments 
Thermocycler Tprofessional TRIO thermocycler Biometra 
 
 
6.1.19. Buffers 
Anode Buffer for SDS-PAGE: 200 mM Tris; pH 8.9 
Blocking buffer for ELISA: 2% BSA in PBS 
Blocking buffer for membrane: 3% BSA in TTBS 
Buffer for gel SDS-PAGE (Schagger/Von Jagow): 3 M Tris, 0.3% SDS; pH 8.45 
Cathode Buffer for SDS-PAGE: 100 mM Tris, 100 mM Tricine, 0.1% SDS; pH 8.25 
EB Buffer for nuclear extractions: 0.35 M NaCl, 5 mM EDTA, 1 mM DTT, 10 mM Na-
Hepes, 0.2 mM phenylmethylsulfonyl fluoride (PMSF)  
Electrotransfer buffer for Western blot: 25 mM Tris, 192 mM Glycine, 20% Methanol 
PAD assay buffer: 100 mM Tris-HCl, 5 mM CaCl2, 5 mM DTT; pH 7.6 
RIA buffer: 1% BSA, 350 mM NaCl, 10 mM Tris-HCl, 1% Triton X-100, 0.5% Na-
deoxycholate, 0.1% SDS; pH 7.6 
RSB buffer for nuclear extractions: 10 mM NaCl, 3 mM MgCl2, 10 mM Tris (pH 7.5), 0.2 
mM (PMSF)  
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TAE buffer for EMSA: 40 mM Tris, 20 mM Acetate, 1 mM EDTA 
TBS: 1 M Tris, 3 M NaCl; pH 7.5 
TE buffer: 10 mM Tris, 1 mM EDTA; pH 8.0 
TTBS: 20 mM Tris, 500 mM NaCl, 0.05% Tween-20; pH 7.5 
Washing buffer for ELISA: 0.05% Tween-20 in PBS 
 
 
6.1.20. Sequences of the peptides used in this study 
Peptide Sequence 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 
LL-377 LLGDFF(Cit)KSKEKIGKEFKRIVQRIKDFLRNLVPRTES 
LL-377,29 LLGDFF(Cit)KSKEKIGKEFKRIVQRIKDFL(Cit)NLVPRTES 
LL-377,29,34 LLGDFF(Cit)KSKEKIGKEFKRIVQRIKDFL(Cit)NLVP(Cit)TES 
LL-37all cit. LLGDFF(Cit)KSKEKIGKEFK(Cit)IVQ(Cit)IKDFL(Cit)NLVP(Cit)TES 
LL-37K1 LLGDFFR(e-carb-K)SKEKIGKEFKRIVQRIKDFLRNLVPRTES 
LL-37K2 LLGDFFRSKE(e-carb-K)IG(e-carb-K) 
EFKRIVQRIKDFLRNLVPRTES 
LL-37K3 LLGDFFRKSKEKIGKEFKRIVQRI(e-carb-K)DFLRNLVPRTES 
sLL-37 RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL 
hArg-LL-
37 
LLGDFF(hR)KSKEKIGKEFK(hR)IVQ(hR)IKDFL(hR)NLVP(hR)TES 
CRAMP GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ 
CRAMPcit. GLL(Cit)KGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ 
Modified residues (Cit, e-carb-K, and hR) are shown in bold. 
e-carb-K, lysine carbamylated on the e-carb; cit, citrullinated arginine; hR, homoarginine 
(hArg) 
 
 
6.2.  Methods 
 
Biochemical analysis 
 
Concentrations mentioned in this section are the final concentrations of the respective 
compounds. 
 
 
6.2.1. Amplification of bacterial DNA  
  
Genomic DNA of Tannerella forsythia, which was used as a template for the PCR assay, 
was a kind gift from Danuta Mizgalska, Ph.D. Concentration of nucleic acids was quantified 
with NanoDrop before performing PCR. PCR was conducted using 20 µl reaction mixture, 
which consisted of 20 ng of template DNA, 2 µl of Taq buffer KCl, 1.5 µl of 2 mM mixed 
dNTPs, 0.5 µl Taq DNA Polymerase and 10 µM of forward (5’-
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CTCGTAGTGTGCCTTCTTCCAC-3’) and reverse (5’-GCCTGATCGGCATTCATTCGG-
3’) primers. PCR was performed with the following conditions: initial denaturation at 95°C for 
3 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 53°C for 
20 seconds, extension at 72°C for 30 sec and final extension at 72°C for 5 minutes. Then, the 
spin column-based PCR purification was performed as per the manufacturer’s instructions. A 
5:1 ratio of binding solution was added to the PCR product prior transferring the sample onto 
minicolumn, which consists silica membrane. Minicolumn attaching to the tube was 
centrifuged for 30 sec at 16,100 x g. The flow-through in the tube were discarded before 
attaching the minicolumn to the same tube. The DNA binds to the silica membrane and 
contaminants were washed away by following washing steps: 600 µl of wash solution was 
added to the minicolumn before the centrifugation at 16,100 x g for 30 seconds. The flow-
through was discarded and this step was repeated twice before the final centrifugation at 16,100 
x g for 2 minutes. The minicolumn was then placed into a new 1.5 ml eppendorf tube. Thirty 
µl of nuclease-free water was added to the silica membrane and DNA bound to the silica 
membrane was harvested by collecting the eluent after 1 minute of centrifugation at 16,100 x 
g. The pure DNA was quantified with NanoDrop to determine its concentration. 
 
6.2.2. Isolation of HeLa genomic DNA 
  
HeLa cells were grown in culture medium (DMEM supplemented with 10% FBS and 
50 µg/ml PEST (penicillin/streptomycin) at 37°C in a humidified 5% CO2 atmosphere. To 
isolate genomic DNA from HeLa cells, the culture was first trypsinized after washing the cells 
with PBS, and then centrifuged for 10 min at 4°C, 280 x g. The cell pellet was resuspended in 
fresh culture medium and number of cells were counted using Fuchs-Rosenthal 
haemocytometer as described in section 6.2.9.  
Genomic DNA of the HeLa cell line was isolated using the Genomic Mini kit as 
according to the manufacturer's instructions. The genomic DNA was isolated from one million 
of cells, which were resuspended in 100 µl Tris buffer with 200 µl lysis buffer and 20 µl 
proteinase K, which were all provided in the kit. The sample was incubated for 20 min at 37°C, 
followed by 5 min at 70°C. Next, the sample was vortexed for 20 sec and centrifuged for 3 min 
at 13,200 x g at 4°C. Supernatant was collected and transferred to a microcolumn for genomic 
DNA purification, followed by centrifugation at 13,200 x g for 1 min at 4°C. Then 500 µl of 
the rinsing solution was added to the DNA bound to the column bed and centrifuged for 1 min 
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at 13,200 x g, 4°C. Subsequently, the microcolumn was moved to a new tube and 400 µl of 
rinse solution was added to the microcolumn. After 2 min of centrifugation at 13,200 x g, 4°C, 
the dried microcolumn was placed in a new 1.5 ml eppendorf tube and 200 µl of DNase-free 
water which was preheated to 75°C was added to the microcolumn. After 5 min incubation at 
room temperature, the sample was centrifuged for 1 min at 13,200 x g, 4°C. Finally, the 
microcolumn was removed and the purified genomic DNA contained in the eppendorf tube 
was stored at -20°C. The concentration of the isolated genomic DNA was measured using the 
Nano Drop 1000 device. 
 
6.2.3. In vitro citrullination of LL-37 
  
To determine the process of LL-37 citrullination, peptide was incubated with either 
recombinant human PAD2 or PAD4. The in vitro citrullination of native LL-37, CRAMP, 
scrambled LL-37 (sLL-37), hArg-LL-37 and carbamylated LL-37 (K1-K3) was performed 
according to the previously described protocol [67]. Briefly, peptides were diluted to a 
concentration of 1 mg/ml in PAD assay buffer and incubated with either recombinant human 
PAD2 or PAD4 at concentration of 23 U/mg, for different time points (0, 15, 30, 120 minutes 
or just 120 minutes for CRAMP, sLL-37, hArg-LL-37 and carbamylated LL-37) at 37°C. 
Citrullination was terminated by freezing.   
 
 
6.2.4. Gel retardation assay 
  
The interaction of LL-37 and DNA was evaluated with a gel retardation assay. 
Complexes of nucleic acid with the peptide were generated as described by Chuang et al. [95]. 
PCR product obtained from T. forsythia genomic DNA as described in 6.2.1. was mixed with 
either the synthetic native or modified forms of LL-37 or CRAMP at a 1:5 molar ratio 
(DNA:peptide) and incubated at room temperature for 10 minutes. The complex formation was 
determined with a gel retardation assay by running probes on 1.5 % agarose gel. 
 
6.2.5. Spectra analysis 
 
Another approach to evaluate the complex formation between DNA and LL-37 was 
based on the fluorescence of nucleic acid as described by Lande et al. [32]. Complexes were 
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generated as mentioned above (section 6.2.4.). The complexes were treated with diluted Quant-
iT PicoGreen dye solution (1:200) according to manufacturer’s instructions and the amount of 
unbound DNA was analyzed across a spectrum of wavelengths 500 nm - 600 nm after 
excitation at 480 nm. 
 
6.2.6. Surface plasmon resonance (SPR) 
  
Surface Plasmon Resonance used for more detailed and quantitative studies of 
interaction between DNA and LL-37 (native and different modified forms) was performed by 
Prof. Maria Rąpała-Kozik, Ph. D. from the Department of Comparative Biochemistry and 
Bioanalytics, FBBB, Jagiellonian University. Selected fragment of DNA (5’ 
ggGGGACGA:TCGTCgggggg- 3’), biotinylated at the 5′ end of the antisense strand (Bt-DNA) 
was immobilized on the streptavidin (SA) sensor chip (GE Healthcare) with streptavidin 
covalently attached to the dextran. For the immobilization, the sensor surface was pre-treated 
according to the manufacturer’s instruction and the solution of Bt-DNA (0.05 ng/µl) in 0.5 M 
NaCl was injected into the cell at a flow rate of 2 µl/min for 7 minutes.  The chip surface was 
then washed with subsequent solutions of 0.5 M NaCl, 1 M NaCl and 0.1% SDS, for 3 minutes 
each at a flow rate of 20 µl/min to remove the non-specifically bound ligand. Further 
conditioning of the chip surface was performed with the running buffer (10 mM HEPES, 150 
mM NaCl, pH 7.4 with 0.05% P20 surfactant) until a stable baseline signal was obtained. The 
amounts of coupled DNA correspond to 210 response units (RU). A flow cell without DNA 
was used as a reference. For the binding experiments a series of native and different variants 
of the modified LL-37 peptide samples were prepared by dilution of 100 µM peptide stock 
solution in running buffer. In some experiments, ApoA-1 was mixed with native and different 
variants of the modified LL-37 peptide samples ranging from 0 – 20 µM. The samples were 
injected over the sensor surface at 30 µl/min flow rate using 2 minutes interval for association 
and for dissociation process. The surface regeneration with 1 M NaCl for 30 seconds was 
performed after each sample injection. Mass transfer effects did not influence the LL-37 
binding. The collected data were analysed using BIAevaluation software version 4.1 (Biacore). 
 
6.2.7. DNase protection assay 
  
Free DNA is susceptible to degradation by DNases. However, the electrostatic 
interaction of DNA and LL-37 has provided the possibility of protection of these condensed 
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particles against extracellular enzymatic degradation [83]. To verify the protection of DNA by 
its binding to peptide we applied the assay published by Lande et al. [32]. For that purpose, 
mixtures of isolated HeLa DNA with either LL-37 or LL-377 prepared as described above 
(section 6.2.4) were treated with 100 U/ml DNase A (A&A Biotechnology) for 60 min at 37°C, 
followed by inactivation of the enzyme by incubating the samples at 75°C for 10 minutes. The 
protection from extracellular degradation was analyzed as described in 6.2.18. with Quant-iT 
PicoGreen, upon excitation at 480 nm and emission at 520 nm. 
 
In vitro studies 
 
6.2.8. Cell cultures 
  
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy human 
EDTA-treated blood, collected from Regional Blood Centre (Krakow, Poland), using density 
gradient centrifugation. Blood cells were first separated from plasma by centrifuging at 400 x 
g for 12 min at 20°C. Plasma was collected and centrifuged for 15 min, 3,000 x g at 20°C. 
Supernatant was collected and this was followed by incubation at 56°C for 30 minutes. The 
clean autologous plasma was obtained by another centrifugation at the same condition (3,000 
x g/ 15 min/ 20°C). Whilst phosphate-buffered saline (PBS) was added to the blood and the 
diluted cell suspension was carefully layered over 15 ml of lymphocyte separation medium 
before centrifuging at 400 x g for 35 min at 20°C. Whitish buffy coats were collected into 
RPMI containing 1% Fetal Bovine Serum (FBS) and cell pellet was obtained by centrifuging 
at 350 x g for 12 min at 20°C. Then, cells were overlaid on FBS and centrifuged at 280 x g for 
10 min at 20°C. After the final centrifugation, cells were resuspended in RPMI supplemented 
with 2 mM L-Glutamine, 10% of the autologous plasma and 50 µg/ml gentamicin. Three 
million PBMCs/well were seeded on 24-well plate and incubated overnight at 37°C in a 
humidified 5% CO2 atmosphere. Non-adherent cells were removed next day by washing with 
PBS and fresh media (RPMI supplemented with 2 mM L-Glutamine, 10% of the autologous 
serum and 50 µg/ml gentamicin) were replaced for each well. Adherent monocytes 
differentiated within one week into monocyte-derived macrophages (hMDMs).  
Isolated PBMCs were also used to obtain plasmacytoid dendritic cells (pDCs) with BD 
IMAGTM Cell Separation System (BD Biosciences). Firstly, clumps of cells from PBMCs were 
removed by passing the suspension through a 70 µm nylon cell strainer. The suspension was 
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centrifuged at 300 x g for 10 min at 4°C to remove the media and cells were resuspended in 
BD IMAGTM buffer (commercialized buffer containing bovine serum albumin, EDTA, and 
sodium azide in PBS - recommended for optimal cell separation) at the concentration of 5 x 
107 cells/ml. Next, Human Dendritic Cell Enrichment Cocktail from BD IMagTM Human 
Dendritic Cell Enrichment Set was added to the cell suspension with the amount of 5 µl per 1 
x 106 cells. After 15 min incubation at room temperature the labelled cells were washed with 
10 times excess volume of BD IMAGTM buffer, followed by centrifugation at 300 x g for 7 
min at 4°C. Cell pellet was resuspended with BD IMAGTM Streptavidin Particles Plus at the 
amount of 7.5 µl of particles per 1 x 106 cells and incubated for 30 min at room temperature. 
BD IMAGTM buffer was added up to the volume of 1 ml, the labelled cells were transferred to 
a 12 x 75 mm round bottom test tube and placed on the BD IMagnetTM for 7 minutes. 
Supernatant was collected into new sterile tube and 1 ml of BD IMAGTM buffer was added to 
resuspend the pellet carefully. Then, the tube was placed again on the BD IMagnetTM for 7 
minutes. This process was repeated twice and to increase the purity of the cells, the tube 
containing collected supernatant was placed on the BD IMagnetTM for 10 min before 
centrifugation at 300 x g for 10 min at 4°C. Cell pellet was resuspended with RPMI containing 
10% FBS and 50 µg/ml of gentamicin. Eighty thousand cells were seeded per well of 96 round-
bottom plate followed by centrifugation at 300 x g for 10 min at 4°C before proceeding with 
the stimulation.  
 RAW264.7, a murine macrophage cell line, was maintained in DMEM supplemented 
with 10% FBS and 50 µg/ml PEST (penicillin/streptomycin) at 37°C in a humidified 5% CO2 
atmosphere. Cells were passaged, when they reached 60-75% of confluence on the flask by 
detaching them using a cell scraper. Then the cell suspension was collected and centrifuged at 
280 x g for 10 min at 4°C. Obtained cell pellet was resuspended in fresh media and cells were 
seeded in the flask for further cultivation or in 96-well plate when used for experiments with 
the cell concentration of 0.2 x 106 cells/well.  
 
6.2.9. Counting of cells and cell viability 
  
Trypan blue exclusion method was used for cell count and to determine the cell viability. 
Trypan blue (180 µl) was added to 20 µl of cell suspension and next 20 µl of the mixture was 
transferred to Fuchs-Rosenthal haemocytometer, where the non-stained viable cells were 
calculated under the bright field microscope.  
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6.2.10. Cell stimulation with DNA – LL-37 complexes 
  
Mixture of CpG (final concentration 3 µM) and different forms of modified LL-37 
(final concentration 6.4 µM) was first incubated in PBS 10 min prior to cell stimulation. 
Plasmacytoid DCs were seeded at 0.8 x 105 cells/well in 200 µl of complete medium (RPMI 
1640 medium supplemented with 10% FBS and 50 µg/ml gentamicin) and stimulated with 
CpG:peptide mixtures overnight or for 15 minutes, before their washing with PBS (3 times), 
followed by overnight incubation in fresh complete medium at 37°C in a humidified 5% CO2 
atmosphere. Supernatant was collected for further analysis with ELISA and cell morphology 
was visualized with bright-field microscopy. Murine macrophages RAW264.7 were seeded in 
a density 0.2 x 106 cells/well of 96–well plate. Next day adherent cells were washed with PBS, 
fresh medium was added followed by CpG:peptide mixtures stimulation as described above 
for pDCs. 
 
6.2.11. Internalization of DNA upon interaction with LL-37 
  
To study the uptake of DNA by phagocytes in the presence of LL-37 and its modified 
forms, flow cytometry analysis was applied. RAW264.7 (2 x 106 cells/well) or isolated 
plasmacytoid DCs (0.8 x 105 cells/well) was incubated with mixtures of FITC-labelled CpG (3 
µM) and native/fully citrullinated LL-37 respectively (6.4 µM) for 15 min before washing the 
cells three times with PBS. The cell pellet was resuspended with cold PBS before FACS 
analysis. The uptake of the mixtures was determined by measuring the fluorescence intensity 
with flow cytometry (BD Biosciences). The mean fluorescence intensity and percentage of 
positive cells labelled with FITC-conjugated CpG were measured. In some experiments, 
cytochalasin D (5 µM), used to study the phagocytosis inhibition, was added for 30 min before 
the treatment of plasmacytoid DCs with complexes CpG-peptide. 
 
6.2.12. Transduction of RAW264.7 cells and NF-κB activity measurement 
  
To investigate the activation of NF-κB transcription factor following cell stimulation 
with CpG:peptide mixtures we used RAW264.7 cells expressing inducible reporter constructs 
for NF-κB and luciferase gene as an indicator of the signal transduction activity. Transduction 
of cells was performed with CignalTM Lenti NF-κB Reporter systems by SA Biosciences. 
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Selection of successfully transduced cells was based on their resistance to puromycin. 
RAW264.7 cells were seeded in 24-well plate with the concentration of 0.1 x 106 cells/well in 
DMEM supplemented with 10% FBS. Next day cells were infected with MOI 1:50 of CignalTM 
lentiviral particles in DMEM supplemented with 10% FBS. Eight µg/ml of SureENTRYTM 
transduction reagent was added to enhance transduction efficiency. Transduction medium was 
removed after overnight incubation and 1 ml of fresh medium supplemented with 4 µg/ml of 
puromycin was added to each well. Next day, floating cells were discarded and adherent 
(transduced) cells were harvested by scraping in fresh medium before their transferring to cell 
culture flask. Transduced cells were incubated in DMEM supplemented with 10% FBS and 4 
µg/ml of puromycin for 3 days and fresh culture media (DMEM/ 10% FBS/ 4 µg/ml of 
puromycin) were replaced until further use. 
 For analysis of NF-κB activity, transduced RAW264.7 cells were seeded on opaque 96-
well plate (0.2 x 106 cells/well) and incubated overnight. Then, 20 µl of CpG:peptide mixtures 
(prepared as described in section 6.2.10) were added and incubate for 6 h. Activation of NF-
kB was measured with luciferase assay system as per manufacturer’s instructions. Cells were 
first lysed with 20 µl of cell culture lysis reagent provided in the kit followed by the addition 
of 100 µl luciferase assay reagent to each well. Luciferase activity was measured instantly with 
luminometer (FlexStation 3, Molecular Devices).  
 
6.2.13. Enzyme linked immunosorbent assay (ELISA)  
  
Commercialized sandwich ELISA (BD OptEIA™, US) kits were used to quantify 
cytokines (murine TNF-a, human IL-6, human IL-1b) secreted by phagocytes. Briefly, wells 
of Nunc-ImmunoTM strip with MaxiSorpTM surface were coated with capture monoclonal 
antibody specific for murine TNF-a, human IL-6 and human IL-1b respectively. The plates 
were incubated overnight at 4°C and excess capture antibody was removed by washing three 
times with PBS containing 0.05% Tween-20 (washing buffer). Non-specific peptide binding 
was blocked by incubating each well with assay diluent (PBS supplemented with 10% FBS) 
for 2 hours, followed with three times washing. Samples and standards were prepared in assay 
diluent. Multiple dilutions with concentration suggested by the manufacturer were prepared. 
Standards and samples were incubated for 2 h and unbound cytokine was washed away with 
washing buffer for 5 times. Biotinylated anti-mouse TNF-a, human IL-6 and human IL-1b 
conjugated with avidin-horseradish peroxidase (HRP) was added to each well respectively and 
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incubated for 1 hour. After 7 washes, chromogenic substrate solution of tetra-methylbenzidine 
(TMB) was added and incubated in dark. Reaction was stopped adding 1 M H2SO4. The colour 
intensity of developed colour was proportional to the amount of cytokine present in the samples 
measured at 450 nm within 30 minutes, using the standard curve as a reference. 
 Type I IFN-a from cell supernatant was measured by ELISA using VeriKine Human 
IFN-a kit. Standards and samples were prepared with provided dilution buffer and added to 
each well, which was pre-coated with monoclonal antibody specific for human IFN-a. After 1 
h of incubation at room temperature, wells were washed once with provided wash solution and 
diluted detection antibody was added to each well as according to manufacturer’s instructions. 
Next, wells were washed three times with washing solution and incubated with diluted HRP 
solution (prepared as according to manufacturer’s instructions) for 1 h at room temperature. 
After 4 times washing, TMB substrate solution was pipetted into each well and the plate was 
incubated in the dark for 15 min to allow the reaction development. Stop solution (1 M H2SO4) 
was added to each well and absorbance was measured at 450 nm within 5 minutes.  
 Specificity of antibody against native LL-37 towards modified forms of peptides was 
estimated using a commercial human LL-37 ELISA ready-to-use kit. Briefly, standards and 
samples (10 ng/ml native and differently modified forms of LL-37) were prepared in assay 
diluent and transferred into respective wells and incubated for 1 h at room temperature. Wells 
were washed with wash buffer provided by the kit for 4 times followed by the addition of 
diluted tracer to each well and incubated at room temperature for 1 hour. The wells were 
washed as mentioned before and working solution of streptavidin-peroxidase was added to 
each well and incubated 1 h at room temperature before the washing steps as previously. One 
hundred µl of TMB substrate were added to each well and incubated until the development of 
TMB reaction was observed. The reaction was stopped by adding stop solution and the plate 
was read at 450 nm within 30 minutes. 
  
6.2.14. ELISA based measurement of NF-kB and IRF7 DNA binding activity  
  
Activation of NF-kB in RAW264.7 cells and IRF7 in pDCs were analyzed using 
TransAM® DNA-binding ELISA. Cells were incubated for 15 min with CpG-LL-37 and 
mixture of CpG with modified forms of LL-37 (mixtures generation as per section 6.2.10.), 
then nuclear extracts were isolated according to following procedure. Briefly, cells were rinsed 
with PBS and scraped with a plate scraper in 0.5 ml of PBS. The samples were collected and 
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centrifuged at 400 x g for 5 min at 4°C. The resulting pellet was resuspended in 400 µl of RSB 
buffer and incubated 15 min on ice. Next, 25 µl of 10% NP-40 was added to the samples and 
after 30 sec, the samples were centrifuged at 500 x g for 1 min at 4°C. The nuclear fraction was 
extracted in 50 µl EB buffer and incubated on ice for 20 minutes. The suspension was 
centrifuged at 500 x g for 5 min at 4°C and supernatant was collected. The protein concentration 
was determined using BCA test. The activity of the NF-kB or IRF7 was measured using the 
commercialized available TransAm® NF-kB ELISA kit or TransAm® IRF7 ELISA kit 
respectively. Thirty µl of complete binding buffer provided by the kit and 20 µl of sample 
containing 10 µg of nuclear extracts was loaded in to a 96-well assay plate, coated with 
oligonucleotide representing a consensus-binding site for NF-kB (5'-GGGACTTTCC-3') or 
IRF7 (5 ́-GAAAGCAAAAA- GAGAAGTAGAAAGTAA-3 ́) respectively. The plates were 
incubated for 1 h at room temperature with mild agitation. Wells were washed 3 times with 
wash buffer and 100 µl of diluted anti-p50 or anti-IRF7 were added to respective wells and 
incubated for 1 h at room temperature without agitation. Wells were washed 3 times and 100 
µl of diluted HRP-conjugated antibody were added and incubated at room temperature for 1 
hour. Wells were washed 4 times before the addition of developing solution. Hundred µl of 
stop solution was added and the plates were read on a spectrophotometer within 5 min at 450 
nm with the reference wavelength of 655 nm.  
 
6.2.15. Measurement of protein concentration- BCA test 
 
The total protein concentration was determined using the commercialized kit PierceTM 
BCA protein assay. This assay was developed based on the reduction of Cu2+ to Cu1+ by protein 
in an alkaline medium with the highly sensitive and selective colorimetric detection of the 
cuprous cation (Cu1+) by bicinchoninic acid., which is strongly influenced by four amino acid 
residues (cysteine, cystine, tyrosine and tryptophan) in the amino acid sequence of the protein. 
Total of 10 µl of samples or standards containing 2 µl of the protein lysates or standards (BSA) 
were added to each respective well. Next, 190 µl of a 1:50 ratio mixture of CuSO4:BCA was 
added to all wells and the plate was incubated in the dark for 30 min at 37°C. The plate was 
measured at 562 nm using a spectrophotometer plate reader and the concentration of the test 
protein was determined using the standard curve of BSA. 
 
 
 55 
NETs studies 
 
 
6.2.16. Neutrophils isolation 
  
Neutrophils were isolated from granulocyte-enriched fractions, which were harvested 
using a lymphocyte separation medium density gradient as described in 6.2.8. Briefly after 30 
min incubation in 1% solution of polyvinyl alcohol, the upper phase that contains neutrophils 
were carefully collected into a new tube and centrifuged at 280 x g for 10 minutes, at room 
temperature. Supernatant was removed and the pellet was subjected to hypotonic lysis to 
remove contaminating RBCs. For that purpose, pellet was resuspended in 2 ml of sterile water, 
pipetted for 30 sec and 2 ml of 2x PBS was added. Then, cells were centrifuged at 280 x g for 
10 min and the pellet containing purified neutrophils was resuspended in DMEM without 
phenol red. 
 
6.2.17. Induction of NETs  
 24-well plate was treated with poly-D-lysine prior the seeding of 2 x 106 
neutrophils/well. The plate was centrifuged at 200 x g for 5 min to enhance attachment process. 
Then, neutrophils were stimulated with 25 nM phorbol 12-myristate 13-acetate (PMA) for 3 h 
to induce NETs. For PAD inhibition, neutrophils were first treated with 100 µM Cl-amidine 
for 1 h under the same incubation conditions before the induction of NETs or 2 h after PMA 
stimulation. In some experiments, neutrophils were pre-treated with 5 µM native or different 
modified forms of LL-37 for 1 h before the induction of NETs with PMA for 3 hours. Anti-
LL-37 antibodies (10 µg/ml) were added 2 h post PMA activation in specified experiments. 
Induction of NETs by pathogen was performed using Staphylococcus aureus (Newman strain). 
Bacteria were grown overnight in Tryptic Soy Broth culture at 37°C in an orbital shaker at 180 
rev./min. The bacterial cultures were centrifuged at 4,500 x g at 4°C for 5 min after overnight 
incubation. Pellet was washed twice with PBS and centrifuged at the same condition as 
mentioned above. After the last wash, the pellet was resuspended with 5 ml of PBS and 
centrifuged at 800 x g at 4°C for 2 min and supernatant that contains live bacteria was collected. 
The number of S. aureus bacterial cells was determined based on previously established growth 
curve of colony forming units (CFU) calibrated to the optical density of the bacteria suspension. 
Isolated neutrophils were infected with S. aureus at the MOI of (1:10) and incubated for 1 hour. 
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After stimulation as described above, supernatant containing released NETs was collected for 
subsequent analysis.  
6.2.18. Quantification of NETs 
  
The release of extracellular NET-DNA was quantified using PicoGreen dye. Assays 
were performed in black 96-well microplates. A working solution of the PicoGreen reagent 
was prepared by diluting the reagent with TE buffer at 1:200. Ninety µl of working solution 
was added to 10 µl of tested samples and fluorescent of NET-DNA were measured using a 
spectrofluorometer with excitation wavelengths 480 nm and emission 520 nm. 
 
6.2.19. Western blot 
  
Protein concentration in NETs was determined using the BCA protein assay (as 
described in section 6.2.15.) to calculate an equal amount of proteins in each sample that was 
subjected to SDS-PAGE. SDS-PAGE for the separation of proteins was done according to 
Schagger and Von Jagow [96] with the gel composition shown in Table IV. 
 
 Resolving Gel 
16% 
Stacking Gel 
4% 
Acrylamide/Bisacrylamide 4.88 ml 1.00 ml 
Buffer for gel 5.00 ml 3.10 ml 
glycerol 2.00 ml - 
dH2O 3.03 ml 8.33 ml 
10% w/v APS 75 µl 60 µl 
TEMED 7.5 µl 6 µl 
 
Table IV. Polyacrylamide gel composition according to Schagger and Von Jagow system. 
 
Samples were incubated at 95°C for 5 min with sample loading buffer (Pierce™ Lane 
Marker Reducing Sample Buffer) containing DTT and separated on a 16% polyacrylamide gel 
at 100 V for 2 hours. After electrophoresis, separated proteins were transferred to a methanol-
activated PVDF membrane at 60 V for 180 min at 4°C. Non-specific binding sites on the 
membrane were blocked with 5% skimmed milk in TTBS buffer for 4 h at room temperature 
before overnight incubation with anti-human LL-37 monoclonal antibody diluted 1,500-fold 
in TTBS buffer containing 3% BSA. The membrane was washed three times, each for 5 min, 
with TTBS buffer before incubation with anti-mouse IgG (1:20,000 dilution in TTBS buffer 
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containing 3% BSA) for 2 h at room temperature. This step was followed by 5 washes with 
TTBS buffer before the blots were developed with ECL. 
 
6.2.20. Detection of citrullinated proteins with anti-modified citrulline antibody  
            (AMC ab) 
 
 Proteins in NET samples were resolved on SDS-PAGE at the same conditions as 
described in section 6.2.19. and transfer onto PVDF membrane. Citrullinated proteins were 
visualized using anti-modified citrulline detection kit according to the manufacturer’s protocol. 
Briefly, the membrane was blocked with 0.1% ovalbumin in TBS at room temperature for 15 
minutes. Next, the membrane was subjected to chemical modification at highly acidic pH by 
incubating the membrane for 7 h at 37 °C with 1:1 solution from mixture A (0.025% FeCl3 
solubilized in 98% H2SO4 and 85% H3PO4) and mixture B (0.25% antipyrine, 0.5% 2,3-
butanedione monoxime and 0.5 M acetic acid). The membrane was incubated with 3% 
skimmed milk in TBS (TBS-MLK) for 30 min after thorough rinsed with water. Antibodies 
specific for chemically modified citrulline (AMC ab) diluted 1,000-fold in TBS-MLK were 
incubated with the membrane overnight at 4°C. After washing the membrane with water, it 
was incubated with 5,000-fold diluted goat anti-rabbit HRP-conjugated IgG in TBS-MLK for 
1 h at room temperature with agitation. After final wash with water (twice) and 0.05% Tween 
20 in TBS-MLK (twice, each 5 minutes), the membrane was developed with ECL detection 
reagent.  
 
6.2.21. Rhodamine-phenylglyoxal citrulline-labelled probes 
  
To investigate protein citrullination in NETs, we used a citrulline specific chemical 
probe, rhodamine-phenylglyoxal (Rh-PG), which is highly sensitive and react with any 
citrulline in proteins and peptides [97]. NET samples (100 µl) in 50 mM HEPES (pH 7.6) were 
treated with 20% trichloroacetic acid, followed by the incubation with 0.5 mM Rh-PG at 37°C 
for 30 minutes. The reaction was quenched by treating samples with 100 mM citrulline in 
HEPES (pH 7.6) for 30 min at 37°C. This was followed by incubating samples on ice for 30 
min to facilitate protein precipitation with trichloroacetic acid. Samples were then centrifuged 
at 16,000 x g for 15 min at 4°C. The pellet was washed with 250 µl ice-cold acetone, 
centrifuged at 16,000 x g for 10 min at 4°C and left to dry for 10 min. Then, 20 µl of 100 mM 
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arginine in HEPES (pH 7.6) were added to quench the residual free probe, followed by 2 x 5 
sec interval sonication. Samples were incubated at 95°C for 5 min before storage at -20°C. 
Samples were run on 16% polyacrylamide gel at 120 V and fluorescent bands were visualized 
using Bio-Rad Gel Imager with a Rhodamine filter (560/50). 
 
6.2.22. Mass spectrometry 
  
NanoESI-MS/MS analyses were performed by Carsten Scavenius, Ph.D. from 
Interdisciplinary Nanoscience Center, Aarhus University according to the procedure described 
below. For measurement, either an EASY-nLC II system (ThermoScientific) connected to a 
TripleTOF 5600 mass spectrometer (AB Sciex) or a NanoLC 415 (Eksigent) connected to a 
TripleTOF 6600 mass spectrometer (AB Sciex) was used. The micro-purified peptides were 
dissolved in 0.1% formic acid, injected and trapped on an in-house packed trap column (2 cm 
x 100 µm i.d.) with RP ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). Peptides were 
eluted from the trap column and separated on a 15 cm analytical column (75 µm i.d.) packed 
in-house in a pulled emitter with RP ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). 
Elution from the analytical column was performed with a linear gradient from 5% to 35% phase 
B (90% acetonitrile with 0.1% formic acid) over 20 or 50 minutes. The collected MS files were 
converted to Mascot generic format (MGF) using the AB SCIEX MS Data Converter beta 1.1 
(AB SCIEX) and the “proteinpilot MGF” parameters. The generated peak lists were searched 
against the swiss-prot database or a local database containing mature LL-37 using in-house 
Mascot search engine (matrix science). Search parameters were adjusted to the applied protease 
and either propionamide (SDS-PAGE) or carbamidomethyl (iodoacetamide) was set as a fixed 
modification with peptide tolerance and MS/MS tolerance set to 10 ppm and 0.1 Da 
respectively.  
 
6.2.23. The estimation of LL-37 half-life in biological fluids 
  
Stability of citrullinated forms of LL-37 added to NETs, inflamed sera and the synovial 
fluid obtained from rheumatoid arthritis patients was determined by Prof. Adam Lesner, Ph.D. 
from Faculty of Chemistry, University of Gdansk. Human probes of inflamed serum and the 
synovial fluid were performed according to the agreement of the Committee of Ethics at the 
University of Bergen (nr. 242.06) and a courtesy from Piotr Mydel, D. Sc., MD. Briefly, all 
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biological samples were centrifuged at 16,000 x g for 15 min to remove lipids and precipitated 
material. Supernatants (900 µl) were mixed with 100 µl peptides (1 mg/ml solution in PBS). 
Peptides mixed with PBS were used as a control. Samples were incubated at 37°C and at 
different time points, aliquots (50 µl) were withdrawn and treated with 50 µl of 6 M urea and 
50 µl 6% TFA to denature all proteins in a sample. Next, samples were centrifuged at 16,000 
x g for 15 min and peptides in supernatants were separated by UPLC Nexera (Shimadzu Japan) 
on the C8 analytical column (Aeris) equilibrated with 0.1 TFA in water at flow rate 0.4 
ml/minutes. Peptides were eluted with acetonitrile gradient up to 55% developed in 12 minutes. 
Proteinaceous material eluted from the column was detected at 208 nm.    
 
6.2.24. Detection of LL-37 in NETs with immunofluorescence microscopy 
  
Neutrophils were isolated as described in section 6.2.16. and seeded at density of  
1 x 105 cells on coverslips treated with syringe-filtered 1% BSA. After 30 min incubation to 
allow cell adherence, neutrophils were either pre-treated with or without 100 µM Cl-A for 1 h 
prior stimulation with 25 nM PMA for 3 h. Cells were fixed with 3.7% paraformaldehyde for 
10 min at room temperature and after 3 washes with PBS, coverslips were incubated with 
mouse anti-human LL-37 (1:50 dilution factor) for 1 h at room temperature. This was followed 
by 45 min incubation with Alexa-Fluor-647 goat anti-mouse antibody (1:1000) and subsequent 
staining with 1 µg/ml Hoechst 33342 for 10 minutes. Then, coverslips were visualized with a 
fluorescence microscope at 20 x magnification. 
 
6.2.25. Activation of antigen-presenting cells by NETs 
  
Human monocyte-derived macrophages (hMDMs) were obtained as described in 
section 6.2.8. Cells were primed with 100 ng/ml LPS for 4 h prior to stimulation with either: 
synthetic native, differentially citrullinated forms of LL-37 and mixtures of synthetic modified 
forms of LL-37 (mPAD2 and mPAD4); or NETs collected from either PMA or S. aureus 
activated neutrophils treated with Cl-A or without as described in section 6.2.17. Two hours 
later media were collected and quantification of IL-1b was performed with commercially 
available ELISA as mentioned in section 6.2.13.  
 Plasmacytoid DCs were seeded in a density of 0.8 x 105 cells/well in 96-well plate 
before an overnight stimulation with NETs and anti-LL-37 antibodies (10 µg/ml), native LL-
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37 (5 µM) or hArg-LL-37 (5 µM). Secreted IL-6 in the supernatant of pDCs was quantified 
with commercially available ELISA as described in section 6.2.13., whilst cells were lysed, 
and RNA were isolated and used for analysis of IFN-a dependent genes (MxA) expression as 
described in following sections. 
 
6.2.26. RNA isolation  
  
RNA was isolated with TRIzol method as per manufacturer’s instructions. Briefly, 200 
µl of TRIzol reagent was added to each well and cells were lysed by pipetting the cells up and 
down a few times. Homogenized samples were collected and stored at -20°C before proceeding 
to phase separation on the next day. Forty µl of chloroform was added to the homogenized 
samples, samples were incubated for 5 min at room temperature and then shook vigorously by 
hand for 15 seconds. After incubating for 2 min at room temperature, samples were centrifuged 
at 12,000 x g for 15 min at 4°C. Colourless, upper aqueous phase containing RNA was carefully 
collected, 120 µl of 100% cold isopropanol was added and probes were incubated at room 
temperature for 10 min, followed by centrifugation 12,000 x g for 10 min at 4°C. Supernatant 
was carefully removed, the RNA pellet was washed with 1 ml 75% cold ethanol and 
centrifuged at 7,500 x g for 5 min at 4°C. Supernatant was discarded and the pellet was air 
dried for 10 min before resuspended with 20 µl RNase-free water. The samples were incubated 
at 56°C for 15 min and concentration of RNA was quantified with NanoDrop 1000 device.  
 
6.2.27. cDNA synthesis  
  
cDNA was prepared from up to 700 ng of total RNA isolated using high-capacity cDNA 
reverse transcription kit. Random primers scheme was used for initiating cDNA synthesis. 
Master mix of required reagents prepared as according to manufacturer’s instructions 
(described as in Table V) was mixed with 10 µl of RNA. cDNA synthesis was carried out in 
room temperature for 10 minutes, then 37°C for 2 h and finished in 85°C for 5 minutes. cDNA 
samples were stored at -20°C until further use. 
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Components Volume/Reaction (µl) 
10x RT buffer 2.0 
25x dNTP Mix (100 mM) 0.8 
10x RT Random Primers 2.0 
Reverse Transcriptase 1.0 
Nuclease-free water 4.2 
 
Table V. Master mix for cDNA synthesis. 
 
6.2.28. Real-time PCR  
  
To evaluate the activation of IFN-a dependent gene expression, we selected genes 
regulated by that signalling pathway, as MxA. Its expression was analyzed using Bio-Rad 
CFX96 Real-Time PCR Detection System and SYBR Green-based JumpStartTM Taq 
ReadyMixTM. The relative expression of MXA (5′-ACTCTGTCCAGCCCCGTAGAC-3′ 
(Forward); 5′ TCACAGCTTCCTGCTAAATCACC-3′ (Reverse)) was normalized to the 
expression of EF2 (5’-GACATCACCAAGGGTGTGCAG-3’(Forward);  
5’-TTCAGCACACTGGCATAGAGGC-3’ (Reverse)). Five µl (15 ng) of cDNA was first 
pipetted to each well before 10 µl of the master mix (as listed in Table VI) was added. After 
the denaturation step (5 min at 95 °C), conditions for cycling were: 39 cycles of 30 sec at 95°C, 
30 sec at 56°C and 45 sec at 72°C. The fluorescence signal was measured after the extension 
step at 72°C and a melting curve was generated to verify the specificity of the PCR product 
after the end of the PCR cycling. All samples were run in triplicates. Means threshold cycle 
(Ct) values were calculated and analyzed using the DDCt method [98]. 
 
Component Volume per reaction (µl) 
Nuclease-free water 1.5 
Forward primer (10 µM; Sigma) 0.5 
Reverse primer (10 µM; Sigma) 0.5 
SyBR Green 7.5 
 
Table VI. PCR reaction master mix and volumes 
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Patient Studies 
 
6.2.29. Patient study group and serum sampling 
  
Rheumatoid arthritis patients that fulfilled the criteria of 2010 Rheumatoid Arthritis 
Classification Criteria of the American College of Rheumatology / European League Against 
Rheumatism Collaborative Initiative were recruited from Department of Rheumatology, 
Clinical Immunology and Allergology of the University Hospital of Bern. Periodontitis 
patients and control donors (patients without RA and periodontitis) were selected from 
Department of Periodontology and Department of Preventive, Restorative and Paediatric 
Dentistry, School of Dental Medicine, University of Bern respectively. The study cohort was 
reviewed and approved by the Ethical Committee of the Canton Bern, Switzerland (KEK 
approval # 236/10). All individuals’ consent was obtained before the participation in the study. 
Serum from all individuals were collected after centrifugation of venous blood samples at 400 
x g for 10 min and were stored at -20°C until further analysis. 
 
6.2.30. Identification of antibodies against LL-37 and citrullinated LL-37 
  
A non-competitive indirect ELISA to detect the levels of IgG antibodies against native 
and citrullinated LL-37 was performed on human sera. Plates were first coated with 10 µg/ml 
of either native and citrullinated LL-37 in coating buffer and incubated overnight at 4°C. After 
washing 4 times with washing buffer, remaining peptide-binding sites were blocked with 
blocking buffer for 2 hours. Serum samples diluted 1:100 in RIA buffer were added to wells 
after discarding blocking buffer. Plates were incubated for 1.5 h followed with 4 times of 
washing before peroxidase-conjugated mouse anti-human IgG (diluted 1:5,000 in RIA buffer) 
were added to each well. After 1 hour, wells were washed 4 times with washing buffer and 
TMB substrate solution were pipetted into each well for substrate colour development. 
Absorbance was measured immediately at 450 nm after a uniform yellow colour was formed 
in each well after the addition of stop solution (1 M sulphuric acid). 
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6.2.31. Statistical analysis 
  
Results obtained under different experimental conditions were analyzed for statistical 
significance using unpaired Student's t tests when independent variables were being assessed 
or by ANOVA when analyses of trends were being determined. All values are expressed as 
means ± standard deviation (SD) and results were considered to be significant at p < 0.05. 
Statistical analysis for level of antibodies against citrullinated and native LL-37 in patient 
studies were analyzed using Mann-Whitney test. Ratio IgGs against LL-37all cit./LL-37 in 
healthy donors and patients with inflammatory diseases was conducted. Statistical analysis was 
performed using GraphPad Prism 7.0. 
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7. Results 
 
7.1. Citrullination affects the interaction of LL-37 with DNA 
 
7.1.1. The binding of LL-37 to DNA 
  
The common feature of LL-37 being cationic and having high affinity for nucleic acids 
enable the peptide to form complexes with DNA [80]. However, LL-37 may be deiminated 
upon released into the inflammatory milieu in the presence of PADs, what modifies the 
function of the peptide [67][68]. Therefore, we assumed that the process of peptide deimination, 
which strongly decreases the cationic character of LL-37 may influence the binding of nucleic 
acids. To verify our hypothesis initially we established the optimal molar ratio of binding 
between LL-37 and DNA using bacterial nucleotide sequence of 148 bp amplified from T. 
forsythia genomic DNA. The fluorometric assay utilizing PicoGreen, an ultra-sensitive 
fluorescent nucleic acid stain to quantify DNA was applied. The special feature of PicoGreen 
is that the dye itself shows no fluorescence until binds to DNA. Free DNA binds the dye most 
efficiently, whereas the process is inhibited upon the interaction of nucleic acid with proteins 
and peptides, including LL-37. Decrease of fluorescence intensity is an important indication 
that complexes between DNA and LL-37 are formed [99]. As such, the optimal molar ratio of 
the DNA-LL-37 complex formation can be determined. Therefore in our study, DNA was 
mixed with LL-37 at different molar ratio (DNA:LL-37 = 1:0.5; 1:2; 1:10) and incubated for 
10 minutes. A reduction of PicoGreen fluorescence was observed with the increased ratio of 
LL-37 to DNA. The complex formation of LL-37 with DNA was dose dependent and 10-fold 
excess of peptide to nucleic acid nearly completely silenced the emission of fluorescence (Fig. 
8).  
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Fig. 8. The fluorescence of DNA after binding to LL-37. The optimum ratio between DNA 
and LL-37 was established by incubating the molecules at different molar ratio of 1:0.5, 1:2, 
1:10 (DNA:peptide) respectively for 10 min at room temperature prior spectral analysis using 
fluorescent dye PicoGreen to measure the unbound DNA. Data is shown as relative 
fluorescence units (RFU) and the results are representative of 3 independent experiments. 
(Copyright 2018. The American Association of Immunologists, Inc.) 
 
7.1.2. The role of LL-37 deimination (catalysed by PADs) on binding to DNA 
  
PADs are capable to modify positively charged peptidyl arginine and methylarginine 
residues inside a peptide chain to uncharged citrulline [97]. LL-37 consists of 5 arginines 
making the peptide a favourable substrate for PAD enzymes, what has been already shown by 
Koziel et al. [67]. Hence, we investigated the time dependent effect of PADs mediated 
citrullination of LL-37 on DNA binding. PAD2 and PAD4 were chosen, as they are released 
in inflammatory conditions [100] and their activities are positively correlated with disease 
severity [67].  
By using the fluorometric assay as described above (7.1.1.), we determined that both 
PADs exert time dependent effect on LL-37 binding to DNA. LL-37 was first incubated with 
PAD2 and PAD4 for a different time (0, 15, 30 and 120 min), before added to DNA for another 
10 minutes. Unbound DNA was quantified by spectral analysis using PicoGreen as described 
in 7.1.1. Higher fluorescence was observed with the increased incubation time of peptide with 
PADs, revealing the decreased affinity between DNA and LL-37 (Fig. 9 A & 9 B). On the 
other hand, we also observed that PAD2 appeared to be more efficient in LL-37 citrullination 
compared to PAD4, which requires twice more time (PAD2 : PAD4 – 30 min : 60 min) to 
achieve the same effects as PAD2 (Fig. 10). Obtained data suggests the gradual dissipation of 
the cationic charge of the peptide due to the conversion of arginine residues to citrulline. Higher 
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DNA-PicoGreen fluorescence signal is detected with the increased of time, as less LL-37 binds 
to DNA, allowing the DNA-PicoGreen interaction. The role of citrullination in regulating the 
formation of DNA-LL-37 complexes was further confirmed by using hArg-LL-37, containing 
homo-Arg guanidinium side chains that are insensitive to enzymatic citrullination (sequence 
of hArg-LL-37 is shown in section 6.1.20.). As a control we applied the scrambled version of 
LL-37 (sequence of sLL-37 is shown in section 6.1.20.). Both peptides (sLL-37 and hArg-LL-
37) were incubated with PAD2 for 2 h, as mentioned earlier. We found that sLL-37 did not 
bind to nucleic acids (Fig. 11 A) indicating that the interaction of the peptide with DNA 
strongly depended on amino acids sequence. The citrullinated counterpart of sLL-37 also 
remained unbound. Moreover, we observed that hArg-LL-37 interacted equally efficient with 
DNA regardless of treatment with PAD2 (Fig. 11 B) due to inability of PADs to deiminate 
guanidium side chain in hArg. All together, the presented data revealed that the LL-37 
interaction with nucleic acids is not limited to the peptide cationicity but depends on the proper 
distribution of guanidinium side chains of Arg (hArg) in the context of the native sequence of 
LL-37.  
 
 
 
Fig. 9. Time dependent effect of LL-37 incubated with PAD2 (A) and PAD4 (B) on DNA 
binding. The capability of citrullinated LL-37 binding to DNA was analyzed using PicoGreen 
fluorescent dye by incubating DNA with LL-37 exposed to PADs at different incubation time: 
0, 15, 30 and 120 min respectively. Unbound DNA was quantified with spectral analysis using 
PicoGreen and is shown as relative fluorescence units (RFU). Data shown are representative 
of 3 independent experiments. (Copyright 2018. The American Association of Immunologists, 
Inc.) 
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Fig. 10. The time dependent effect of LL-37 citrullination by PAD2 and PAD4 on the 
capability of peptide to bind DNA. Data collected over the fluorescence range (500 – 600 
nm) from Figure 9 was analysed using Prism’s area-under-the-curve (AUC) analysis. Statistical 
significance was evaluated by one-way ANOVA, followed by Tukey’s multiple comparisons 
post-test (****p<0.0001; ##p<0.01; ####p<0.0001- comparing to the control DNA-LL-37 
(second bar from left) ). Data shown are collective of 3 independent experiments. (Copyright 
2018. The American Association of Immunologists, Inc.) 
 
 
 
Fig. 11. The enzymatic deimination of modified forms of LL-37 on formation of DNA-
LL-37 complexes. DNA binding by scrambled version of LL-37 (sLL-37) (A) and peptide 
with homo-Arg guanidinium side chains (hArg-LL-37) (B) with or without preincubation with 
PAD2.  Unbound DNA was quantified with the spectral analysis using PicoGreen and is shown 
as relative fluorescence units (RFU). Data shown are representative of 3 independent 
experiments. (Copyright 2018. The American Association of Immunologists, Inc.) 
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7.1.3. Interaction of synthetic citrullinated LL-37 with oligonucleotides 
 
Having observed that citrullination of LL-37 catalysed by PADs influences its binding 
to DNA, we expanded our studies implementing synthetic, differentially citrullinated forms of 
LL-37 harbouring different numbers of citrullinated arginine residues (Arg7Cit = LL-377; 
Arg7,29,34Cit = LL-377,29,34; Arg7,19,23,29,34Cit = LL-37all cit), which sequences are shown in 
section 6.1.20. Above mentioned peptides were selected based on the data published by Koziel 
et al., where the citrullination profile exerted upon enzymatic modification of native LL-37 by 
PAD2 enzyme was determined by automated Edman degradation [67]. 
As described previously [80], the complex formation between anionic nucleic acids 
(DNA) and the cationic peptide LL-37 is based on the electrostatic interaction between both 
molecules, therefore we apply a classical electrophoresis mobility shift assay (EMSA) [95].  
The assay is not limited to nucleic acid sizes and structures, thus provides a straightforward 
measure on protein-DNA interaction [101]. The unbound, negatively charged DNA migrates 
towards the anode when electric current is applied, however DNA bound with peptide retains 
in the well and couldn’t migrate as corresponding to the free nucleic acid (Fig. 12 A). 
Interestingly, the intensity of the bands with mobility that resemble free DNA increased with 
the number of citrullinated arginine residues of LL-37, revealing the decreased binding of DNA 
with more citrullinated forms of LL-37 (Fig. 12 A). We also applied CpG oligonucleotides, 
which are short single-stranded synthetic DNA molecules that mimic bacterial DNA. CpG 
ODN 2216, a class A CpG was selected for our study as it was reported to elicit a substantial 
immunological response on TLR9-expressing cells [82], which we were interested to introduce 
for subsequent in vitro studies. Using CpG oligonucleotides we confirmed the observation of 
decreased nucleic acids binding together with the increase level of LL-37 citrullination (Fig. 
12 B).   
To quantify the interaction of citrullinated peptides with DNA, surface plasmon 
resonance (SPR) analysis was performed in the Department of Comparative Biochemistry and 
Bioanalytics, Jagiellonian University. The amount of DNA bound by respective native and 
modified LL-37 was measured at 210RU. As expected, native LL-37 bound DNA tightly and 
the affinity of such interaction decreased about 3-fold, with just a single arginine residue 
substitution at position 7 in LL-37 (Fig. 13). In case of fully citrullinated peptide the binding 
to DNA was totally abolished (Fig. 13). As citrullination of LL-37 by PAD2 and PAD4 
generates the different profile of citrullinated peptides [68], we tested two mixtures of synthetic 
modified forms of LL-37, which composition resembles the final products of LL-37 
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citrullination generated by PAD2 (mPAD2) and PAD4 (mPAD4) (refer Table VII). The SPR 
analysis has shown that the global DNA binding by the peptides in the mixture was a result of 
additive binding of the individual modified peptides (Fig. 14). This excludes any interaction 
between the peptides themselves and argues that deimination of particular arginine residues 
within LL-37 does not affect the peptide interactions.  
Taken together, citrullination of LL-37 diminishes the binding of the peptide to DNA, 
as we confirmed by both enzymatic deimination (Fig. 9, 10) and using synthetic peptides (Fig. 
12, 13). The interaction between DNA and LL-37 strongly depends on the numbers of citrulline 
residues within the peptide. PAD enzymes may variably affect the level of citrullination, as 
shown by amino acid sequence analysis of the peptide incubated with PAD2 and PAD4 [67]. 
 
Peptide mPAD2 mPAD4 
LL-37 1% 49% 
LL-377 77.5% 35% 
LL-377,29,34 20% 14% 
LL-37all cit. 1.5% 2% 
 
Table VII. Mixture composition of synthetic modified forms of LL-37 that resembles the 
catalytic modification of LL-37 by PAD2 (mPAD2) and PAD4 (mPAD4). (Copyright 2018. 
The American Association of Immunologists, Inc.) 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Binding efficiency of bacteria (T. forsythia) genomic DNA and synthetic 
oligonucleotide CpG with synthetic native and citrullinated forms of LL-37 determined 
by EMSA. Synthetic native or differentially modified forms of LL-37 were mixed with 
bacteria genomic DNA or CpG, respectively, at a 1:5 (DNA-peptide) molar ratio and incubated 
at room temperature for 10 min prior running samples on 1.5% agarose gel. Decreased intensity 
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of DNA band and its retardation are indicative for the complex formation with the peptide. 
Data shown are representative of 3 independent experiments. (Copyright 2018. The American 
Association of Immunologists, Inc.) 
                             
 
 
 
 
 
 
 
Fig. 13. The efficiency of DNA binding by native and differentially citrullinated forms of 
LL-37 (LL-377, LL-377,29, LL-377,29,34, and fully citrullinated LL-37) determined by SPR. 
CpG biotinylated at the 5′ end of the antisense strand was immobilized on the SA sensor chip 
(GE Healthcare) with streptavidin covalently attached to the dextran. Next, a series of native 
and modified LL-37 peptide samples were injected over the sensor surface at 30 µL/min flow 
rate using 2 min interval for association and for dissociation process. Binding efficiency was 
evaluated with SPR analysis (LL-37 1 µM/Bt-DNA 210RU). Data shown are amounts of 
immobilized DNA corresponding to 210 response units (RU). Sensorgram (insert) showed an 
overview of binding curves between DNA and peptides. Analysis was performed in the 
Department of Comparative Biochemistry and Bioanalytics, Jagiellonian University. 
(Copyright 2018. The American Association of Immunologists, Inc.) 
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Fig. 14. Efficiency of DNA binding by mixtures of synthetic peptides resembles catalytic 
modification of LL-37 by PAD2 (mPAD2 - A) and PAD4 (mPAD4 - B) respectively. The 
binding efficiency of DNA by mixtures of synthetic native and differentially citrullinated forms 
of LL-37 (composition see Table VII) was analysed by SPR. The R max values of the mixtures 
were compared with the quota determined separately for the mixed components at the same 
concentration level. Response units (RU) were used to describe the amounts of immobilized 
DNA. Analysis was performed in the Department of Comparative Biochemistry and 
Bioanalytics, Jagiellonian University. (Copyright 2018. The American Association of 
Immunologists, Inc.) 
 
7.1.4. Evaluation of specificity of studied interaction 
 
7.1.4.1. Binding of murine cathelicidin to DNA 
  
 We next explored if deimination of cathelicidin originated from different species than 
human also interferes with their ability to bind DNA. We examined native and deiminated 
variants of CRAMP (sequences as shown in section 6.1.20.), a murine analog of human LL-
37, on its binding affinity with nucleic acids. CRAMP contains a single Arg residue so the 
citrullinated form of CRAMP also encompasses only a single deiminated arginine residue. 
Results of the gel retardation assay has revealed the ability of CRAMP to form 
complexes with nucleic acids, and reduced binding with the citrullinated form of peptide 
manifested by a slight band of released DNA (Fig. 15). This observation revealed that 
decreased complex formation between modified cathelicidin and nucleic acids is not species-
specific. It occurs regardless the origin of the peptide. Moreover, these data revealed decrease 
of DNA binding by modified CRAMPs mimicking the effect documented for a single 
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substitution of Arg in the sequence of LL-37 (Fig. 12). 
 
                                   
 
Fig. 15. Binding of CRAMP and its deiminated form to DNA. Bacterial genomic DNA (T. 
forsythia) was incubated with either the native (CRAMP) or the citrullinated peptide 
(CRAMPcit.) in molar ratio (1:5) at room temperature for 10 min prior running samples on 1.5% 
agarose gel. DNA can bind with CRAMP, murine analogue of LL-37, but less efficiently than 
the citrullinated form of the peptide. Data shown are representative of 3 independent 
experiments. (Copyright 2018. The American Association of Immunologists, Inc.) 
 
7.1.4.2. Interaction of LL-37 with other molecules - apolipoprotein A-1 
 
Electrostatic character of proteins determines their reciprocal charge-dependent 
interactions. Therefore, we decided to investigate how citrullination of LL-37 will affect its 
binding with other molecules. For that purpose, the serum apolipoprotein A-1 (ApoA-1) has 
been chosen as it can form the complex with LL-37 [102]. The interaction was analyzed with 
SPR, which was performed in the Department of Comparative Biochemistry and Bioanalytics, 
Jagiellonian University. We confirmed concentration-dependent binding of LL-37 binding 
affinity to ApoA-1 with the increasing concentration of LL-37, ranging from 0 – 20 µM (Fig. 
16). Next, we examined the effects of citrullination on the formation of ApoA-1-peptide 
complexes, finding the reduced affinity of modified LL-37 for ApoA-1 (Fig. 17). Complete 
citrullination of LL-37 attenuated its ability to bind with ApoA-1. However, the amount of 
ApoA-1 coupled with deiminated LL-37 increased with the peptide concentration. To conclude, 
deimination of LL-37 affecting its interaction with other molecules is not limited to DNA. 
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Fig. 16. Interaction of LL-37 with apolipoprotein A-1. ApoA-1 was incubated with different 
concentrations of synthetic native LL-37 ranging from 0 – 20 µM and the binding efficiency 
was estimated with SPR analysis. Data shown are amounts of coupled ApoA-1 corresponding 
to 270 response units (RU). The sensogram (insert) showed an overview of binding curves in 
the interaction between ApoA-1 and LL-37. Analysis was performed in the Department of 
Comparative Biochemistry and Bioanalytics, Jagiellonian University.  
 
 
Fig. 17. Comparison of concentration-dependent interaction of LL-37 in native and 
citrullinated forms with ApoA-1. ApoA-1 immobilized on a sensor chip was interacting with 
native and differentially citrullinated forms of LL-37 (LL-377, LL-377,29, LL-377,29,34, and LL-
37all cit.) applied at 1, 5, 10 and 20 µM concentration and the binding was estimated with SPR 
analysis. Data shown are amounts of coupled ApoA-1 correspond to 270 response units (RU). 
Analysis was performed in the Department of Comparative Biochemistry and Bioanalytics, 
Jagiellonian University.  
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7.1.4.3. Specificity of posttranslational modifications on the binding   
             affinity of LL-37 to DNA 
 
We have shown that citrullination of LL-37 and CRAMP efficiently abolished the 
interaction of these antibacterial peptides with nucleic acid. We now investigated how other 
modifications affecting e.g. charge of the peptide influence LL-37 interaction, with DNA. To 
this end, we focused on carbamylation process since this posttranslational modification of 
proteins/peptides is well known for its association with inflammatory diseases [103]. Of note, 
carbamylation is a chemical reaction that converts lysine into homocitrulline, leading the 
decrease of peptides’ positive charge. LL-37, which contains six lysine residues, serves as 
potentially highly susceptible substrate for carbamylation, which alter its cationic and 
amphipathic nature. Thus, we next analyzed if DNA binding is affected by LL-37 
carbamylation. Koro et al. [51] documented that in the presence of physiological 
concentrations of cyanate, three different carbamylated forms of LL-37 are generated 
(Sequences see section 6.1.20.).  
Each of the three forms of synthetic carbamylated LL-37 (K1, K2 and K3) was 
incubated with DNA at room temperature for 10 min before proceeding to gel electrophoresis 
analysis. Interestingly, the binding affinity between modified LL-37 and DNA was not affected 
by carbamylation (Fig. 18), suggesting the importance of Arg but not Lys residues in LL-37 
interaction with DNA. That conclusion was fully confirmed by the results of another 
experiment (Fig. 19), showing that preincubation of carbamylated forms of LL-37 with PAD2 
totally abolished their binding ability to DNA. Taken together, the formation of complexes 
between LL-37 and DNA was dependent on the positively charged guanidinium groups of Arg 
residues but not on the global cationicity of LL-37 or the peptide amphipathic nature. 
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Fig. 18. Gel retardation assay using carbamylated LL-37 peptides. Bacterial DNA from T. 
forsythia was incubated with different forms of carbamylated LL-37 (K1, K2 and K3) at the 
molar ratio 1:5 (DNA-peptide) at room temperature for 10 min prior to electrophoresis. Data 
shown are representative of 3 independent experiments. (Copyright 2018. The American 
Association of Immunologists, Inc.) 
 
 
 
Fig. 19. Effect of enzymatic deimination of arginines in native and carbamylated forms 
of LL-37 on binding to DNA. The binding of different variants of LL-37 to DNA before (A) 
and after (B) preincubation with PAD2. Amount of unbound DNA was quantified with spectral 
analysis using PicoGreen and is shown as relative fluorescence units (RFU). Data shown are 
representative of 3 independent experiments. (Copyright 2018. The American Association of 
Immunologists, Inc.) 
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7.1.5. Effects of LL-37 citrullination on protection of DNA complexed with  
          peptide  
  
 As it was described previously the interaction of LL-37 to DNA protects bound nucleic 
acid against nucleases [80]. Therefore, we decided to analyze if citrullination of LL-37 can 
influence that process. For experiment we have chosen the modified form of LL-37 with only 
one substituted Arg residue (LL-377), since in case of more extensive modification we observed 
practically no binding to DNA. DNA was incubated with either native or modified LL-37 (LL-
377) for 10 minutes ensuring the complex formation. Then, the complex was exposed to DNase 
for 60 minutes, after which fluorometric assay using Picogreen dye was applied to determine 
the residual amount of DNA. Percentage of intact DNA complexed with LL-37 and LL-377 
before DNase treatment was normalized to 100% and the percentage of residual DNA after 
DNase treatment was calculated against appropriate control. Our results have showed that 
native LL-37 can protect DNA from nuclease activity with ~70% of DNA staying intact, as 
compared to the modified LL-37, where only ~35% DNA of initially bound DNA was detached 
(Fig. 20). Based on these results, we can conclude the citrullination of LL-37 not only 
diminished the binding of DNA, but also reduced the protection of entrapped nucleic acid from 
degradation. Possibly such complex might have a more relaxed structure than that with native 
LL-37.  
 
 
Fig. 20. Citrullination of LL-37 diminishes protection of complexed DNA against 
degradation of DNase.  The efficiency of native and modified LL-37 to protect DNA against 
degradation is represented as the percentage of DNA bound to the peptide after 60 min of 
DNase treatment. Percentage of intact DNA before DNase treatment for native LL-37 and 
modified LL-37 (LL-377) was normalized to 100% respectively and the percentage of 
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remaining DNA after DNase treatment was calculated by dividing the treatment values with 
its’ corresponding control values. Data shown are representative of 3 independent experiments. 
Statistical significance was evaluated by one-way ANOVA, followed by Tukey’s multiple 
comparisons post-test (****P<0.0001). (Copyright 2018. The American Association of 
Immunologists, Inc.) 
 
 In summary, citrullination interferes the interaction of LL-37 with DNA, and 
deimination of even a single Arg residue has a significant effect on the peptide ability to form 
complexes with DNA. 
 
7.2. The role of citrullinated LL-37 on immune cells activation by oligonucleotides 
 
 Nucleic acids are usually rapidly degraded in the extracellular environment, however, 
LL-37 increases the immunogenic potential of DNA by acting as a carrier molecule. In addition, 
this facilitates the internalization of bacterial or self-DNA molecules into the endosomal 
compartment of pDCs. Large amount of IFN-a is secreted when pDCs are exposed to such 
complexes (DNA-LL-37) [80]. Therefore, we attempt to investigate how citrullination can 
affect LL-37-dependent DNA-mediated activation of myeloid cells. 
 
7.2.1. The activation of human plasmacytoid dendritic cells (pDCs) by  
          oligonucleotides (CpG) in the presence of deiminated peptides 
 
Human plasmacytoid dendritic cells (pDCs) characterized by elevated expression of 
TLR9 were chosen in that part of study, as they are highly sensitive to oligonucleotides 
recognition. Those cells provide protective immunity by generating type I IFNs [104]. 
Oligonucleotides used in this study CpG ODN 2216 is a class A of CpG, which is known to 
induce higher and longer secretion of IFN-a in pDCs [105] as compared to CpG class B. In 
addition, the nuclease-resistant phosphorothrioate-modified backbone of CpG oligonucleotides 
(typical for both classes) improves their cellular uptake. Lande et al. reported in 2007, that the 
activation of pDCs upon the exposure of complexes formed between DNA and LL-37 is 
manifested by a robust IFN-a expression [80]. This observation has prompted us to apply the 
same model to investigate the effect of deiminated LL-37 on pDCs activation induced by DNA. 
Initially, after stimulation of pDC cultures with mixture of CpG (3 µM) : peptides (6.4 µM) 
 78 
(native or different modified forms of LL-37), we examined the morphology of cells. Bright-
field microscopy analysis has revealed the formation of cell clumps, a distinct feature of pDCs 
activation, which was observed mainly after stimulation of cells with CpG-LL-37 (Fig. 21 C). 
We also documented, that the amount of cell clumps decreased with the increase numbers of 
citrullinated Arg residues as depicted in Fig. 21 D-F, with the least clumping of cells reported 
for cells treated with CpG alone (Fig. 21 B) or mixture of CpG with fully citrullinated LL-37 
(Fig. 21 F). Taken together, we assumed that citrullination of LL-37 affects the DNA-induced 
activation of the myeloid cells. 
 
 
 
Fig. 21. Morphology of pDCs culture exposed to oligonucleotides (CpG) in the presence 
of the native and deiminated forms of LL-37. CpG alone (final concentration 3 µM) or CpG 
with synthetic native and modified forms of LL-37 (final concentration 6.4 µM) were incubated 
for 15 min before pDCs were washed with PBS for 3 times and incubated overnight with fresh 
RPMI medium supplemented with gentamycin. Formation of cell clumps reflects the activation 
of human pDCs. Images shown are representative of 3 independent experiments. (Copyright 
2018. The American Association of Immunologists, Inc.) 
 
7.2.2. The induction of cytokine expression in pDCs by DNA in the presence of  
          native and citrullinated forms of LL-37 
 
The inverse relationship on the degree of cell clumping with the level of peptide 
citrullination in the presence of CpG (Fig. 21) has prompted us to verify the level of pDCs 
activation by analyzing the cytokines expression induced by CpG in the presence of native and 
citrullinated LL-37. Human pDCs were exposed to CpG complexed with either native LL-37 
or different forms of modified LL-37 for 15 minutes as published previously by Hurtado et al. 
[82]. In this report authors shown that a short exposition of cells to DNA complexed with LL-
37 was sufficient to induce elevated cytokine secretion. Accordingly, we confirmed high level 
CpG CpG-LL-37 Control CpG-LL-377 CpG-LL-377,29,34 CpG-LL-37all cit. 
A. B. C. D. E. F. 
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of IFN-α generated by pDCs upon stimulation with the CpG-LL-37 complexes as compared to 
native LL-37 or CpG alone (Fig. 22 A). Such observation indicates that cell activation mediated 
by CpG is strongly enhanced by LL-37. In corroboration with our findings, citrullination 
interferes with DNA binding. Interferon-α released by DNA-LL-37 were reduced when CpG 
was mixed with LL-377 or LL-377,29,34, or fully-citrullinated LL-37 (LL-37all cit.). The latter 
complex led to approximately 3-fold reduction of IFN-a secretion compared to the CpG-LL-
37 (Fig. 22 A). We have also included controls: the scrambled form of LL-37 (sLL-37), hArg-
LL-37 and carbamylated forms of LL-37 (K1-K3) in our study. Our analysis has showed that 
scrambled LL-37 peptide, which does not bind DNA (Fig. 11), could not promote 
immunoregulatory effect on pDCs compared to the native peptide. However, hArg-LL-37 and 
carbamylated forms of LL-37 exerted effects similar to the native peptide when complexed 
with CpG. The secretion of IL-6 showed totally different pattern in comparison to IFN-α 
response (Fig. 22 B). The elevated level of IL-6 was mainly observed in cell culture exposed 
to CpG alone or when CpG was accompanied by fully citrullinated LL-37. In conclusion, 
DNA-LL-37 complexes induced nearly inverse effects on pDCs response regarding on the 
secretion of IFN-α and IL-6. 
 
 
 
 
 
 
 
 
Fig. 22. Cytokines expression in pDCs after short contact with CpG combined with native 
or citrullinated LL-37. Primary human pDCs (8 x 105 per well/200 µL) were incubated with 
CpG (3 µM) or CpG combined with differentially citrullinated forms of LL-37 (6.4 µM) for 
15 minutes. Thereafter cells were washed 3 times with PBS and incubated for additional 20 
hours. (A) IFN-α and (B) IL-6 levels were measured by ELISA in culture supernatant. 
Statistical significance was evaluated by one-way ANOVA, followed by Tukey’s multiple 
comparisons post-test (*P<0.05, ***P<0.001, ****P<0.0001- comparing to CpG alone; 
##P<0.01, ###P<0.001, NS, non-significant- comparing to CpG-LL-37). Results shown are 
representative of 3 independent experiments. (Copyright 2018. The American Association of 
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Immunologists, Inc.) 
 
In the follow up experiment we decided to prolong the time exposure of pDCs to tested 
complexes that resembles in vivo conditions. Human pDCs were treated overnight with CpG 
alone or with a mixture of CpG and either the native or 3 deiminated forms of LL-37. Similarly, 
as before, CpG-LL-37 mixture induced the strongest IFN-α secretion and the effect was 
significantly weaker when pDCs were exposed to CpG complexed with modified forms of LL-
37 (Fig. 23 A). The profile of IL-6 secretion was also similar to that observed after short-time 
exposition to pDCs complexes, with respect to high level of IL-6 released by cells only in 
response to CpG alone (Fig. 23 B). Together, the prolonged incubation with the CpG-native 
LL-37 complex enhanced secretion IFN-α by ~10-fold comparing to CpG alone (Fig. 23 A), 
apparently in the arginine guanidinium dependent-manner (Fig. 23 A, B). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23. Cytokines expression in pDCs after prolonged contact with CpG combined with 
native or citrullinated LL-37. (A) IFN-α and (B) IL-6 levels measured by ELISA in 
conditioned media after overnight incubation with CpG-LL-37 complexes or mixture of CpG 
with different modified forms of LL-37. Primary human pDCs (8 x 105 cells/200 µl) were 
incubated overnight with CpG (3 µM) or CpG combined with differentially citrullinated LL-
37 forms (6.4 µM). Results shown are representative of 3 independent experiments. Statistical 
significance was evaluated by one-way ANOVA, followed by Tukey’s multiple comparisons 
post-test (**P<0.01, ***P<0.001- comparing to CpG alone; #P<0.05, ##P<0.01, comparing to 
CpG-LL37).  
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7.2.3. The activation of macrophages by oligonucleotides (CpG) in the presence   
          of deiminated peptides 
 
Having observed the effects of LL-37 citrullination on activation of pDCs by CpG, we 
next explored another immune cell subset that expresses TLR9. Murine macrophages model 
(RAW264.7) was chosen for the study as this cell line was reported to be sensitive for CpG 
activation [106]. We challenged RAW264.7 with mixtures of CpG with the native/modified 
forms of LL-37 as described previously for pDCs (section 7.2.1.). We found that CpG-LL-37 
complexes triggered RAW264.7 to secrete high amount of TNF-α. On the other hand, an 
inverse relationship of TNF-α secretion was observed with the mixture of CpG with the 
increase numbers of citrullinated arginine residues (Fig. 24), which is similar to results 
obtained for pDCs. Of note, the complex containing LL-377 induced a strong stimulatory effect 
in macrophages. The TNF-α secretion level in response to treatment with a mixture of CpG 
with control peptides (sLL-37, hArg-LL-37, K1-K3) was similar to that observed in pDCs, 
with sLL-37 being unable to sensitize macrophages to nucleic acid recognition. In contrast 
hArg-LL-37, similar to native peptide and carbamylated variants of LL-37 (K1-K3) stimulated 
the secretion of high amounts of TNF-α, in the latter case the effect was exerted despite the 
diminished cationic character ot the peptide with carbamylated Lys residues (Fig. 24). We also 
applied the murine form of cathelicidin – CRAMP. As expected, complexes of native CRAMP 
with CpG activated RAW264.7, but the effect was absent in the presence of modified CRAMP 
(Fig. 25). Taken together, our results have shown that deimination of arginine residues in native 
LL-37 affects the proinflammatory response of APCs to cell-free DNA. 
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Fig. 24. Activation of murine macrophages by CpG in the presence of the native and 
deiminated or carbamylated LL-37. RAW264.7 cells were stimulated with either CpG (final 
concentration 3 µM) alone or mixtures of CpG with the native and modified forms of LL-37 
(final concentration 6.4 µM) for 15 minutes. Cells were washed with PBS and TNF-α level in 
conditioned medium was measured with ELISA after overnight activation. Data shown are 
representative of 3 independent experiments. Statistical significance was evaluated by one-way 
ANOVA, followed by Tukey’s multiple comparisons post-test (***P<0.001- compared to CpG 
alone; #P<0.05, ###P<0.001, NS, non-significant- compared to CpG-LL-37). (Copyright 2018. 
The American Association of Immunologists, Inc.) 
 
 
Fig. 25. The expression of TNF-α in murine macrophages upon exposition to CpG alone 
or mixed with the native or citrullinated murine cathelicidin (CRAMP). RAW264.7 cells 
were stimulated with either CpG (final concentration 3 µM) alone or CpG with murine native 
(CRAMP) or modified cathelicidin (CRAMPcit) (final concentration 6.4 µM) for 15 minutes. 
Cells were washed with PBS and cultured overnight. TNF-α secretion to the conditioned 
medium was measured with ELISA. Data shown are representative of 3 independent 
experiments. Statistical significance was evaluated by one-way ANOVA, followed by Tukey’s 
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multiple comparisons post-test (**P<0.01, ****P<0.0001). (Copyright 2018. The American 
Association of Immunologists, Inc.) 
 
7.2.4. Effect of CpG binding and internalization by phagocytes in the presence of  
          LL-37 or its modified forms 
 
Lande et al. [80] has showed that the activation of pDCs by CpG-LL-37 is a 
consequence of the internalization of the complex, and thus we next wanted to determine the 
degree of complex penetration into cells. Firstly, we studied such effects on RAW264.7 by 
incubating the cells with FITC-labeled CpG in the presence or absence of LL-37 or LL-37all cit. 
and showed significant internalization of CpG only in the complex with native LL-37. The 
modified peptide had no effect on engulfment process (Fig. 26). This remarkable finding has 
prompted us to proceed the study with human pDCs. 
 
 
Fig. 26. LL-37 enhances the uptake of CpG. RAW264.7 were treated with either CpG-FITC 
or CpG-FITC + LL-37 or LL-37all cit. for 15 minutes. Cells were washed with PBS and analyzed 
for FITC fluorescence by flow cytometry. Data are shown as mean fluorescence intensity 
(MFI) of gated cells. Statistical significance was evaluated by one-way ANOVA, followed by 
Tukey’s multiple comparisons post-test (*P<0.05, NS, non-significant). 
 
Human pDCs were exposed to mixture of FITC labelled CpG with either native or 
differentially citrullinated peptides, washed with PBS and analyzed by FACS as described 
previously. We found that internalization of CpG was reduced as the level of peptide 
citrullination increased (Fig. 27 A). The same staining profile in the presence and absence of 
cytochalasin D has suggested that the impairment of CpG internalization was due to the weaker 
binding affinity of oligonucleotide to the cell membrane in the presence of citrullinated 
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peptides (Fig. 27 B). This implies that citrullination affects nucleic acids access into the 
intracellular/endosomal compartment of pDCs.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 27. The effect of LL-37 or its’ modified forms on CpG binding and internalization by 
pDCs. (A) Human pDCs were treated with either FITC-labeled CpG alone or mixture of CpG-
FITC with native or modified forms of LL-37 for 15 min before FACS analysis; (B) Staining 
profile showing the uptake of CpG-FITC in the presence or absence of cytochalasin D. Data 
are shown as mean fluorescent intensity (MFI) of gated cells or percentage of FITC positive 
cells respectively. (Copyright 2018. The American Association of Immunologists, Inc.) 
 
7.2.5. The mechanism of regulation of the CpG-induced inflammatory response  
          by native or citrullinated LL-37  
 
7.2.5.1. Effects of LL-37 citrullination on NF-kB transcription factor  
             activation induced by oligonucleotides  
 
As our results have shown (Fig. 24, 25) the differentiated role of native and modified 
LL-37 on TNF-a secretion induced by DNA thus, we analyzed the activation of transcription 
factor NF-kB that regulates the expression of TNF-a [107]. Initially, we used an ELISA-based 
kit, which can detect and quantify NF-kB activation. Nuclear extracts were isolated from 
RAW264.7 cells after stimulation with the mixtures (CpG with native or different citrullinated 
LL-37) for 15 minutes, however we observed no activation of NF-kB signalling as shown in 
Fig. 28.  
A. B. 
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Fig. 28. Effects of LL-37 citrullination on NF-kB activation induced by CpG measured 
by ELISA. RAW264.7 were incubated for 15 min with CpG (final concentration 3 µM) or 
mixtures of CpG with the native and variable modified forms of LL-37 (final concentration 6.4 
µM). Then cells were washed 3 times with PBS and subjected to 1.5 h incubation before nuclear 
extraction. The active form of NF-kB containing in the nuclear cell extract was quantifified 
using commercial NF-kB calorimetric kit and the activation was measured at OD 450nm. 
Positive control of the nuclear extract was provided in the kit. Data shown are collective of 3 
independent experiments. 
 
We next employed another method to quantitate the signal transduction pathway by 
measuring the luciferase activity in RAW264.7, which were transduced with lentiviral particles 
expressing NF-kB reporter constructs. Macrophages were incubated with CpG-LL-37 or 
mixture of CpG with different modified forms of LL-37 for 1.5 h and 6 h respectively. We 
noted enhanced activation of NF-kB in response to CpG in the presence of native peptide, 
while with the increase number of citrullinated arginine residues the effect was reduced (Fig. 
29 A). The prolonged to 6 h stimulation of cells revealed sustain activation of cells in the 
presence of the partly citrullinated peptides (LL-377, LL-377,29,34) with significantly strong 
upregulation observed for LL-377 (Fig. 29 B). These findings indicate that citrullination of LL-
37 diminish ability of the peptide to enhance the oligonucleotide-induced NF-kB signalling 
pathway and subsequent expression of inflammatory genes in cells briefly exposed to the 
complex, with the prolonged exposition partly reversing that effect. 
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Fig. 29. Effects of LL-37 citrullination on the CpG induced NF-kB activity. Activation of 
the NF-kB pathway was determined in RAW264.7 cells transduced using Cignal Lenti 
Reporter Assay. Activity of NF-kB was measured after 1.5 h (A) and 6 h (B) incubation with 
CpG-LL-37 complex or mixtures of CpG with different forms of modified LL-37. Cells were 
lysed and assayed for luciferase activity (RLU). Data shown are representative of 3 
independent experiments. Statistical significance was evaluated by one-way ANOVA, 
followed by Tukey’s multiple comparisons post-test (**p<0.05, ****p<0.0001- compared to 
CpG alone; #p<0.05, ##p<0.01, ###p<0.001- compared to CpG-LL-37).  
 
7.2.5.2. Effects of LL-37 citrullination induced by oligonucleotides on  
             IRF7 transcription factor activation  
 
We next evaluated IRF7 activity in human pDCs, given that IFN-a production (Fig. 22 
- 23) depends on the activation and translocation of IRF7 to the nucleus. For this study, we 
used an ELISA-based kit, which can detect and quantify IRF7 transcription factor activation. 
Initially we treated human pDCs with either CpG alone or CpG-LL-37 for 15 minutes before 
cells were washed three times with PBS, followed by 3 h cultivation with fresh media. Then 
nuclear extraction was performed and subsequent ELISA analysis according to manufacturer’s 
instructions. Although IRF7 was reported to express at very high levels in pDCs upon 
stimulation with CpG [108], we did not observe IRF7 activation even after exposition of cells 
to CpG complexed with LL-37 (Fig. 30).  
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Fig. 30. IRF7 activity upon pDCs treatment with oligonucleotides. Human pDCs were 
incubated with either CpG alone or CpG-LL-37 for 15 min before cells were washed three 
times with PBS, followed by 3 h cultivation with fresh media. Nuclear extractions of pDCs 
were performed and subjected to analysis of IRF7 activity as per manufacturer’s instructions. 
Positive control is the nuclear extract of IRF-7 transfected Cos-7 (fibroblast-like cell-lines) 
provided in the kit. Data shown are collective of 3 independent experiments. 
 
 To sum up, our findings indicate that citrullination of LL-37 strongly and specifically 
affects the immunostimulatory potential of the native peptide complexed with DNA abolishing 
(dendritic cells) or delaying (macrophages) activation of myeloid cells. The observed effect is 
due to reduced recognition of nucleic acids by the intracellular receptor (TLR9) as a 
consequence of limited penetration via cell membrane.  
 
7.3. Identification of citrullinated LL-37 
 
7.3.1. Direct identification of citrullinated LL-37 in NETs 
 
Neutrophils have been demonstrated to form web-like structures, termed NETs 
(neutrophil extracellular traps), which contains de-condensed DNA decorated with histones 
and proteins originated from dying neutrophils. High concentration of antimicrobial 
components, such as myeloperoxidase, neutrophil elastase and cathelicidin LL-37 has been 
reported as released during the event of NETosis [32]. Thus, NET structures serve as a good 
model for our study to identify the presence of citrullinated LL-37, given that both LL-37 and 
active PAD enzymes co-exist at relatively high concentrations. Apart from that, various studies 
have associated NETs with inflammatory diseases, such as psoriasis, systemic lupus 
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erythematoses (SLE) and rheumatoid arthritis (RA), where NETs play a role as a source for 
citrullinated antigens [84].  
 
7.3.1.1. Using Rh-PG to detect protein citrullination 
  
First, we used a citrulline specific chemical probe, Rh-PG (rhodamine-phenylglyoxal), 
which chemoselectively reacts with citrulline thus fluorescently labelling citrullinated LL-37. 
Cl-amidine, which is known to be an inhibitor of NETs formation, was used as a control for 
our study. Fluorescent imaging of NETs stimulated by PMA, revealed a faint band similar 
molecular mass or electrophoretic mobility as the exogenous, citrullinated LL-37 added to 
NETs (Fig. 31). A decreased intensity of this band in Cl-amidine treated PMN corroborates 
our prediction that LL-37 is at least partially citrullinated in NETs. 
 
 
 
 
 
 
 
 
 
Fig. 31. A profile of citrullinated proteins labelled with the Rh-PG labelling probe in 
NETs. PMA induced NETs in the presence and absence of PAD inhibitor (Cl-A) were treated 
with Rh-PG probe and thereafter separated with SDS-PAGE. NETs supplemented with 
synthetic fully citrullinated LL-37 (LL-37all cit.) was used as the control for citrullinated LL-37 
migration in the gel (blue bracket). Red rectangles indicate modified human cathelicidin 
hCAP18/LL-37 in PMA induced NETs in the presence or absence of Cl-A. Data shown are 
representative of 3 independent experiments. (Copyright 2018. The American Association of 
Immunologists, Inc.) 
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7.3.1.2. Detection of LL-37 in NETs samples with mass spectrometry  
             analysis  
  
To confirm our observation (7.3.1.1.), we employed mass spectrometry to detect LL-
37 and citrullinated forms of the peptide in PMA-induced NETs. The analysis was performed 
in Interdisciplinary Nanoscience Center, Denmark. Bands corresponded to cathelicidin were 
excised, in-gel digested with trypsin and analyzed by MS. N-terminal peptide LLGDFFRK, 
indicator of mature LL-37, was identified in the samples (Fig. 32), however, no citrullinated 
variant of LL-37 was detected. Next, we tried another approach by ultra-filtrating and treating 
the samples (supernatant containing PMA-induced NETs) with LysC endopeptidase, resulting 
in identification of N- terminal (Fig. 33 A) and C-terminal (Fig. 33 B) fragments of the LL-37 
peptide, but not citrullinated forms of LL-37. Different methods have been used, such as in-gel 
digestion, precipitation, ultrafiltration, and combination of the mentioned methods, all reported 
failure in detection of peptides derived from modified forms of LL-37. Since inability to detect 
modified LL-37, we examined the stability of synthetic peptides in cooperation with Prof. 
Adam Lesner, from Faculty of Chemistry, University of Gdansk. Those studies were conducted 
in different conditions. We verified peptides stability in sera from healthy and RA patients, 
synovial fluid from RA patients and NET samples in the presence and absence of protease 
inhibitor. Different synthetic forms of native and modified LL-37 were incubated in tested 
biological fluids and their half-life was estimated. As revealed, LL-37 was equally stable as 
LL-377, but we observed significant decrease of the life span in case of LL-37 that contained 
more than two deiminated arginine residues (LL-377,29,34 and LL-37all cit), which was most 
marked in synovial fluid from RA patients (Fig. 34 A).  
 Intriguingly, the half-life for all native and modified forms of LL-37 in the NET 
samples was significantly lower, when compare to sera or synovial fluid. The stability of the 
peptide strongly increased in the presence of protease inhibitors (Fig. 34 B), thus we decided 
to analyze the role of neutrophil elastase (HNE), which is a major serine protease released 
during NET formation in observed phenomenon. We found that all modified LL-37 peptides 
have shorter half-life compared to the native LL-37 when added to HNE. In the presence of a 
HNE inhibitor, the half-life of the modified LL-37 peptides was comparable to the native LL-
37 (Fig. 34 B). All these findings might be the plausible explanation why direct detection of 
citrullinated LL-37, especially in NETs, failed. 
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Fig. 32. MS/MS spectra of the LL-37 N-terminal tryptic peptide (LLGDFFR), confirming 
the presence of mature LL-37. The analysis was performed in Interdisciplinary Nanoscience 
Center, Denmark. (Copyright 2018. The American Association of Immunologists, Inc.) 
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Fig. 33. MS/MS data of the LysC generated N- and C-terminal peptide of LL-37. NETs 
sample digested with LysC were compared with MS/MS spectra of (A) N-terminal unmodified 
(top) and modified (middle) peptide LLGDFFRK; and (B) C-terminal unmodified (top) and 
modified (middle) peptide DFLRNLVRPTES. NETs samples digested with LysC produced a 
A. 
B. 
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weak signal of the unmodified version of the peptide. The analysis was performed in 
Interdisciplinary Nanoscience Center, Denmark. (Copyright 2018. The American Association 
of Immunologists, Inc.) 
 
 
 
          
 
 
 
 
 
 
 
Fig. 34. The half-life of the native LL-37 and its variably citrullinated forms in different 
biological fluids. The half-life of LL-37 and its citrullinated forms was estimated in healthy 
and inflamed sera (RA serum), synovial fluid of RA patients (A); NETs in the presence or 
absence of protease inhibitors (inh) and HNE in the presence or absence of a HNE inhibitor 
(inh) (B). The analysis was performed in Faculty of Chemistry, University of Gdansk. Unpaired 
t-test was used to calculate the p values between groups (*p<0.05; **p<0.01). 
 
7.3.1.3. Estimation of specificity of antibody against native LL-37 towards  
             modified forms of peptides 
 
We next validated specificity of available antibodies to recognize the native LL-37 and 
the fully citrullinated forms of the peptide. To this end, synthetic native and fully citrullinated 
LL-37 were subjected to western blot analysis using antibodies against native LL-37 (LL37 
ab) and antibodies reacting with chemically modified citrulline residues in proteins or peptides 
(AMC ab). Blotted membrane was cut into 3 pieces in the middle of lanes with resolved 
antigens to allow the testing of both antibodies respectively on the same loaded sample. As 
shown in Fig. 35 (left part of the blot), no reaction of fully citrullinated LL-37 was detected 
with antibody against native LL-37. This indicates that reactivity of this antibodies depends on 
recognition of epitopes containing Arg side chains. Apparently, conversion of Arg to citrulline 
destroyed these epitopes and, the citrullinated peptide can be now detected using AMC ab, 
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antibodies specific chemically derivatized citrulline residues (Fig. 35- middle part of the blot). 
Furthermore, we found in both Western blot (Fig. 36) and ELISA (Fig. 37) that the affinity of 
antibody against native LL-37 decreased as the number of citrullinated arginine residues 
increased in the peptide. Figure 36 shows that intensity of the bands for synthetic LL-377 and 
LL-377,29 was less than native LL-37 and no bands were observed when LL-37 consisted of 
more than two citrullinated arginine residues. This observation was supported by a commercial 
ELISA assay. The antibodies used in this ELISA kit were able to recognize native LL-37 and 
certain differentially citrullinated synthetic LL-37 peptides (LL-377, LL-377,29, and LL-
377,29,34), but not fully citrullinated synthetic LL-37 peptide (LL-37all cit.) (Fig. 37). Taken 
together, antibody specific for the native LL-37 failed to detect the modified forms of LL-37. 
 
                                   
 
 
 
 
 
Fig. 35. Specificity of antibody against the native LL-37 and its fully citrullinated form of 
the peptide. Shown are representative western blot analysis of the native and fully citrullinated 
LL-37 using antibodies against native LL-37 (LL37 ab) and chemically modified citrulline 
(AMC ab). Detection of citrullinated LL-37 can only be recognized by anti-citrulline 
(modified) polyclonal antibodies but not anti-LL-37 antibodies. The dashed line showed the 
section where the membrane was cut to allow the incubation of different antibodies. (Copyright 
2018. The American Association of Immunologists, Inc.) 
 
 
 
                                  
Fig. 36. Recognition of citrullinated LL-37 by antibodies against the native LL-37 using 
Western Blot. Shown are representative Western Blot analysis of native and citrullinated 
forms of LL-37 using antibodies against native LL-37. (Copyright 2018. The American 
Association of Immunologists, Inc.) 
     LL37 ab AMC ab    LL37 ab 
 LL37all cit  LL37 
LL-37         LL-377        LL-377,29    LL-377,29,34   LL-37all cit. 
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Fig. 37. Recognition of the citrullinated LL-37 by antibodies against the native LL-37 
using commercial ELISA kit. Wells of a microtiter plate were coated with 10 ng/ml of the 
native LL-37 or LL-37 forms harbouring different numbers of citrulline residues (LL-377, LL-
377,29, LL-377,29,34 and LL-37all cit.) and incubated with antibodies recognizing human LL-37. 
The analysis was performed as per manufacturer’s instructions. 
7.3.2. Indirect identification of LL-37 citrullination in NETs 
 
As we were unable to directly determined the presence of citrullinated LL-37 partly 
due to the short life-span of the modified peptide. Thus, we employed an indirect approach to 
identify citrullinated LL-37 in NETs. For that purpose, we selected NET structures in which 
the relatively high concentration of active PAD enzymes and citrullinated proteins was 
documented. The leading idea was to show that inhibition of citrullination process increase 
with the level of native peptide, proving indirectly that extensive deamination of LL-37 occurs 
in NETs. We applied Cl-amidine, a PAD inhibitor, which irreversibly inhibits PADs through 
covalent modification at the enzyme active site.  
 
7.3.2.1. Immunoblot analysis of the presence of LL-37 in NETs  
 
PAD plays an important role in NET formation by inducing chromatin decondensation 
and facilitating the formation of web-like structures containing both DNA and antimicrobial 
peptides. As we would like to apply PAD inhibitor in our study, therefore we first estimated 
the NETs generation in the presence of Cl-amidine. Picogreen assay was used to measure the 
released DNA of NETs in supernatant. We noted that neutrophils treated with 25 nM PMA 
formed NETs in the process partly reduced when neutrophils were treated with 100 µM Cl-A 
prior stimulation with PMA (Fig. 38).  
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Fig. 38. The reduction of NET formation upon Cl-amidine treatment of neutrophils. 
Isolated human neutrophils (2 x 106 cells/ 400µl) were treated either with or without 100 µM 
Cl-amidine (Cl-A) for 1 h prior stimulation with or without 25 nM PMA for 3 hours. Formation 
of NETs was quantified using PicoGreen and shown as relative fluorescence units (RFU). 
Results shown are representative from 3 independent experiments. Statistical significance was 
evaluated by one-way ANOVA, followed by Tukey’s multiple comparisons post-test 
(***p<0.001; ###p<0.001, ####p<0.0001- compared with control). (Copyright 2018. The 
American Association of Immunologists, Inc.) 
  
 Then, we performed immunoblot analysis of PMA-induced NETs. Keeping in mind 
that antibodies against native LL-37 (LL37 ab) can only recognize the native form of LL-37 
(Fig. 36), immunoblot to analyze PMA- induced NETs in the presence or absence of Cl-A was 
conducted. The monoclonal antibody used for Western blot studies can recognize both 
precursor (hCAP18) and mature form of LL-37, and our results revealed that both forms are 
externalized during NETosis induced by PMA or Staphylococcus aureus (Fig. 39). Notably, 
our observation showed stronger band corresponding to hCAP18 (18 kDa) and LL-37 (4.7 
kDa) in neutrophils pre-treated with Cl-A, when compared with samples without PAD inhibitor 
(Fig. 39). Our results suggest that citrullination of mature form of LL-37, as well as its 
precursor takes place during NET formation.  
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Fig. 39. The identification of the LL-37 in NETs generated in the presence of PAD 
inhibitor. Shown are representative of Western Blot analysis on the mature peptide (LL-37 - 
4.7 kDa) and its precursor (hCAP18 - 18 kDa) in NETs generated in presence/absence of 100 
µM Cl-A and PMA (25 nM) or Staphylococcus aureus (SA) (MOI 1:10) using antibodies 
against native LL-37. (Copyright 2018. The American Association of Immunologists, Inc.) 
 
7.3.2.2. Detection of LL-37 in NETs samples with immunofluorescence  
             microscopy  
  
Next, we conducted immunofluorescence analysis to confirm our observation. 
Neutrophils were added to the coverslips in the presence or absence of PAD inhibitor (Cl-A) 
for 1 h prior stimulation with PMA for 3 hours. Cells were fixed and stained for native LL-37 
with specific antibodies, while Hoechst was used to visualized DNA. As we observed, NETs 
generated in the presence of Cl-A showed more positive staining corresponding to LL-37 (red) 
compared to NETs without the inhibitor (Fig. 40). The ratio between LL-37-positive staining 
and amount of NETs revealed that PMA-induced NETs in the presence of Cl-A generated three 
times more LL-37 fluorescence spots (PMA:Cl-A/PMA=0.136:0.306). Numbers of 
fluorescence spots of LL-37 was calculated from 20 independent images and presented in Fig. 
41. This observation correlates with the immunoblot analysis (Fig. 39), with more native LL-
37 quantified in neutrophils exposed to the PAD inhibitor. 
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Fig. 40. Immunofluorescence analysis of native LL-37 on PMA-induced NETs in the 
presence or absence of the PAD inhibitor. Isolated neutrophils were treated either with or 
without 100 µM Cl-Amidine (Cl-A) for 1 h prior stimulation with or without 25 nM PMA for 
3 hours. Formation of NETs and detection of LL-37 was visualized using Alexa Flour 647-
labelled antibody against Mouse Anti-human LL-37 (red) and counterstained with Hoechst 
(blue) and imaged by fluorescent microscopy. The representative images from 3 independent 
experiments were taken at the magnification x 20. (Copyright 2018. The American Association 
of Immunologists, Inc.) 
 
 
Fig. 41. The presence of native LL-37 visualized by fluorescent microscopy. Fluorescence 
specific for LL-37 visualised by fluorescence microscopy was quantified from 20 independent 
images and presented as the number of spots. Statistical significance was evaluated by one-
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way ANOVA, followed by Tukey’s multiple comparisons post-test (*p<0.05; ####p<0.0001- 
compared with control) (Copyright 2018. The American Association of Immunologists, Inc.) 
 
7.3.3. Identification of LL-37 and citrullinated LL-37 in serum from patients 
 
The conversion of arginine to citrulline can change the structure and function of a 
protein. Moreover, as citrulline is not a natural amino acid, thus its presence in a protein 
structure may induce immune response manifested by antibodies generation [60]. Various 
studies have showed the presence of antibodies against citrullinated proteins/peptides in the 
development of inflammatory and autoimmune diseases [61]. As it has been previously 
reported the elevated expression of LL-37 is identified in RA and periodontal disease patients 
[28]. Therefore, we applied yet another indirect method to show the presence of citrullinated 
proteins that relies on detection of specific antibodies. According to this we tempt to estimate 
the level of antibodies directed against LL-37 and/or citrullinated LL-37 in sera obtained from 
different cohorts of donors, including: healthy individuals, periodontitis patients, rheumatoid 
arthritis patients, and patients suffer from both RA and periodontitis. Healthy individuals have 
the highest level of antibodies against native LL-37 compared to other cohorts (Table VIII). 
Although we found no significant difference in the level of antibodies against citrullinated LL-
37 among all tested groups (Fig. 42 A, B), the ratio of antibodies against citrullinated LL-
37/LL-37 had tendency to be elevated but without reaching statistical significance, in patients 
with inflammatory diseases (periodontitis, rheumatoid arthritis and both RA and periodontitis) 
(Fig. 42 C) compared to control (healthy). All together, obtained data may suggest the presence 
of deiminated LL-37 in inflamed patients that leads to the generation of relevant antibodies.  
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Fig. 42. The antibody response to citrullinated and native LL-37. The level of antibodies 
against citrullinated (A) and native LL-37 (B) in sera of healthy donors and patients with 
inflammatory diseases (periodontitis (PD), rheumatoid arthritis (RA), RA patients with 
periodontitis (RA + PD)) were analyzed using an ELISA method. (C) Ratio of antibodies 
against citrullinated LL-37 and LL-37 for respective different cohorts of donors. The black line 
indicates median corresponding for OD 450 nm.  
 
 Healthy  
(n=16) 
PD 
(n=24) 
RA 
(n=6) 
RA + PD 
(n=40) 
Median (Range) 
LL-37all cit.  (OD) 0.24 
(0.12-0.52) 
0.22 
(0.08-0.46) 
0.21 
(0.13-0.37) 
0.21 
(0.08-0.55) 
LL-37 (OD) 0.41 
(0.17-1.69) 
0.29 
(0.14-0.71) 
0.28 
(0.15-0.47) 
0.31 
(0.10-0.92) 
 
LL-37all cit./LL-37 
(OD) 
0.77 
(0.07-1.96) 
0.87 
(0.21-1.65) 
0.83 
(0.4-1.04) 
0.80 
(0.12-1.61) 
 
Table VIII. Analysis for antibody levels against citrullinated (LL-37all cit.) and native LL-37 
(LL-37) in sera of healthy donors and patients with inflammatory diseases by calculating the 
ratio of IgG against LL-37all cit./LL-37. 
 
 To conclude, our observation suggested the presence of modified forms of LL-37 
within inflammatory milieu, especially in NETs, given that NETs generated in the presence of 
PAD inhibitor revealed more native LL-37 than control NETs.  
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7.4. Biological confirmation of the presence of citrullinated LL-37 in NETs 
 
Results of our experiments strongly argue for the presence of citrullinated LL-37 in the 
NETs structures. Therefore, we applied several methods to explore the immunomodulatory 
potential of LL-37 citrullination within NETs, which may regulate the functions of phagocytic 
cells. 
 
7.4.1. NETs induction by anti-LL-37 antibodies 
 
Lande et al. [32] have demonstrated that anti-LL-37 Abs can trigger NETosis upon 
specific binding to LL-37 released by neutrophils isolated from SLE patients [32]. We could 
not replicate such observation using neutrophils from healthy donors in the PMA-induced 
NETs model. However, the effect was visible when neutrophils were pretreated with PAD 
inhibitor, Cl-A. We found that incubation of PMA-induced NETs with anti-LL-37 Abs did not 
enhance NETosis. The significantly enhanced NETosis was however observed in the presence 
of Cl-A (Fig. 43). Keeping in observation that anti-LL-37 Abs can only recognize the native 
form of the peptide (Fig. 36), this result suggests that higher amount of the native LL-37 was 
present in neutrophils exposed to Cl-A. Moreover, our findings showed that Cl-A itself did not 
contribute to the increased NETosis with the presence of anti-LL-37 Abs (Fig. 44). These data 
have suggested that LL-37 are citrullinated by PADs during NET formation, and Cl-A-
treatment of neutrophils led to NETs containing higher amount of native LL-37. 
 
 
 
 
 
 
                                        
 
Fig. 43. Antibodies against LL-37 enhanced PMA-induced NETosis in the presence of 
PAD inhibitor. Neutrophils from 3 different healthy donors were pre-treated either with or 
without 100 µM Cl-Amidine (Cl-A) for 1 h prior stimulation with or without 25 nM PMA for 
3 h. Anti-LL-37 antibodies (aLL37) were added 2 h post PMA activation. Formation of NETs 
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was quantified using PicoGreen. Statistical significance was evaluated by one-way ANOVA, 
followed by Tukey’s multiple comparisons post-test (**P<0.01; ****p<0.0001; NS, non-
significant). Data shown are from 3 different donors. 
 
 
Fig. 44. PAD inhibitor (Cl-A) alone did not enhance NETosis in the presence of anti-LL-
37 Abs. Neutrophils were pre-treated either with or without 100 µM Cl-Amidine (Cl-A) for 1 
h prior stimulation with or without 25 nM PMA for 3 h; or 100 µM Cl-Amidine (Cl-A) alone. 
Anti-LL-37 antibodies (aLL37) were added 2 h post PMA activation. Formation of NETs was 
quantified using PicoGreen. Results shown are representative from 3 independent experiments. 
Statistical significance was evaluated by one-way ANOVA, followed by Tukey’s multiple 
comparisons post-test (*p<0.05; ***P<0.001; NS, non-significant). 
 
7.4.2. Activation of the inflammasome pathway in macrophages by NETs 
  
We next identified the presence of citrullinated LL-37 within NETs in an indirect 
approach by using a model described by Kahlenberg et al. [30]. In this model, priming of 
hMDMs with LPS increases surface expression of the P2X7 receptor thus sensitizing 
macrophages to respond to LL-37. The activation of P2X7 upon stimulation with LL-37 leads 
to the release of high level of IL-1β. As LL-37 is one of the major NETs components that can 
activate the P2X7 receptor-signalling pathway, we decided to apply this model in our studies. 
First, we determined the effects of the synthetic, modified forms of LL-37 on promoting the 
capacity of hMDMs in releasing IL-1β. Our results have showed that citrullination of LL-37 
decreased the response measured as the level of secreted IL-1β in the citrullination-degree 
dependent manner as demonstrated in Fig. 45. Moreover, we stimulated primed macrophages 
with mixtures of the synthetic modified forms of LL-37, that resembles the composition of 
peptides obtained after enzymatic modification of LL-37 by PAD2 or PAD4 (mixture 
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composition as per Table VII in section 7.1.3.) and observed a significant reduction in the 
ability of such mixtures to stimulate the release of IL-1β. Our results confirmed that 
citrullination of LL-37 abrogated the secretion of IL-1β by primed macrophages.  
 
 
Fig. 45. The release of IL-1b from primed macrophages in response to LL-37 and 
deiminated forms of the peptide. Human macrophages were primed with or without LPS for 
4 h, then treated with the synthetic native or differentially citrullinated forms of LL-37 (LL-
377, LL-377,29,34, and fully citrullinated LL-37) or mixtures of synthetic modified forms of LL-
37 (mPAD2 and mPAD4). Supernatants were collected and secretion of IL-1b was quantified 
using commercial ELISA. Results shown are representative of 3 independent experiments. 
(Copyright 2018. The American Association of Immunologists, Inc.) 
 
Next, we compared the effects of NETs generated by PMA or S. aureus in the absence 
or presence of Cl-A, on the ability to promote the release of IL-1b from LPS-primed 
macrophages. We found, that NETs derived from Cl-A pretreated neutrophils induced higher 
expression of IL-1b in LPS-primed macrophages than “native” NETs (Fig. 46 A and B). Taken 
together, the inhibition of citrullination in NETs potentiated their proinflammatory potential in 
the applied model, probably via maintaining of the high level of native LL-37. 
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Fig. 46. The activation of IL-1b release from macrophages by NETs. Macrophages primed 
with or without LPS were treated with NETs triggered by PMA (A) or S. aureus (SA) (B) in 
the presence or absence of Cl-A. Supernatants were collected and concentration of IL-1b was 
quantified by ELISA. Results shown are representative from 3 independent experiments. 
Statistical significance was evaluated by one-way ANOVA, followed by Tukey’s multiple 
comparisons post-test (**P<0.01). (Copyright 2018. The American Association of 
Immunologists, Inc.) 
 
7.4.3. Activation of pDCs by NETs 
 
To further explore the immunomodulatory role of LL-37 citrullination in NETs we 
examined the effect of NETs on human pDCs. Taking into account the possibility of NETs 
being the source of citrullinated LL-37 and the fact that LL-37 is required for the activation of 
pDCs by nucleic acids, we sought to investigate the pDC activation by PMA-induced NETs 
with the presence or absence of Cl-A. Activation of pDCs is manifested by characteristic 
aggregation of cells. We documented such morphology when phagocytes were exposed to CpG 
complexed with LL-37 (Fig. 47 B). Aggregation was also clearly visible upon exposition of 
pDCs to PMA-induced NETs but the effect was much stronger if neutrophils were pretreated 
with Cl-A (Fig. 47 D, E). This finding collaborates the contention that LL-37 is citrullinated 
in NETs. 
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Fig. 47. Activation of pDCs by NETs with differential content of citrullinated proteins. 
pDCs were incubated with CpG (final concentration 3 µM) with native LL-37 (final 
concentration 6.4 µM) (B); NETs induced by PMA (25 nM) (C); NETs induced by PMA (25 
nM) from neutrophils pretreated with 100 µM Cl-A (Cl-A/PMA: Neutrophils preincubated 
with Cl-A for 1 h before stimulation with PMA for 3 hours (D); PMA/Cl-A: Cl-A was added 
after 2 h of PMA stimulation (E) ). Morphology of the cell clumps formation reflecting the 
activation of human pDCs. Images taken were representative of 3 independent experiments. 
(Copyright 2018. The American Association of Immunologists, Inc.) 
 
We next assessed the molecular parameters of pDCs activation by PMA-induced NETs 
collected from neutrophils pre-treated with or without Cl-A. Initially, we analyzed the secretion 
of IFN-a. However, this approach failed as the level of IFN-a was below detection range of 
the commercial ELISA (Fig. 48). Thus, we decided to analyze the expression of genes 
dependent on type I IFN-a using real-time PCR. MxA was chosen, as the gene highly expressed 
after the engagement of the type I IFN-a receptor. Our data has shown the upregulation of MxA 
gene expression occurred only when pDCs were exposed to PMA-induced NETs in the 
presence of Cl-A (Cl-PMA). Remarkably, NETs induced without Cl-A pretreatment or if the 
PADs inhibition was added to pre-formed NETs did not affect the MxA gene expression (Fig. 
49). 
 
Control CpG/LL-37 PMA Cl-A/PMA PMA/Cl-A 
A. B. C. D. E. 
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Fig. 48. The IFN-a level secreted by pDCs incubated with NETs. pDCs were exposed to 
NETs as described in Fig. 47. Production of IFN-a in supernatants collected from pDCs was 
measured with commercial ELISA. Data shown are representative of 3 independent 
experiments.  
 
 
Fig. 49. Expression of the type I IFN-a dependent MxA gene in pDCs. The level of MxA 
gene expression was measured by real-time PCR and quantified in relation to the house-
keeping gene EF2. Statistical significance was evaluated by one-way ANOVA, followed by 
Tukey’s multiple comparisons post-test (*P<0.05, **P<0.01). Results shown are representative 
from 3 independent experiments. (Copyright 2018. The American Association of 
Immunologists, Inc.) 
 
 Another hallmark of pDC activation is the secretion of IL-6. Although we observed 
upregulation of that cytokine in conditioned medium of pDCs incubated with PMA-induced 
NETs, nonetheless a higher IL-6 level was noticed for pDCs treated with NETs obtained in the 
presence of Cl-A (Fig. 50). The data correlates with the observation of cell clumping in Fig. 
47. 
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Fig. 50. Activation of pDCs with NETs induced by PMA without any additional treatment 
(PMA) or from neutrophils pretreated with Cl-A (Cl-A/PMA) or preformed NETs 
treated with Cl-A (PMA/Cl-A). pDCs were seeded and stimulated overnight with PMA-
activated NETs. Production of IL-6 in supernatants was measured with ELISA. Data shown 
are from 3 different donors. (Copyright 2018. The American Association of Immunologists, 
Inc.)  
 
To confirm that citrullination of LL-37 in NETs abolish inflammatory reaction of pDCs 
(Fig. 47, 49, 50), we supplemented NETs with either the native LL-37 or its peptide resistant 
for citrullination - hArg-LL-37. Intriguingly, pDCs treated with NETs containing hArg-LL-37 
induced the substantial inflammatory response manifested by both MxA expression (Fig. 51) 
and IL-6 secretion (Fig. 52) compared to native LL-37.  
 
 
Fig. 51. Activation of pDCs by NETs supplemented with LL-37 or hArg-LL-37. The level 
of MxA gene expression in relative to the house-keeping gene, EF2 in pDCs measured by real-
time PCR. Statistical significance was evaluated by one-way ANOVA, followed by Tukey’s 
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multiple comparisons post-test (**P<0.01). Results shown are representative from 3 
independent experiments. (Copyright 2018. The American Association of Immunologists, Inc.) 
 
 
 
Fig. 52. Activation of pDCs by NETs supplemented with LL-37 or hArg-LL-37. The level 
of IL-6 in pDCs were measured with ELISA as per manufacturer’s instructions. Data shown 
are from 3 different donors. (Copyright 2018. The American Association of Immunologists, 
Inc.) 
 
7.4.4. The role of LL-37 citrullination in the generation of NETs 
  
Expression of LL-37 is augmented during inflammatory response. The peptide is 
secreted by epithelial cells, but also released from dying neutrophils. Recently, LL-37 was 
reported to increase NETs activation upon exposure to PMA [109]. We confirmed that 
phenomenon in our studies (Fig. 53), but keeping in mind that citrullination of LL-37 occurs 
in NETosis, we examined also NETs formation induced by PMA in the presence of 
citrullinated LL-37. Our results showed that neutrophils pre-treated with the modified peptides 
before exposition to PMA underwent accelerated NETosis, which intensity positively 
correlated with the amount of substituted arginines (Fig. 53). Next, we confirmed the above 
observation using other stimulant of NETs formation – gingipain RgpA, the virulence factor 
of Porphyromonas gingivalis (data not shown). As in the case of PMA stimulation we observed, 
a slight but the significant increased level of NETs upon preincubation of neutrophils with 
some modified peptides.  
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Fig. 53. The intensity of NETs formation induced by PMA in the presence of the native 
or citrullinated LL-37 peptides. Neutrophils were pre-treated with 5 µM native or modified 
forms of LL-37 for 1 hour, followed by 3 h incubation in the presence or absence of 25 nM 
PMA. NETs were collected and quantified with PicoGreen Assay. Results were representative 
of 3 independent experiments. Unpaired t-test was used to calculate the p values (*p<0.05; 
**p<0.01- compared with control in the presence of 25 nM PMA).  
 
 Taken together our studies revealed that the process of LL-37 citrullination occurs in 
NETs affecting the inflammatory potential of those structures. On the other hand, we 
documented that citrullinated peptides intensify the process of NETs formation what can be 
considered as a mechanism of positive feedback what might promote further uncontrolled 
inflammation. 
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8.  Discussion 
 
 The innate immune system plays a crucial role to safeguard the host from invading 
microorganisms. Initiation of the immune response occurs via pattern recognition receptors 
(PRR), which recognize an array of pathogen associated molecular patterns (PAMPs), 
including among other nucleic acids. Nucleic acids are common inherent molecular signatures 
present in both pathogen and host, leading to the potential risk of self-recognition by innate 
immune receptors. Few studies have emphasized the deleterious consequences of self-DNA 
recognition, which has established a link to many autoimmune diseases. Our studies focused 
on a human peptide LL-37, that displays natural antimicrobial activity but can elicit an immune 
response in the absence of an infection by binding with high affinity to released nucleic acids. 
This pathway is likely a key driver of autoimmune diseases, which are enhanced by LL-37, by 
facilitating DNA uptake into the endosomal compartment of APCs via the recognition of 
genomic DNA by intracellular TLR9 receptors. Through binding of nucleic acid to LL-37, a 
condensed aggregate structure is formed and translocated to the early endosomes thus 
upregulating the production of IFN-a. Altogether, it leads to the overwhelming pro-
inflammatory responses such as in the case of systemic lupus erythematosus and psoriasis 
patients [32][80]. On the other hand, the enhanced recognition of nucleic acids with CpG motifs 
by LL-37 benefits our immune system especially in the event of bacterial infection, as LL-37 
is capable to form complexes with nucleic acids released from lysed bacterial cells, sufficient 
to protect them from nucleases degradation and deliver them into host cells [110]. 
 Recent observations have highlighted the denoting effect of posttranslational 
modifications (PTM) in the regulation of the inflammatory reaction. Posttranslational 
regulation of protein function and activity is one of the mechanisms developed by the host to 
avoid uncontrolled innate inflammatory responses and also to regulate PRR signalling. One of 
the most extensively studied PTM is phosphorylation which plays an important role in 
regulating the activation and deactivation of multiple TLR-dependent signalling molecules 
such as MAPKs, NF-kB inhibitor kinases and IRF3, that is essential in the antiviral response 
[111]. Another common PTM that is important in controlling innate immunity and 
inflammatory responses is ubiquitination. Protein ubiquitination is known as the regulatory 
mechanism for inhibition of TLR signalling, for example, suppressing cytokine signalling 1 
(SOCS1) or neuroregulin receptor degradation protein 1 (Nrdp1) [112]. On the other hand, 
increased level of acetylation and SUMOylation are widely linked to various neurological and 
cardiac diseases. For instance, acetylation of tau, which is the major microtubule associated 
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protein (MAP) of a mature neuron, at lysine 174 (K174) affects its stability and toxicity in early 
stages of the Alzheimer’s disease. The alterations in SUMOylation can lead to the heart failure. 
SUMOylation of Lamin A at lysine 201, which is a critical scaffolding protein important for 
the nuclear structure, can cause human familial dilated cardiomyopathy (a genetic form of heart 
disease) [113]. The carbonylation of amino acids like proline, arginine, lysine, threonine, 
glutamate and aspartate is irreversible and has been reported to act as a mediator in a number 
of chronic diseases such as chronic renal failure, cystic fibrosis, psoriasis and etc. The elevation 
of protein carbonyl derivatives (aldehydes and ketones) correlates with the severity of the 
disease [114]. In this context, we focused on citrullination, a process catalyzed by calcium-
dependent PAD enzymes to generate citrulline from arginine residues. As it was documented, 
LL-37 is susceptible to be citrullinated as it contains five Arg residues [67]. Moreover, it has 
been reported that such modification of peptide abrogates its anti-inflammatory functions. One 
of the most significant effect of peptide citrullination is abbrogation of its immunomodulatory 
activity manifested by neutralization of LPS proinflammatory ability. This may result in the 
lost of protection against sepsis exerted by the native LL-37 [67]. Furthermore, Klisgård and 
co-workers have demonstrated that citrullination of LL-37 dampens its bactericidal effect. 
Authors proposed that citrullination of LL-37 could be enhanced by the increased local 
production of PAD2 and recruitment of neutrophils containing PAD4 during inflammation 
suggesting the role of LL-37 deimination in the course of chronic obstructive pulmonary 
disease (COPD) [68]. 
  LL-37 exerts several immunomodulatory functions that regulate host responses to 
pathogens. Among them is formation of complexes with negatively charged oligonucleotides 
derived from both dying host cells and pathogens. Our observation has showed that 
citrullination affects the affinity with which LL-37 binds DNA. LL-37 is highly susceptible to 
citrullination by PAD2 and PAD4 [67][68] and our studies showed that both PADs reduced 
the binding of LL-37 to DNA, with PAD2 to be reported being more efficient. PAD2 has a 
higher efficiency in citrullinating LL-37 compared to PAD4 which might due to the differences 
in the catalytic potency of the LL-37 sequence of these two PAD isoforms or their specificity 
for Arg residues in the context of the specificity exerted on the peptide [115].  In conjunction 
with the HPLC analysis on the level of citrullination of LL-37, we hypothesized the possibility 
of differentially modified forms of the peptide being generated in vivo as PAD2 and PAD4 has 
its’ own preference in citrullinating peptidylarginines [67]. This is illustrated by the fact that 
histone H3 is citrullinated by both PAD2 and PAD4, but fibrinogen is predominantly 
citrullinated by PAD2 [100]. Furthermore, it is broadly proposed that endogenous PADs could 
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have stricter substrate selection than recombinant enzymes [116]. Our findings were confirmed 
using synthetic citrullinated LL-37 forms, since their binding to DNA was gradually reduced 
with the increase number of deiminated arginine residues within the peptide. We have also 
shown that the affinity of LL-37 to DNA does not depend entirely on the peptide cationicity 
alone, but also the proper distribution of guanidinium side chains of Arg and specific PTMs. 
This was illustrated by using carbamylated forms of LL-37 which represents a good example 
of changes in cationicity of LL-37, since six lysine residues within the peptide are susceptible 
to carbamylation, which alters the cationic and amphipathic nature of the peptide [51]. 
Nevertheless, carbamylated LL-37 still had affinity for DNA comparable to that of the native 
LL-37. Remarkably however, upon enzymatic deimination of Arg residues in carbamylated 
LL-37, the binding affinity was totally abolished. The role of guanidinium side chains of Arg 
(hArg) was verified by using hArg-LL-37, which is insensitive to enzymatic deamination [57]. 
We observed equally efficient binding of hArg-LL-37 to nucleic acids compare to the native 
peptide, and the binding affinity was not affected upon incubation with PAD2, confirming the 
role of guanidinium side chains of Arg or hArg residues in LL-37 for DNA binding. In contrast 
to carbamylated LL-37 and hArg-LL-37, scrambled peptide (sLL-37) did not bind to DNA, 
similarly to its citrullinated version, revealing that the defined sequence of the amino acids in 
the polypeptide chain is essential for LL-37 binding to DNA. 
 Our results obtained with murine analog of LL-37, the CRAMP peptide revealed that 
even the single Arg residue in CRAMP is essential for DNA binding. The loss of one positive 
charge that caused the change in protein structure and/or function is a phenomenon not only 
limited to LL-37. It was also described in case of a myelin basic protein (MBP), which 
contributes to the pathogenesis of multiple sclerosis. The conversion of arginine to citrulline in 
the brain carried out by PAD2 has compromised the ability of MBP to interact with lipid bilayer. 
The reduced ability of the deiminated protein to bind and aggregate lipid vesicles and the 
presence of such highly deiminated form of MBP caused the fragmentation of lipid vesicles, 
leading to myelin breakdown in multiple sclerosis. Moreover, the elevated levels of PAD4 
observed in the brain might deiminate the arginyl residues of histones and compromise its 
ability to interact with DNA hence resulting in the induction of apoptosis of oligodendrocytes 
and suggesting an important role of its citrullination in the pathogenesis of multiple sclerosis 
[117]. The impairment of binding by citrullination was observed also in chemokines CXCL10 
and CXCL11. The heparin binding capacity of citrullinated forms of CXCL10 and CXCL11 
was significantly diminished compared to the native chemokines, with just the loss of one 
positive charge [118]. 
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 Our data has shown that citrullination of LL-37 effectively abolished the binding of 
peptide to DNA irrespectively to the length and origin of nucleic acid, as it was demonstrated 
using T. forsythia DNA, DNA isolated from human epithelial cells (HeLa) and synthetic 
oligonucleotides containing CpG motifs. Changes in the cationic charge of the peptide 
efficiently affects also its interaction with other molecules such as lipoproteins e.g. ApoA1. 
Moreover, we found that the change in the positive overall charge of LL-37 is also essential in 
stabilizing nucleic acids against nucleases. Such conclusion is supported by results, showing 
that the modified peptide with a single substituted residue that still binds to nucleic acid shows 
significantly diminished protection of DNA against nuclease degradation. This phenomenon 
might be explained by a less condensed structure formed between monocitrullinated LL-37 and 
nucleic acids, which allow nucleases to access cleavage sites of DNA. Taken together, these 
data reflect the unique role of deimination in LL-37 that alters the peptide interaction with 
nucleic acids and ability to provide associated DNA with resistance to nucleases.  
 Deimination does not only contribute to the significant changes in physiochemical 
properties of LL-37, but also alters the biological function of the peptide. As reported by Koziel 
et al. [67] and Kilsgard et al. [68], modified peptide loses its’ antimicrobial and chemotactic 
activity, including its anti-inflammatory role as an antagonist of TLR-dependent signalling 
induced by LPS, lipoteichoic acid, and peptidoglycan [67][68]. Our study aimed to investigate 
the immune response elicited by DNA, a key ligand for the TLR9 receptor. Recent findings 
have emphasized the role of host DNA in the development of inflammatory and/or autoimmune 
diseases. This has suggested that the greater level of inflammation correlates with intensity of 
cell death accompanied with the release of host DNA [119]. Innate immune recognition of 
bacterial DNA is considered as a beneficial mechanism to confer protection against invading 
pathogens, however, when host DNA is recognized, it becomes detrimental. Activation of 
TLR9 by self-DNA is prevented by DNA degradation by nucleases preventing DNA uptake by 
phagocytes. DNA in inflammatory milieu is usually removed by the action of DNases released 
by dying cells. However, Lande et al. [32] have reported that LL-37 forms complexes with 
DNA, protecting it against extracellular degradation, acting as a carrier molecule and 
facilitating the uptake of nucleic acid by immune cells [32]. The cationic charge of LL-37 plays 
an essential role in binding to DNA via electrostatic interactions and enhance the transfer of 
DNA over the plasma membrane which involved noncaveolar lipid raft domains, as well as 
cell surface proteoglycans [81]. Moreover, penetrating complex of DNA with LL-37 induces 
potent activation of pDCs [82]. As demonstrated in current dissertation this phenomenon is 
altered, when LL-37 undergoes citrullination. This was illustrated by using different forms of 
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the synthetic citrullinated LL-37 peptide. Citrullination regulates the LL-37-dependent 
immune response of APCs to the CpG motifs, in the citrullination-level dependent manner as 
the degree of activation of cells inversely correlated with numbers of modified Arg residues. 
This is in accordance with the studies conducted by Lande et al. [80], which indicates that 
DNA uncomplexed with LL-37 does not activate TLR9, as there were less CpG entering the 
endosomal compartment of pDCs, thereby abolishing the IFN-a production and desensitizing 
the cells to DNA. Our data mechanistically confirmed such observation as the consequence of 
reduced complex formation between citrullinated peptides and DNA diminished binding of 
nucleic acid to the cell membrane.  
 In presented studies we documented stronger immunostimulatory effect induced by 
CpG-LL-37 complexes observed after continuous overnight incubation with phagocytes 
compared to short exposure time (15 min). This might be a result of enhanced recognition of 
DNA or self-priming of pDCs mediated by type I IFN [120]. Moreover, our data revealed 
differential induction of inflammatory mediators, while IFN was elevated upon CpG-LL-37 
complex recognition, the level of IL-6 was diminished. Few studies have suggested that IFN-
a production by pDCs is the consequences of activation of TLR9 signalling in early endosomes, 
whilst its induction in late endosomes leads to pDC maturation and secretion of IL-6. In 
accordance with Lande et al. [80] observation, CpG in the complex with LL-37 stimulated the 
production of IFN-a, without inducing pDC maturation, as low levels of IL-6 secretion was 
observed, suggesting the retainment of complexes in early endosomes. Apart from that, 
uncomplexed LL-37 was unable to induce pDCs to produce IFN-a but IL-6, suggesting the 
effects of LL-37 on TLR9 activation solely depends on DNA binding. The carbamylated forms 
of LL-37 exerted the immunoregulatory effects on pDCs at the same level as native LL-37, 
with sLL-37 reported to be neutral for pDCs response to DNA. Although carbamylated 
peptides showed decreased cationicity, such modification did not affect the immunostimulatory 
potential of DNA complexed with the peptide, emphasizing that citrullination strongly and 
specifically affects the immunomodulatory function of LL-37. This conclusion corroborates 
with the idea that PAD regulates the local immune responses through posttranslational 
modification of immunomodulators [118]. Above described phenomenon was also 
documented in the model of murine macrophages RAW264.7, cells that express TLR9. 
Mixture of synthetic modified peptides harboring different deiminated residues mimicking in 
vivo citrullination catalysed by PAD2 and PAD4, respectively, triggered the release of 
significantly lower level of TNF-a in response to DNA as compared to the native peptide. 
 114 
Taken together, deimination of LL-37 downregulates host response to nucleic acids, which is 
not limited only to the reduced cationicity of peptide, but rather related to arginine modification. 
This was confirmed with the observations of binding affinity of carbamylated peptides and 
hArg-LL-37 to DNA, suggesting the essential role of the guanidinium side chain of Arg and 
hArg residues in protein/peptide interaction with DNA, RNA and other proteins [121]. The 
guanidinium functional group acts as a unique biomolecular recognition property for Arg 
residues. This group is particularly adept at multidentate hydrogen bonding and electrostatic 
interactions. Cell-penetrating peptides are reported to be arginine-rich peptides, and thus their 
properties are dependent on the guanidinium functional groups of the peptides [122]. 
 The diverse induction of the inflammatory response in phagocytes mediated by 
modified LL-37 and DNA has prompted us to study the cell signalling cascades. First, we 
wanted to determine how citrullination regulates the inflammatory response by investigating 
the uptake mechanism of native and citrullinated LL-37. To estimate the interaction of the 
native and modified LL-37 with cell membrane and intracellular penetration of peptides we 
tried to adapt the method published by Tang et al. [123]. One of the most well-characterized 
mechanism for the entry of molecules into cells is via early and late endosomes to lysosomes. 
Lysosome is a major degradation site for internalized material and cellular membrane proteins 
[124]. And thus, we wanted to establish the mechanism of LL-37 internalization by analyzing 
the lysosome formation. However, the lysosomes labelling pattern displayed by RAW264.7 
cells did not discriminate between the uptake of native and citrullinated LL-37 (data not shown). 
Further studies utilizing fluorescent-labelled native and citrullinated LL-37 can be done to 
observe the potential difference in a penetration of such peptides into the host cells.  
 As we proved differentiated regulation of cytokines secretion in response to CpG 
combined with the native and citrullinated forms of LL-37, therefore we attempt to identify a 
signalling pathway. For that purpose, we used both RAW264.7 cells and pDCs, which are both, 
classified as well-defined in vitro models sensitive to CpG [125]. Initially, we attempt to 
determine the activation of transcription factors. For that purpose, we used RAW264.7 cells 
transfected with a NF-kB-luciferase reporter plasmid. Exposition of those cells to DNA in a 
presence of native or modified LL-37 has revealed that NF-kB activation corroborates with 
TNF-a expression, and regardless of the duration of exposure, similar manner of NF-kB 
activity was observed. There was a decline of NF-kB activity when the deiminated residues 
increased within the peptide. Such data states in accordance to our FACS results that have 
demonstrated that citrullination affects the uptake of CpG into the cell. Based on obtained 
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results we can conclude that the downstream activation of NF-kB requires first the CpG to be 
endocytosed and upon endosomal acidification, it is specifically engaged by TLR9 and initiates 
a signalling cascade [126]. Moreover, this process is most efficient in the presence of native 
LL-37. 
 As the regulation of TLR9 activation varies between cell types and culture conditions 
[82], thus we studied the signalling pathways also in primary cells using CpG DNA well 
recognized by pDCs. Interestingly, not all known CpG DNA can induce pDCs to produce type 
I IFNs. We have selected A-type oligonucleotides such as 2216 for our studies as it is reported 
to be a strong stimulus for type I IFN production and promotes transcriptional activity of IRF-
7, triggering an autocrine feedback loop involving the IFN receptor-dependent pathway [127]. 
Of note, induction of type I IFN genes requires the activation of IRF7 [128]. However, we did 
not observe IRF7 activation after exposition of cells to CpG-LL-37 complexes. One of the 
plausible explanations might be that the IRF7 activity was below detection range of the applied 
ELISA assay. However, we confirmed the role of this pathway observing significant 
upregulation of type I interferon-dependent genes, including MxA. However, the process of 
pDCs activation should be further examined as Guiducci et al. reported that pDCs can induce 
a different mechanism of cell activation in response to TLR9 ligands, which depends on their 
location in an intracellular compartment [129]. Kim et al. [120] have reported that IRF3 and 
IRF7 are specific for PRR-triggered type I IFN production, whilst AP-1 and NF-kB 
components are essential for spontaneous type I IFN production, suggesting type I IFN 
production by pDCs cannot simply be explained at the cellular or subcellular level. Future 
studies are needed to verify the endosomal location of CpG-LL-37 complexes in pDCs that 
will provide a new insight into the mechanism of their activation.    
To further explore if LL-37 citrullination plays a role in inflammatory conditions, we 
employed neutrophils as our study model. LL-37 is found abundantly within the azurophilic 
granules of neutrophils. While NETs formation facilitates the interaction between bacteria and 
antimicrobial effectors leading to enhanced bacteria killing, they also contribute to the 
detrimental effects such as excessive inflammation and tissue damage in the host by release of 
proinflammatory, immunostimulatory molecules and various autoantigens [130]. The 
interaction between DNA and LL-37 in NETs was well described in a few studies where the 
presence of DNA-LL-37 complexes was identified [32][42]. They analyzed NETs released by 
neutrophils activated for 3 hours with phorbol 12-myristate 13-acetate (PMA) and using 
confocal microscopy, they show long stretches of DNA filaments of NETs consist DNA 
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decorated with LL-37. Treatment of NETs with DNase I degraded DNA stretches but not of 
the globular DNA domains containing LL-37 [32][42]. The important role of LL-37 generated 
through NETs has been described to have numerous immunomodulatory functions as 
according to environmental and cellular contexts. Apart from its antimicrobial activity, LL-37 
also protects NETs against degradation by bacterial nucleases [109]. Another unique function 
of LL-37 in NETs was reported to induce inflammasome via the activation of the P2X7R 
inflammatory signalling pathway in macrophages and monocytes [30]. Moreover, upon NETs 
formation, the presence of enzymatically active PAD [131] might catalyse the citrullination 
process of LL-37 exposed on DNA fibers. Thus, we tried to identify modified forms of LL-37 
in NETs directly with a citrulline specific chemical probe, rhodamine-phenylglyoxal (Rh-PG), 
however, only faint band correspond to the band size of citrullinated LL-37 was observed. And 
thus, we proceed with another approach by using mass spectrometry analysis. Nonetheless, our 
attempts failed with this method, which might be an effect of peptide degradation catalysed by 
the neutrophil proteases. This conclusion is strongly supported with our finding that LL-37 
stability was increased in the presence of a general inhibitor of proteases. As far as we 
documented the protective effect of elastase inhibitors one may propose that it is one of the 
crucial enzymes responsible for degradation of the peptide in NETs. Moreover, all modified 
LL-37 peptides have shorter half-life compared to the native LL-37 when added to HNE. The 
presence of HNE was documented in NETs and synovial fluid from RA patients. Of note 
enhanced NETosis was reported in synovial fluid from RA patients [84]. O’Donoghue and co-
workers have demonstrated in their study that NETs are enriched in serine proteases, with HNE 
(neutrophil elastase) and PR3 (neutrophil proteinase 3) as the main contributors to NETs 
associated proteolytic activity [132]. As both enzymes are released from vacuoles upon the 
event of NETosis, their activity may no longer spacially restricted leading to enhanced local 
proteolysis of liberated proteins [132]. This can be an explanation why the proteomic analysis 
might have failed to identify citrullinated LL-37. Apart from that, the oxidative environment 
created from myeloperoxidase activity during NETosis can lead to further modification on 
citrulline and other residues in LL-37 [103], and thus interfering with identification of 
citrullinated LL-37 by mass spectrophotometry due to mass shift. Of note, both native and 
modified forms of LL-37 have a longer half-life in healthy donor’s sera. Keeping in mind that 
less proteolytic activity occurs in healthy sera, this suggest that proteolytic degradation can be 
a cause to a short half-life of modified LL-37 in NETs. Such conclusion supports the studies 
conducted by Klisgard et al., where the citrullinated LL-37 peptide is rapidly degraded due to 
the change of its’ molecular structure [68]. Hahn and co-workers recently documented the role 
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of neutrophils and NETs in the regulation of the life-span of the immunoregulators. They 
reported the immunoregulatory effects of neutrophil serine proteases [133] whihch degrade 
several cytokines/chemokines, such as IL-1b, IL-6, MCP-1 and IL-8. Described degradation 
of proinflammatory mediators dampens the inflammation in gout and an animal model of lupus 
[134][135]. This implies a strategy of the host to interrupt the self-positive feedback loop with 
neutrophil recruitment and activation, providing a safeguard of neutrophilic inflammation 
[133]. 
Experiments using antibodies against native LL-37 have revealed that more unmodified 
LL-37 was found in NETs generated in the presence of a nonselective PAD inhibitor – 
chloramidine (Cl-A) [130]. We confirmed this using fluorescent microscopy as well as Western 
blot analysis. Moreover, the increase level of hCAP18 was found in neutrophils pretreated with 
Cl-A in our immunoblot analysis, suggesting the inhibition of hCAP18 deimination by PADs.  
These data have strongly suggested that both cathelicidin and mature LL-37 are citrullinated 
by PADs during NET formation, both in vitro and ex vivo. This observation was further 
supported by examining the biological effect of the native peptide on macrophages using a 
model based on an approach published by Kahlenberg et al. [30]. The authors reported that 
primed human monocyte-derived macrophages with increased surface expression of the P2X7 
receptor released high levels of IL-1b upon stimulation with LL-37. As LL-37 is one of the 
major NETs components that can activate the P2X7 receptor-signalling pathway, our results 
can serve as a strong evidence of the presence of modified LL-37 in NETs, where NETs 
pretreated with Cl-A had stronger effect on primed macrophages, as shown by the IL-1b 
secretion, compared to native NETs. 
Few studies have reported the role of citrullinated proteins/peptides in the onset of 
inflammatory responses, such as in rheumatoid arthritis, multiple sclerosis and systemic lupus 
erythematosus patients. Apparently citrullination leads to the generation of antibodies against 
citrullinated proteins/peptides. NETs are known as an important source of autoantigens that 
contribute to autoinflammatory conditions and in concordance we found an elevated antibody 
response against citrullinated LL-37 in RA patients, which elevated levels of NETs have been 
reported in RA patients [136]. Our studies have shown the slight increase of the ratio of IgGs 
against citrullinated LL-37/LL-37 in patients with inflammatory disease (periodontitis and 
rheumatoid arthritis), suggesting the presence of citrullinated LL-37 and induction of adaptive 
immunity in the response to this peptide. The explanation of observed phenomenon is likely 
chronic inflammation typical for both groups of patients [137]. Moreover, in both diseases the 
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detrimental role of NETs is postulated [84]. A study conducted by Kienhöfer et al. [138] has 
showed a significant difference in the level of IgGs against LL-37 between healthy controls 
and SLE patients, but not in RA, which corroborates with our results. They also showed that 
autoantibodies to LL-37 in sera of the two tested cohorts did not correlate with the disease 
activity, organ involvement or treatment. That suggested that the autoreactivity against exposed 
cathelicidins is an epiphenomenon due to extensive disease-induced overexpression. However, 
further studies involving a larger cohort of patients shall be conducted for better explanation 
of above observation. Darrah et al. [115] have reported that PAD enzymes are active 
extracellularly in RA. That raised the possibility of LL-37 citrullination and presentation of 
modified antigens to T cells. Such modifications may alter the processing and presentation on 
antigen by antigen presenting cells and thus production of IgGs might be triggered. NETosis 
was observed to be enhanced in RA patients which elevates the members of this cascade, such 
as the increased intracellular ROS production, enhanced expression of HNE and MPO, 
increased nuclear translocation of PAD4, and citrullination of proteins/peptides [115], 
providing the immune system with access to abundant sources of citrullinated proteins. 
Finally, one cannot exclude the possibility that citrullination of LL-37 can be executed 
by peptidyl deiminase expressed by P. gingivalis, the only one PAD ortholog identified in 
prokaryotes [139]. Studies conducted by Bielecka et al. [140] have showed the effect of 
bacterial citrullination on proinflammatory functions of anaphylatoxin C5a, where a reduced 
chemotactic activity for neutrophils and impairment to induce calcium influx in a myeloid-
derived cell line (U937) transfected with C5aR (C5a receptors) were observed [140]. Moreover, 
Moelants and co-workers have suggested that chemokine citrullination such as CXCL8 by 
bacterial PAD (PPAD) may lead to negative feedback on local leukocyte-mediated 
inflammation and bacterial clearance [141]. Besides that, Wegner et al. [56] have demonstrated 
the citrullination of host peptides (human fibrinogen and a-enolase) by P. gingivalis, where 
the host peptides were first subjected to proteolytic cleavage by arginine-gingipains followed 
by citrullination of carboxy-terminal arginines by PPAD. This has led to the generation of 
antigens driving autoimmune response in RA. P. gingivalis can also induce NETs formation, 
as an increased NETosis have been reported in gingival crevicular fluid from periodontitis 
patients. This has opened the window of possibilities that enhanced citrullination and NETosis 
induced in the oral cavity by P. gingivalis could be an initial event that leads to the generation 
of autoantigens and autoantibodies corroborating an autoimmune response in RA patients [142]. 
Taken together, we postulate that citrullinated LL-37 is generated during NETs formation. 
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Several studies have reported the crosstalk between neutrophils and DCs [32][42][143]. 
Neutrophils death, such as apoptosis, necrosis and NETosis has contributed to the potential 
resource of self-DNA in patients with autoimmune diseases. Besides that, psoriasis is 
characterized by the overexpression of LL-37. LL-37 was also found to be present at high 
levels in the blood of SLE patients. The presence of the LL-37 in such disorder has suggested 
the involvement of DNA-LL-37 complexes in the disease pathogenesis. Thus LL-37 can be 
considered a stable ligand that promotes loss of tolerance and TLR9 stimulation in pDCs 
[32][80]. Furthermore, SLE patients selectively develop antibodies against LL-37 derived from 
neutrophils, which in turn could activate neutrophils to release NETs containing complexes of 
DNA and the antimicrobial peptide. These autoantibodies were also reported to enhance the 
uptake of DNA-antimicrobial peptide complexes into pDCs by enhancing FcgRII recognition 
of the DNA complexes, leading to the release of IFN-a and exacerbating the inflammation and 
disease [32]. 
Collectively our studies have shown the critical role of citrullinated LL-37 in the host 
response. There’s a growing interest on the role of PTM in the context of NETs and its link 
with autoimmunity. The presence of modified forms of LL-37 which are released abundantly 
during NETosis play an important role in modulating myeloid cell response to nucleic acids. 
APCs exposed to NETs generated in the presence of a PAD inhibitor exhibit stronger activation 
compared to native NETs, suggesting the protective role of protein citrullination, including LL-
37 on the enhanced response of myeloid cells to host DNA. Above statement is strongly 
supported by results of efficient pDCs activation by NETs supplemented with resistant to 
deimination hArg-LL-37. Thus, we postulate that the proinflammatory potential of NETs could 
be regulated at the level of posttranslational modification of proteins associated with nucleic 
acids. Such regulation of protein activity and stability by the host can provide the control of 
inflammatory reaction needed for elimination of pathogens without triggering further 
proinflammatory response. This can be critical in the context of immune system regulation and 
in the development of autoimmune diseases, especially in cases where self-DNA molecules 
triggered an excessive inflammatory response [32]. This has led to the hypothesis that 
posttranslational modification by citrullination may act to protect the host against inflammatory 
activity of proteins associated with DNA fibers [100]. Moreover, small quantities of citrulline-
containing proteins and the soluble PAD2 protein have been detected in healthy human subjects, 
suggesting the physiological roles of these enzymes under healthy conditions, although the 
exact physiological functions still remain unknown [144]. However, this maybe a disadvantage 
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during bacterial infection, since the abrogation of LPS neutralization by citrullinated LL-37 
leads to an exacerbated inflammatory response in the endotoxin-induced model of sepsis [67]. 
Thus, the hArg-LL-37 peptide resistant for deimination might serve a potential candidate for 
apical treatment in patients suffering with microbial related infections such as periodontitis or 
infected wounds. Moreover, a study conducted by Biron et al. has shown that the inhibition of 
Histone 3 citrullination by Cl-Amidine improves survival in murine sepsis model by decreasing 
the proinflammatory response [130].  
 Interestingly, presented data have revealed that citrullination of LL-37 is crucial not 
only for the regulation of the immune response to DNA. We also documented that neutrophils 
pre-treated with citrullinated proteins/peptides exhibited an increased response to further 
stimulation with NETs inducers (PMA or RgpA). Those data corroborate with unpublished 
results of Danuta Bryzek, Ph.D. She proved that some forms of deiminated LL-37 act 
proinflammatory in contrast to native peptide.  As she documented human monocyte-derived 
macrophages (hMDMs) produce an elevated level of pro-inflammatory cytokines upon 
stimulation with some forms of citrullinated LL-37. The effect was observed for 
monocitrullinated LL-37 (LL-377), while the strongest induction was executed by LL-377, 29, 
34. This might be a plausible explanation of the amplified inflammation observed in 
autoimmune disease patients. This phenomenon was observed in RA, that is characterized by 
the increased NETs level and production of autoantibodies to citrullinated protein antigens 
(ACPAs), with citrullinated antigens being mostly derived from NETs [145]. Intriguingly, 
autoantibodies against antimicrobial peptides were found also to activate neutrophils, and thus 
perpetuating a vicious circle of NETs production that maintains the delivery of modified 
autoantigens to the immune system even in the absence of infections. One may propose, that 
modified proteins/peptides released during NETosis might lead to neutrophil priming and 
heightens neutrophil responses manifested by extruding a greater amount of DNA. These 
observations may suggest the amplifying mechanism exerted by citrullinated proteins/peptides, 
which further promote NETs enhancement and exacerbate autoimmune responses [84]. Taken 
together, citrullination in NETs strongly modified the inflammatory potential of those 
structures, changing the primary functions of its proteinaceous components. Thus, our 
observations suggest that the design of PAD inhibitors as therapeutic targets for inflammatory 
diseases must be considered carefully. 
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Fig. 54. An overview of the cross-talk between neutrophils and dendritic cells. All the 
necessary ingredients to trigger the adaptive immune system through a self-amplifying 
pathogenic loop. NETs containing DNA-LL-37 complexes released from dying neutrophils 
are taken up by plasmacytoid dendritic cells and signal via TLR9 in endosomes, leading to the 
release of IFN-a which could prime mature neutrophil and allow the formation of NETs. 
Development of antibodies against both DNA and antimicrobial peptides in NETs could 
promote their transport into pDCs, leading to the amplification of IFN-a production. Abundant 
NET creation also prompts autoreactive B-cell activation, leading to the release of anti-LL-
37/anti-LL-37cit. which might trigger the activation of neutrophils, providing the mechanism of 
continuous release of NETs and augments the inflammatory response.  
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9. Overall Conclusions 
 
1. LL-37 is highly susceptible to be citrullinated by PAD2 and PAD4 during inflammatory 
milieu, with the former being more efficient. Citrullination of LL-37 has a marked 
effect on its affinity for nucleic acids, which is largely dependent on the number of 
modified Arg residues within the peptide. The strength of binding to DNA is inversely 
proportional to the number of citrullinated residues in the peptide. Peptide-DNA 
binding capacity does not depend entirely on the positive charge of LL-37, as illustrated 
by preincubation of carbamylated LL-37 with PAD2, which abrogated the peptide’s 
ability to bind DNA. On the contrary, guanidinium side chain of Arg residues (homo-
Arg) in the peptide, which cannot be deiminated, is essential for the LL-37 interaction 
with DNA, with results shown to bind DNA with the efficiency similar to native LL-
37. 
 
2. Deimination of LL-37 also leads to alteration of the peptide interactions with other 
molecules than DNA, such as lipoprotein, Apo-A1. In the latter case, however, it must 
be examined if the citrullination affects the interaction as specificly as in case of DNA. 
 
3. Deimination of arginine residues within LL-37 strongly and specifically affects the 
immunogenic potential of DNA in the citrullination level-dependent manner. The 
proinflammatory response of APCs sensitive to nucleic acid-induced signalling, 
inversely correlated with the increase number of citrulline residues within the peptide. 
The impairment of APCs activation is caused by the reduced interactions between DNA 
and LL-37. This hinders the delivery of nucleic acids into the intracellular/endosomal 
compartment, diminishing the activation of NF-kB and IRF signalling pathway. 
 
4. The generation of citrullinated forms of LL-37 occurs in NETs. The problems with 
direct identification of modified forms of LL-37 could be related to susceptibility of the 
citrullinated peptides to proteolytic cleavage.  
 
5. Citrullination in NETs regulates the inflammatory potential of those structures, 
changing the primary functions of its proteinaceous components. That phenomenon can 
be important in protecting the host against over-activation of the immune system in the 
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development of autoimmune diseases but on the other hand detrimental, affecting the 
cellular responses to microbial components.  
 
6. Modified LL-37 probably plays a broader immunomodulatory role, as citrullinated LL-
37 itself enhances the generation of NETs formation suggesting the positive feedback 
mechanism.  
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